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A B S T R A C T
Background
Tuberculosis and malnutrition are linked in a complex relationship. Tuberculosis may cause undernutrition through increasedmetabolic
demands and decreased intake, and nutritional deficiencies may worsen the disease, or delay recovery by depressing important immune
functions. At present, there is no evidence-based nutritional guidance for adults and children being treated for tuberculosis.
Objectives
To assess the effects of oral nutritional supplements in people being treated with antituberculous drug therapy for active tuberculosis.
Search methods
We searched the Cochrane Infectious Disease Group Specialized Register, Cochrane Central Register of Controlled Trials (CENTRAL;
Issue 1, 2016), MEDLINE (from 1946 to 4 February 2016), EMBASE (from 1980 to 4 February 2016), LILACS (from 1982 to 4
February 2016), the metaRegister of Controlled Trials (mRCT), the World Health Organization (WHO) International Clinical Trials
Registry Platform (ICTRP), and the Indian Journal of Tuberculosis up to 4 February 2016, and checked the reference lists of all included
studies.
Selection criteria
Randomized controlled trials that compared any oral nutritional supplement given for at least four weeks with no nutritional interven-
tion, placebo, or dietary advice only for people being treated for active tuberculosis. The primary outcomes of interest were all-cause
death, and cure at six and 12 months.
Data collection and analysis
Two review authors independently selected trials for inclusion, and extracted data and assessed the risk of bias in the included trials.
We presented the results as risk ratios (RR) for dichotomous variables, and mean differences (MD) for continuous variables, with 95%
confidence intervals (CIs). Where appropriate, we pooled data from trials with similar interventions and outcomes. We assessed the
quality of the evidence using the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach.
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Main results
Thirty-five trials, including 8283 participants, met the inclusion criteria of this review.
Macronutrient supplementation
Six trials assessed the provision of free food, or high-energy supplements. Only two trials measured total dietary intake, and in both
trials the intervention increased calorie consumption compared to controls.
The available trials were too small to reliably prove or exclude clinically important benefits on mortality (RR 0.34, 95% CI 0.10 to
1.20; four trials, 567 participants, very low quality evidence), cure (RR 0.91, 95% CI 0.59 to 1.41; one trial, 102 participants, very low
quality evidence), or treatment completion (data not pooled; two trials, 365 participants, very low quality evidence).
Supplementation probably produces a modest increase in weight gain during treatment for active tuberculosis, although this was not
seen consistently across all trials (data not pooled; five trials, 883 participants, moderate quality evidence). Two small studies provide
some evidence that quality of life may also be improved but the trials were too small to have much confidence in the result (data not
pooled; two trials, 134 participants, low quality evidence).
Micronutrient supplementation
Six trials assessed multi-micronutrient supplementation in doses up to 10 times the dietary reference intake, and 18 trials assessed single
or dual micronutrient supplementation.
Routine multi-micronutrient supplementation may have little or no effect on mortality in HIV-negative people with tuberculosis (RR
0.86, 95% CI 0.46 to 1.6; four trials, 1219 participants, low quality evidence), or HIV-positive people who are not taking antiretroviral
therapy (RR 0.92, 95% CI 0.69 to 1.23; three trials, 1429 participants, moderate quality evidence). There is insufficient evidence to
know if supplementation improves cure (no trials), treatment completion (RR 0.99, 95% CI 0.95 to 1.04; one trial, 302 participants,
very low quality evidence), or the proportion of people who remain sputum positive during the first eight weeks (RR 0.92, 95% CI 0.63
to 1.35; two trials, 1020 participants, very low quality evidence). However, supplementation may have little or no effect on weight gain
during treatment (data not pooled; five trials, 2940 participants, low quality evidence), and no studies have assessed the effect on quality
of life.
Plasma levels of vitamin A appear to increase following initiation of tuberculosis treatment regardless of supplementation. In contrast,
supplementation probably does improve plasma levels of zinc, vitamin D, vitamin E, and selenium, but this has not been shown to have
clinically important benefits. Of note, despite multiple studies of vitamin D supplementation in different doses, statistically significant
benefits on sputum conversion have not been demonstrated.
Authors’ conclusions
There is currently insufficient research to know whether routinely providing free food, or energy supplements improves tuberculosis
treatment outcomes, but it probably improves weight gain in some settings.
Although blood levels of some vitamins may be low in people starting treatment for active tuberculosis, there is currently no reliable
evidence that routinely supplementing above recommended daily amounts has clinical benefits.
P L A I N L A N G U A G E S U M M A R Y
Nutritional supplements for people being treated for active tuberculosis
Cochrane researchers conducted a review of the effects of nutritional supplements for people being treated for tuberculosis. After
searching for relevant studies up to 4 February 2016, they included 35 relevant studies with 8283 participants. Their findings are
summarized below.
What is active tuberculosis and how might nutritional supplements work?
Tuberculosis is a bacterial infection which most commonly affects the lungs. Most people who get infected never develop symptoms
as their immune system manages to control the bacteria. Active tuberculosis occurs when the infection is no longer contained by the
immune system, and typical symptoms are cough, chest pain, fever, night sweats, weight loss, and sometimes coughing up blood.
Treatment is with a combination of antibiotic drugs, which must be taken for at least six months.
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People with tuberculosis are often malnourished, and malnourished people are at higher risk of developing tuberculosis as their immune
system is weakened. Nutritional supplements could help people recover from the illness by strengthening their immune system, and
by improving weight gain, and muscle strength, allowing them to return to an active life. Good nutrition requires a daily intake of
macronutrients (carbohydrate, protein, and fat), and micronutrients (essential vitamins and minerals).
What the research says
Effect of providing nutritional supplements to people being treated for tuberculosis
We currently don’t know if providing free food to tuberculosis patients, as hot meals or ration parcels, reduces death or improves cure
(very low quality evidence).However, it probably does improve weight gain in some settings (moderate quality evidence), and may improve
quality of life (low quality evidence).
Routinely providing multi-micronutrient supplements may have little or no effect on deaths in HIV-negative people with tuberculosis
(low quality evidence), or HIV-positive people who are not taking anti-retroviral therapy (moderate quality evidence). We currently don’t
know if micronutrient supplements have any effect on tuberculosis treatment outcomes (very low quality evidence), but they may have
no effect on weight gain (low quality evidence). No studies have assessed the effect on quality of life.
Plasma levels of vitamin A appear to increase after starting tuberculosis treatment regardless of supplementation. In contrast, supple-
mentation probably does improve plasma levels of zinc, vitamin D, vitamin E, and selenium, but this has not been shown to have
clinically important benefits. Despite multiple studies of vitamin D supplementation in different doses, statistically significant benefits
on sputum conversion have not been demonstrated.
Authors’ conclusions
Food or energy supplements may improve weight gain during recovery from tuberculosis in some settings, but there is currently no
evidence that they improve tuberculosis treatment outcomes. There is also currently no reliable evidence that routinely supplementing
above recommended daily amounts has clinical benefits.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Food provision compared with nutritional advice or no intervention for patients with active tuberculosis
Patient or population: adults and children with act ive tuberculosis
Settings: low- and middle-income countries
Intervention: calorie supplementat ion as food or energy dense supplements
Comparison: nutrit ional advice, m icronutrient supplement, or no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Standard care Increased calorie in-
take
Death
(at 6 months)
3 per 100 1 per 100
(0 to 4)
RR 0.34
(0.10 to 1.20)
567
(4 trials)
⊕©©©
very low1,2,3
We don’t know if
food supplementat ion
reduces mortality f rom
tuberculosis in food-in-
secure sett ings
Cured
(at 6 months)
48 per 100 44 per 100
(28 to 68)
RR 0.91
(0.59 to 1.41)
102
(1 trial)
⊕©©©
very low2,3,4
We don’t know if
food supplementat ion
increases cure in tuber-
culosis pat ients
Treatment completion
(at 6 months)
79 per 100 85 per 100
(70 to 100)
Not pooled 365
(2 trials)
⊕©©©
very low3,5,6
We don’t know if
food supplementat ion
increases treatment
complet ion in tubercu-
losis pat ients
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Sputum negative
(at 8 weeks)
76 per 100 82 per 100
(65 to 100)
RR 1.08
(0.86 to 1.37)
222
(3 trials)
⊕©©©
very low3,5,6
We don’t know if
food supplementat ion
reduces the durat ion of
sputum posit ivity in tu-
berculosis pat ients
Mean weight gain
(At 8 weeks)
- - Not pooled 883
(5 trials)
⊕⊕⊕©
moderate7,8
Supplementat ion prob-
ably increases weight
gain during treatment
Quality of life
(At 8 weeks)
- - Not pooled 134
(2 trials)
⊕⊕©©
low9,10
Supplementat ion may
increase quality of lif e
scores during the f irst 2
months of treatment
* The assumed risk is taken f rom the mean risk in the control groups in the included studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
Abbreviations: CI = conf idence interval; RR = risk rat io; GRADE = Grading of Recommendations Assessment, Development and Evaluat ion
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1Three trials reported some deaths during the 6 months of treatment (Jahnavi 2010 IND; Jeremiah 2014 TZA; Sudarsanam
2010 IND), and 1 reported that no deaths occurred (Mart ins 2009 TLS). The trials were conducted in Tanzania, Timor-Leste,
and India in part icipants with signs of undernutrit ion. Mart ins 2009 TLS gave a daily hot meal, Sudarsanam 2010 IND gave
monthly rat ion packs, Jahnavi 2010 IND gave daily locally appropriate supplements, and Jeremiah 2014 TZA gave high
energy mult ivitamin enriched biscuits.
2Downgraded by 1 for indirectness: trials are only available f rom lim ited sett ings. Food supplementat ion would plausibly have
its biggest ef fect in highly food-insecure or emergency sett ings which are not ref lected in these trials.
3Downgraded by 2 for imprecision: the trials and meta-analysis are signif icant ly underpowered to either detect or exclude an
ef fect if it exists.
4Data on successful cure at 6 months is only available f rom Sudarsanam 2010 IND which randomized tuberculosis pat ients
in India to monthly rat ion packs or advice only.
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5Two trials report on tuberculosis treatment complet ion at 6 months (Jahnavi 2010 IND; Mart ins 2009 TLS). One trial was
conducted in India and 1 in Timor-Leste in part icipants with signs of undernutrit ion. Both trials gave daily locally appropriate
supplements.
6Downgraded by 1 for inconsistency. Jahnavi 2010 IND found a stat ist ically signif icant benef it while the larger trial, Mart ins
2009 TLS, did not.
7Five studies reported measures of weight gain but at dif f erent t ime-points, which prevented meta-analysis.
8Downgraded by 1 for inconsistency. Praygod 2011b TZA included only HIV-posit ive pat ients and although the trend was
towards a benef it this did not reach stat ist ical signif icance. Jeremiah 2014 TZA noted a greater increase in mean weight
gain in the supplemented group compared to the non-supplemented group af ter 8 weeks; however the dif ference was not
appreciable (1.09 kg, P < 0.6, authors’ own f igures). The 3 other trials all demonstrated clinically important benef its.
9Downgraded by 1 for indirectness. Only 2 small t rials, 1 f rom Singapore (Paton 2004 SGP) and 1 f rom India (Jahnavi 2010
IND) report quality of lif e scores. The results can not be generalized to other populat ions or sett ings with any certainty.
10Downgraded by 1 for imprecision. The presented data appear highly skewed and could not be pooled.
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B A C K G R O U N D
Description of the condition
Tuberculosis is an infection caused by the bacterium Mycobac-
terium tuberculosis, which is spread from person to person by in-
halationof respiratory droplets (Harries 2006). In 2013, theWorld
Health Organization (WHO) estimated that there were nine mil-
lion new cases of active tuberculosis worldwide, and 1.5 million
deaths (WHO 2014).
Most people who are infected withM. tuberculosis develop what is
known as latent tuberculosis. People with latent tuberculosis are
infected with the bacterium Mycobacterium tuberculosis, but the
infection is contained by their immune system. These people re-
main well and do not exhibit any clinical signs or symptoms of ill-
ness (Barry 2009). The immune response to infection is complex,
it initially involves the uptake of the bacterium into macrophage
cells as part of the non-specific ’innate’ immune response, and later
recruitment of both B- and T-lymphocytes of the cellular immune
response (Schluger 1998). These cells isolate the bacterium as a
granuloma, typically in the lung (Saunders 2007).
Active tuberculosis occurs when the infection is no longer con-
tained by the immune system, and can occur at any time follow-
ing infection. The lifetime risk of conversion from latent to active
tuberculosis is around 5% to 10% in an otherwise healthy popula-
tion (Harries 2006), but this can rise to around 50% in people with
severe impairment of their immune system, such as occurs with
human immunodeficiency virus (HIV) infection (Zumla 2000;
Aaron 2004).
Tuberculosis most commonly affects the lungs (pulmonary tuber-
culosis), but can also spread to affect the central nervous system,
lymphatic system, circulatory system, genitourinary system, and
bones and joints. The symptoms of active pulmonary tuberculosis
include cough, chest pain, fever, night sweats, weight loss, and
sometimes coughing up blood (Harries 2006).
Tuberculosis is treated with a combination of antibiotic drugs
(antituberculous therapy), which must be taken for a period of at
least six months to ensure success (WHO 2010). If left untreated,
around half of those with active tuberculosis will die of the disease
(Corbett 2003). With adequate treatment the mortality is around
5% globally (WHO 2009), although this may be higher in HIV-
positive people (Aaron 2004). The WHO target for successful
cure in national tuberculosis control programmes is 85% (WHO
2009).
Throughout the world, poor nutritional status is more common
in people with active tuberculosis than in people without tuber-
culosis (van Lettow 2003), and weight loss, including loss of lean
body mass, is a well-recognized symptom of the disease. Cohort
and cross-sectional studies have suggested that active tuberculosis
is commonly associated with low serum levels of important mi-
cronutrients such as zinc (Taneja 1990), and vitamins A, C, D,
and E (Davies 1985; Plit 1998; Nnoaham 2008). However, the
measurement of serum vitamin levels during an acute infection,
such as tuberculosis, is known to be unreliable, as transient abnor-
malities can occur (Louw 1992).
The daily nutritional requirements for healthy individuals of all
age groups are well described (Meyers 2006), and it is unlikely that
people with active tuberculosis would require less than these rec-
ommended amounts. The two important questions are therefore
whether tuberculosis patients require more, and whether these in-
creased requirements should be provided as part of routine health
care.
The effects of supplementation in people with HIV (but without
tuberculosis) is covered in two other Cochrane Reviews (Irlam
2010; Grobler 2013).
Description of the intervention
Nutritional requirements can be broadly divided into macronutri-
ents (carbohydrate, protein, and fat) and micronutrients (essential
vitamins and trace elements).
Macronutrients
Each day the average 70 kg male requires approximately 2500
kilocalories (kcal) of energy to maintain body weight and compo-
sition; ideally consumed as 55% carbohydrate, 15% protein, and
30% fat (Meyers 2006).
If it was shown that patients with active tuberculosis required ad-
ditional macronutrients; these could be purchased and consumed
by the patient simply following nutritional advice. However, in
many situations, especially in low- and middle-income countries,
the patient may not be able to acquire this additional food due
to economic hardship through illness and loss of work, or due
to local food insecurity (Kamolratanakul 1999; Wyss 2001). In
these situations healthcare services might provide increased nutri-
ents through free provision of meals, take home rations, or specific
high energy supplements. In many crisis or low-income settings
this already happens and the World Food Programme (WFP) in
particular is involved in many food support programmes for tu-
berculosis patients (WFP 2007).
Micronutrients
The daily micronutrient requirements for an adult male are given
in Appendix 1. These are usually expressed as the ’dietary reference
intake’ (DRI), and this is different for each individual micronu-
trient (Meyers 2006).
These requirements can be gained from the consumption of a
healthy, and varied diet, or through pharmaceutical supplementa-
tion as tablets, capsules, or powders. Any additional requirements
could be gained through increased consumption following dietary
advice, or through pharmaceutical provision via the health service
or tuberculosis programme.
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In trials of macronutrient and micronutrient interventions two
important factors should be noted.
• The intervention is a supplement and does not represent
the total daily intake of that nutrient.
• Any benefit derived from the intervention is likely to be
dependant on the initial nutritional status of the patient.
In order to accurately interpret data it is therefore essential to con-
sider both the baseline nutritional status, and the overall nutri-
tional intake of the patients.
How the intervention might work
Tuberculosis and undernutrition interact in a two-way process.
Tuberculosis can lead to weight loss and micronutrient deficien-
cies by increasing nutritional requirements, by changingmetabolic
processes, or by decreasing appetite and causing a reduction in
food intake (Macallan 1999). Alternatively, low body mass index
(BMI; a measure of weight for height that is indicative of nu-
tritional status) and some micronutrient deficiencies can depress
cell-mediated immunity, the key host defence against tuberculo-
sis, increasing the susceptibility to active tuberculosis and delaying
recovery (Chandra 1996; Zachariah 2002; Cegielski 2004).
The micronutrients which have received the most attention are
the following.
• Vitamin A, which is involved in both T- and B-lymphocyte
function, macrophage activity and the generation of antibody
responses (Semba 1998; Stephensen 2001).
• Vitamin D, which is involved in the function of
macrophages, a key component of the immune response to
tuberculosis (Wintergerst 2007).
• Vitamin E, which has anti-oxidant properties and may
protect against T-lympocyte failure due to oxidative stress
(Wintergerst 2007).
• Zinc, which is necessary for adequate functioning of many
aspects of human immunity (Shankar 1998).
• Selenium; which is essential for both cell-mediated and
humoral immunity (Arthur 2003).
Nutritional interventions, in people with active tuberculosis,
therefore have the potential to do the following.
• Improve tuberculosis treatment outcomes; through
restoration of cell-mediated immunity, increasing the
individuals’ ability to fight the infection and hastening recovery
from the illness.
• Promote nutritional recovery; with improved weight gain,
restoration of muscle strength, function, and quality of life.
Nutritional recovery is of great importance in tuberculosis
treatment, allowing the patient to return to work, and recover
economically as well as physically.
Food may also be given to people with tuberculosis for quite dif-
ferent reasons, such as; to promote adherence to treatment, or to
mitigate the financial consequences of prolonged illness. Another
Cochrane Review is addressing the use of food to promote adher-
ence (Lutge 2009).
In addition, it is important to note that pathogens such as tubercu-
losis also require certain micronutrients for their ownmetabolism,
and greater availability of these nutrients through supplementa-
tion could encourage their growth. There is some evidence for this
in the case of iron (Lounis 2001), and so nutritional interventions
cannot be considered entirely benign.
Why it is important to do this review
There is currently no evidence-based guidance on food provision
or supplementation for adults or children being treated for tuber-
culosis, with or without concurrent HIV infection. This Cochrane
Review seeks to assess the evidence for the effectiveness of differ-
ent food and nutritional supplements in helping people to gain
weight and recover from tuberculosis, and highlight where more
research might be needed.
O B J E C T I V E S
To assess the effects of oral nutritional supplements in people being
treated with antituberculous drug therapy for active tuberculosis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs).
Types of participants
Children or adults being treated for active tuberculosis with or
without concurrentHIV infection, andwith orwithout a diagnosis
of being underweight, malnourished, or nutrient deficient.
Types of interventions
Intervention
Any oral macro or micronutrient supplement given for at least
four weeks.
We excluded trials that assessed tube feeding or parenteral nutri-
tion, and trials that assessed dietary advice alone without the actual
provision of supplements.
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Control
No nutritional intervention, placebo, or dietary advice alone.
Types of outcome measures
Primary outcomes
• All-cause death.
• Cure (completed treatment and sputum-smear or sputum-
culture negative) at six and 12 months.
Secondary outcomes
• Completion of treatment.
• Sputum positive at follow-up.
• Self-reported recovery from illness or resolution of
symptoms.
• Change in weight, skinfold thickness, or other measure of
lean or total mass.
• Any measure of growth in children.
• Any measures of physical functioning, quality of life, or
ability to return to work.
• Total calorie intake.
• Micronutrient levels before and after supplementation.
We intended to include cure assessed at six and 12 months, as is
customary. For other outcome measures, we accepted data pre-
sented at any time point.
Search methods for identification of studies
We attempted to identify all relevant trials regardless of language
or publication status (published or unpublished, in press, or in
progress).
Electronic searches
We searched the following databases using the search terms and
strategy described in Appendix 2.
• Cochrane Infectious Disease Group Specialized Register.
• Cochrane Central Register of Controlled Trials
(CENTRAL; Issue 1, 2016).
• MEDLINE (from 1946 to 4 February 2016).
• EMBASE (from 1980 to 4 February 2016).
• LILACS (from 1982 to 4 February 2016).
We checked the metaRegister of Controlled Trials (mRCT) and
the World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en)
up to 4 February 2016, using ’tuberculosis’ and ’supplementation’
as search terms.
In addition we searched the Indian Journal of Tuberculosis using the
keywords given in the search strategy (Appendix 2) on 4 February
2016.
Searching other resources
We also checked the reference lists of all studies identified by the
above methods.
Data collection and analysis
Selection of studies
Two review authors (Liesl Grobler (LG) and Sukrti Nagpal (SN)/
Thambu Sudarsanam (TS)) independently screened all citations
and abstracts identified in the search for potentially eligible stud-
ies. Full reports of potentially eligible studies were obtained and
assessed for inclusion in the review by the same authors using a pre-
designed eligibility form based on the inclusion criteria. Where
it was unclear whether a study was eligible for the review, we at-
tempted to contact the authors for clarification. We resolved dif-
ferences in opinion by discussion and, where necessary, by discus-
sion with a fourth author (David Sinclair). We screened all papers
for multiple publications. We excluded studies that did not meet
the criteria and documented the reasons for their exclusion.
Data extraction and management
Two review authors (LG and SN) independently extracted data
using a tailored data extraction form. We extracted data on study
design, participant characteristics, interventions, and outcomes.
For dichotomous data, we extracted the number of participants
with the outcome and the total number analysed. For continuous
data, we extracted the arithmetic mean and standard deviation
(SD) for each group. If medians were used, we also extracted the
ranges where possible. If there was skewed continuous data, we
planned to extract geometric means where presented by the trial
author(s). We resolved any discrepancies regarding extracted data
by discussion between the review authors.
Assessment of risk of bias in included studies
Two review authors (LG and SN) independently assessed com-
ponents of risk of bias of the included trials using the Cochrane
’Risk of bias’ assessment tool (RevMan 2014), and discussed any
differences of opinion. We followed the guidance to assess whether
adequate steps were taken to reduce the risk of bias across six do-
mains: sequence generation, allocation concealment, blinding (of
participants, personnel, and outcome assessors), incomplete out-
come data, selective outcome reporting, and other sources of bias.
We categorized our judgements as either ’low’, ’high’, or ’unclear’
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risk of bias. Where our judgment was ’unclear’, we attempted to
contact the trial authors for clarification.
Measures of treatment effect
Wecompared interventions using risk ratios (RR) for dichotomous
data, and mean difference (MD) values for continuous data. We
presented all results with 95% confidence intervals (CIs).
Unit of analysis issues
We split trials that included more than two comparison groups
and analysed them as individual pair-wise comparisons. When
we conducted meta-analysis we ensured that we did not count
participants and cases in the placebo group more than once, by
dividing the placebo cases and participants evenly between the
intervention groups.
Dealing with missing data
If data from the trial reports were insufficient, unclear, or missing,
we attempted to contact the trial authors for additional informa-
tion.
Assessment of heterogeneity
Weassessed heterogeneity amongst trials by inspectionof the forest
plots (to detect overlapping CIs), the I² statistic with a level of
50% to denote moderate levels of heterogeneity, and application
of the Chi² test with a P value of 0.10 to indicate appreciable
heterogeneity.
Assessment of reporting biases
We planned to assess the likelihood of publication bias by exam-
ining the funnel plots for asymmetry. However, there were too few
trials to make this assessment meaningful.
Data synthesis
We analysed the data using Review Manager (RevMan) (RevMan
2014).Usingpair-wisemeta-analyseswe compared the treatments.
We stratified meta-analyses by time-point or HIV status where
appropriate.
When there was no statistically significant heterogeneity we used
the fixed-effect meta-analysis model.When we observed moderate
statistically significant heterogeneity within groups that we could
not explain by subgroup or sensitivity analyses we used a random-
effects meta-analysis model to synthesize the data. When a pooled
meta-analysis result was considered to be meaningless because of
clinical or substantial statistical heterogeneity the results are pre-
sented in a forest plot without a pooled estimate of effect.
Data presented as medians and ranges are presented in tables and
described in the narrative. Highly skewed continuous data (where
the SDs were larger than the means) are only presented in tables.
Subgroup analysis and investigation of heterogeneity
Due to the small number of included trials or each comparison,
the investigation of heterogeneity was not necessary or possible. In
future updates of this Cochrane review we may perform subgroup
analyses by: HIV status, nutritional status at baseline, presence of
co-morbidities, and specific micronutrient level at baseline.
Sensitivity analysis
We have planned to perform a sensitivity analysis to investigate
the robustness of the results to the ’Risk of bias’ components.
However, there were too few included trials for each comparison
for this to be possible.
R E S U L T S
Description of studies
Results of the search
The original search (June 2008) identified 47 articles, and the
updated search (July 2011) identified a further 17 articles. The
searches conducted in December 2014 and updated in February
2016 identified 48 published articles and 16 ongoing studies. In
total the current review includes data from 39 reports, covering 35
individually randomized controlled trials (RCTs) (see Figure 1).
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Figure 1. Study flow diagram.
Included studies
Participants
The 35 trials included 8285 participants. Twenty-eight trials in-
cluded only adults being treated for pulmonary tuberculosis, and
three trials also included adults with extrapulmonary tuberculosis
(Wejse 2008 GNB; Jahnavi 2010 IND; Sudarsanam 2010 IND).
Likewise of four studies in children, one included only pulmonary
tuberculosis (Hanekom 1997 ZAF), and three also included extra-
pulmonary tuberculosis (Morcos 1998 EGY; Mehta 2011 TZA;
Lodha 2014 IND).
HIV status
Eleven trials specifically included people with HIV, and presented
some results separately for HIV positive and HIV negative partic-
ipants (Schön 2003 ETH; Range 2005 TZA; Semba 2007 MWI;
Villamor 2008 TZA; Wejse 2008 GNB; Lawson 2010 NGA;
Mehta 2011 TZA; Sudarsanam 2010 IND; Schön 2011 ETH;
Ralph 2013 IDN; Jeremiah 2014 TZA). Four of the trials that pre-
sented results forHIV-positive andHIV-negative participants sep-
arately used stratified randomization (Villamor 2008 TZA; Wejse
2008 GNB; Sudarsanam 2010 IND; Jeremiah 2014 TZA), but six
tested participants for HIV following randomization (Schön 2003
ETH; Range 2005 TZA; Semba 2007MWI; Lawson 2010 NGA;
Mehta 2011 TZA; Schön 2011 ETH), and therefore the sub-
group analyses by HIV status cannot be said to be truly random-
ized. Four trials included both HIV-positive and HIV-negative
individuals and reported on numbers but did not present results
separately (Martineau 2011 GBR; Praygod 2011a TZA; Visser
2011 ZAF; Tukvadze 2015 GEO). One trial included only HIV-
positive participants (Praygod 2011b TZA). None of the HIV-
positive participants were receiving antiretroviral treatment. One
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trial was stopped early when antiretrovirals became locally avail-
able (Semba 2007 MWI). Eleven trials excluded people with HIV
infection (Hanekom 1997 ZAF; Paton 2004 SGP; Pérez-Guzmán
2005 MEX; Nursyam 2006 IDN; Armijos 2010 MEX; Jahnavi
2010 IND; Paliliewu 2013 IDN; Lodha 2014 IND; Daley 2015
IND; Farazi 2015 IRN;Mily 2015 BGD), and eight trials did not
mention HIV infection (Morcos 1998 EGY; Karyadi 2002 IDN;
Seyedrezazadeh 2006 IRN;Martins 2009 TLS; Pakasi 2010 IDN;
Kota 2011 IND; Ginawi 2013 IND; Singh 2013 IND).
Study site
Trials were undertaken in the following locations.
• Africa: Egypt (Morcos 1998 EGY), Guinnea-Bissau (Wejse
2008 GNB), Ethiopia (Schön 2003 ETH; Schön 2011 ETH),
Tanzania (Range 2005 TZA; Villamor 2008 TZA; Mehta 2011
TZA; Praygod 2011b TZA; Praygod 2011a TZA; Jeremiah 2014
TZA), Malawi (Semba 2007 MWI), Nigeria (Lawson 2010
NGA), and South Africa (Hanekom 1997 ZAF; Visser 2011
ZAF).
• Asia: Singapore (Paton 2004 SGP), Indonesia (Karyadi
2002 IDN; Nursyam 2006 IDN; Pakasi 2010 IDN; Paliliewu
2013 IDN; Ralph 2013 IDN), Iran (Seyedrezazadeh 2006 IRN;
Farazi 2015 IRN), Bangladesh (Mily 2015 BGD), and India
(Jahnavi 2010 IND; Sudarsanam 2010 IND; Kota 2011 IND;
Ginawi 2013 IND; Singh 2013 IND; Lodha 2014 IND; Daley
2015 IND).
• Oceania: Timor Leste (Martins 2009 TLS).
• North America: Mexico (Pérez-Guzmán 2005 MEX;
Armijos 2010 MEX).
• Europe: UK (Martineau 2011 GBR) and Georgia
(Tukvadze 2015 GEO).
Interventions
Seven trials assessed macronutrient supplementation (Paton 2004
SGP; Pérez-Guzmán 2005 MEX; Martins 2009 TLS; Jahnavi
2010 IND; Sudarsanam 2010 IND; Praygod 2011b TZA;
Jeremiah 2014 TZA), six trials assessed multi-micronutrient sup-
plementation (Range 2005 TZA; Semba 2007 MWI; Villamor
2008 TZA; Mehta 2011 TZA; Praygod 2011a TZA; Lodha 2014
IND), and 21 trials assessed single or dual micronutrient supple-
mentation. The remaining trial assessed the effect of supplemen-
tation with Channa striata capsules (Paliliewu 2013 IDN). C. stri-
ata is a fresh-water fish found in most tropical and subtropical
countries.
Sample size
Eleven of the 35 trials included less than 100 participants in their
final analysis. To aid interpretation and inform future research we
have calculated the optimal sample size to reliably demonstrate
some suggested clinically important results (Appendix 3; Appendix
4).
As micronutrients are a cheap and easily administered interven-
tion, even a small effect on tuberculosis treatment outcomes might
be considered clinically important. For example, to demonstrate a
reduction in death from the worldwide average of 5% to just 4%
(a relative risk reduction of 20%); a sample size of over 13,000
participants would be necessary. This is far above the data included
in this Cochrane Review. Similarly an increase in successful cure
rate from 80% to 84% would require almost 3000 participants.
For full details of the included trials see the ’Characteristics of
included studies’ table.
Excluded studies
We excluded 17 studies that we had thought were eligible after ini-
tial screening for the reasonswe have given in the ’Characteristics of
excluded studies’ table. Five trials are currently awaiting classifica-
tion pending further information from the author (Chandra 2004;
Guzman-Rivero 2013; Nagrale 2013; Nawas 2013; Al Mamun
2014). In addition we are aware of 17 potentially relevant ongoing
or unpublished trials; see the ’Characteristics of ongoing studies’
table.
Risk of bias in included studies
We have displayed the ’Risk of bias’ assessments in a table and
summarised these results in Figure 2.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included study.
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Allocation
Twenty-four trials described an adequate method of generating
a truly random allocation sequence (Karyadi 2002 IDN; Schön
2003 ETH; Paton 2004 SGP; Range 2005 TZA; Semba 2007
MWI; Villamor 2008 TZA; Wejse 2008 GNB; Martins 2009
TLS; Lawson 2010 NGA; Pakasi 2010 IDN; Sudarsanam 2010
IND; Martineau 2011 GBR; Mehta 2011 TZA; Praygod 2011a
TZA; Praygod 2011b TZA; Schön 2011 ETH; Visser 2011 ZAF;
Ralph 2013 IDN; Jeremiah 2014 TZA; Lodha 2014 IND; Daley
2015 IND; Farazi 2015 IRN; Mily 2015 BGD; Tukvadze 2015
GEO). The other trials did not report how the random sequences
were generated although all were described as “randomized”.
Eighteen trials described an adequate method of ensuring alloca-
tion concealment (Schön 2003 ETH; Semba 2007 MWI; Wejse
2008 GNB;Martins 2009 TLS; Lawson 2010 NGA; Sudarsanam
2010 IND; Martineau 2011 GBR; Mehta 2011 TZA; Praygod
2011a TZA; Praygod 2011b TZA; Schön 2011 ETH; Visser 2011
ZAF; Ralph 2013 IDN; Lodha 2014 IND; Daley 2015 IND;
Farazi 2015 IRN; Mily 2015 BGD; Tukvadze 2015 GEO). The
other trials did not provide sufficient information to determine if
the allocation sequence was truly concealed from the person allo-
cating participants to the treatment groups.
Blinding
It is generally not possible to blind patients to macronutrient sup-
plementation. However, it is possible to blind the outcome asses-
sors but only one of the six studies reports an attempt to do this
(Martins 2009 TLS).
Twenty-one of the 27 trials assessing micronutrients used placebos
and adequately blinded participants and study staff to be consid-
ered at low risk of bias.
Incomplete outcome data
We considered 12 studies at high risk of bias for some outcomes
due to high losses to follow-up (that is, loss to follow-up > 10%
overall, between groups or within a group (Hanekom 1997 ZAF;
Karyadi 2002 IDN; Paton 2004 SGP; Range 2005 TZA; Semba
2007 MWI; Martins 2009 TLS; Pakasi 2010 IDN; Sudarsanam
2010 IND; Visser 2011 ZAF; Ginawi 2013 IND; Jeremiah 2014
TZA; Tukvadze 2015 GEO).
Selective reporting
Although treatment outcomes in tuberculosis such as cure, and
treatment completion are well established in tuberculosis pro-
grammes only one trial reported cure (Sudarsanam 2010 IND),
and five reported treatment completion (Martins 2009 TLS;
Jahnavi 2010 IND; Pakasi 2010 IDN; Sudarsanam 2010 IND;
Farazi 2015 IRN). We were unable to retrieve trial protocols.
Other potential sources of bias
One trial did not adequately describe baseline nutritional status
(Morcos 1998 EGY), one trial had a large imbalance inHIV status
at baseline (Mehta 2011 TZA), and one trial had appreciable dif-
ference in both HIV status and severity of chest X-ray at baseline
(Ralph 2013 IDN).
Effects of interventions
See: Summary of findings for the main comparison ’Summary
of findings’ table 1; Summary of findings 2 ’Summary of findings’
table 2
1. Macronutrients
1.1 Increased energy supplementation (average daily
requirement for a male adult: 2500 kcal)
Six trials examined the effects of providing macronutrient supple-
ments through the health service.
• In Timor Leste, adults with pulmonary tuberculosis and a
mean weight of 43.3 kg (31% of participants had a BMI of less
than 16 kg/m²) were randomized to nutritional advice plus a
daily cooked meal or nutritional advice alone (Martins 2009
TLS). The daily midday meal (administered for two months
during the intensive phase) consisted of a bowl of meat, kidney
beans, and vegetable stew with rice. During the continuation
phase participants in the supplement group also received a
weekly food parcel containing unprepared red kidney beans, rice,
and oil adequate for one meal per day.
• In India, adults with pulmonary tuberculosis and a BMI of
less than 19 kg/m² were randomized to receive a macronutrient
and micronutrient supplement plus standard care versus
standard care alone (Sudarsanam 2010 IND). The supplement
consisted of three daily servings of a cereal and lentil mixture
(providing 930 kcal and 31.5 g protein) and a once-a-day
multivitamin tablet. Participants were given a month’s supply of
supplement at a time.
• The remaining four trials compared daily high energy
supplements with: nutritional advice alone (Paton 2004 SGP;
Jahnavi 2010 IND); a single multi-micronutrient biscuit
(Praygod 2011b TZA); or no supplement (Jeremiah 2014 TZA).
The supplements were described as ’sweetballs’ (made from
wheat flour, caramel, ground nuts, and vegetable ghee) (Jahnavi
2010 IND), high energy ’packets’ (Paton 2004 SGP), and high
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energy ’biscuits’ (Praygod 2011b TZA; Jeremiah 2014 TZA) (see
Appendix 5). None of the studies estimated the total daily energy
intake, but the supplement provided between 600 and 3690 kcal
per day on top of the regular diet. All four studies recruited
people with mean BMI below 20 kg/m².
Only two trials measured total dietary intake. Both trials con-
firmed that supplementation had increased nutritional intake
compared to dietary advice alone, and not simply substituted food
that patients might have obtained elsewhere (Paton 2004 SGP;
Sudarsanam 2010 IND).
Tuberculosis treatment outcomes
The number of deaths reported from these trials was very low, and
trials were too small to reliably detect or exclude important differ-
ences in mortality (risk ratio (RR) 0.34, 95% confidence interval
(CI) 0.10 to 1.20; four trials, 567 participants; Analysis 1.1), or
cure (RR 0.91, 95% CI 0.59 to 1.41; one trial, 102 participants;
Analysis 1.2). Jahnavi 2010 IND found a statistically significant
difference in treatment completion in favour of supplementation,
but this was not seen in the larger trial conducted in Timor Leste
(two trials, 365 participants, Analysis 1.3).
Jahnavi 2010 IND also found that more participants given sup-
plements were smear negative at eight weeks, while Martins 2009
TLS and Jeremiah 2014 TZA found no statistically significant
difference (RR 1.08, 95% CI 0.86 to 1.37; three trials, 222 par-
ticipants; Analysis 1.4).
Nutritional recovery and quality of life
Effects on weight gain were mixed (five trials, 689 participants,
Analysis 1.5). The daily hot meal was associated with an extra 1.7
kgweight gain at eightweeks (95%CI 0.1 to 3.2; P = 0.04; authors’
own figures), and 2.6 kg at eight months (95% CI 0.1 to 5.2;
P = 0.04; authors’ own figures; Martins 2009 TLS), whereas the
monthly ration packwas not associatedwith important differences
(change in lean body mass, and percentage body fat were not
significantly different between groups; P = 0.479 and P = 0.573
respectively; authors’ own figures; Sudarsanam 2010 IND).
Of the trials evaluating high energy supplements, the two smaller
trials in HIV-negative participants found that supplementation
resulted in significantly more weight gain than advice alone at six
weeks (MD 1.73 kg, 95% CI 0.81 to 2.65; one trial, 34 partici-
pants; Analysis 1.5) and 12 weeks, respectively (MD 2.6 kg, 95%
CI 1.74 to 3.46; one trial, 100 participants; Analysis 1.5). Paton
2004 SGP further quantified this as an increase in lean body mass
(MD 1.13 kg, 95% CI 0.37 to 1.89; one trial, 34 participants),
with no significant difference in total fat mass. However, in Tanza-
nia Praygod 2011b TZA found no significant difference in weight
gain with supplementation in HIV-positive participants at eight
or 20 weeks (one trial, 332 participants, Analysis 1.5). Similarly,
Jeremiah 2014 TZA found no difference in final mean weight be-
tween the supplement and no supplement group after twomonths
of supplementation (one trial, 92 participants, Analysis 1.5).
Three trials of high energy supplements (Paton 2004 SGP; Jahnavi
2010 IND; Praygod 2011b TZA) report changes in maximum
grip strength, and again a statistically significant benefit was seen
in the small trials of HIV-negative participants but not the larger
trial of HIV-positive participants although the data appear skewed
(three trials, 466 participants, Analysis 1.6).
Jahnavi 2010 IND and Paton 2004 SGP also reported that the
benefits on weight gain and grip strength were accompanied by
improvements in some quality of life scores. It was not possible to
assess whether these difference were statistically significant because
the data appeared highly skewed (the SDs were larger than the
means for most outcomes); see Analysis 1.7 and Appendix 6.
1.2 Altered dietary composition
One very small trial of 21 participants compared a high cholesterol
diet (2500kcal per daywith 800mg cholesterol per day)with a diet
with a similar nutritional profile but lower in cholesterol (2500kcal
per day with 250 mg cholesterol per day) for eight weeks in adults
being treated for sputum-culture positive pulmonary tuberculosis
(Pérez-Guzmán 2005 MEX).
Tuberculosis treatment outcomes
This trial did not report on death, cure, or treatment completion.
Fewer participants in the high cholesterol group were still sputum-
culture positive at two weeks compared with those in the normal
cholesterol group (RR of remaining sputum positive at two weeks
0.22, 95%CI0.06 to 0.77; one trial, 20 participants, Analysis 2.1),
the difference was not significant at four weeks, and at eight weeks
all participants in both groups were sputum-culture negative. Self
reported cough and dyspnoea are reported to have decreased at
the same rate in both groups (figures not given).
Nutritional recovery and quality of life
This trial did not report on any aspect of the participant’s nutri-
tional recovery or quality of life.
2. Micronutrients
2.1 Multivitamins and trace elements
Four trials in adults being treated for sputum test positive or neg-
ative pulmonary tuberculosis (Range 2005 TZA; Semba 2007
MWI; Villamor 2008 TZA; Praygod 2011a TZA) and two tri-
als in children (Mehta 2011 TZA; Lodha 2014 IND) compared
daily multiple micronutrient supplements (containing a range of
vitamins and trace elements), with placebo. The exact doses of the
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individual constituents ranged from one to 10 times the dietary
reference intake (DRI), and are given in Appendix 1. In summary:
vitamin A (1 to 3 x DRI), B vitamins (1 to 10 x DRI), vitamin C
(1 to 5 x DRI), vitamin D (approximately 1 x DRI), vitamin E (1
to 10 x DRI), zinc (1 to 5 x DRI), and selenium (1 to 4 x DRI).
In two trials participants received daily supplements for two
months (Mehta 2011 TZA; Praygod 2011a TZA), one trial for
six months (Lodha 2014 IND), one trial for eight months (Range
2005 TZA), and in two trials they received daily supplements for
24 months (Semba 2007 MWI; Villamor 2008 TZA).
Tuberculosis treatment outcomes
In trials with HIV negative people the number of deaths from
tuberculosis was low and the trials substantially underpowered to
demonstrate an effect, Consequently, the 95% CI is wide and in-
cludes clinically important benefit and harm (RR 0.86, 95% CI
0.46 to 1.60, four trials, 1219 participants, Analysis 3.1). Deaths
were more common in trials with HIV positive people not taking
antiretroviral therapy, but again no differences between micronu-
trients and placebo were demonstrated (RR 0.92, 95% CI 0.69 to
1.23, three trials, 1429 participants, Analysis 3.1).
Lodha 2014 IND reported no difference in tuberculosis treatment
completion at six months betweenmicronutrients (with and with-
out zinc) and placebo (one trial, 302 participants, Analysis 3.2).
There was no statistically significant difference between the sup-
plement and control groups in the numbers of participants who
remained sputum-culture or sputum-smear positive at one month
(two trials, 1020 participants, Analysis 3.3) or two months (two
trials, 731 participants, Analysis 3.4).
Lodha 2014 IND and Mehta 2011 TZA reported no apprecia-
ble difference in chest x-ray clearance (after two or six months
of supplementation) between the supplemented children and the
placebo children at follow-up (two trials, 497 participants, Anal-
ysis 3.5).
Nutritional recovery and quality of life
Five trials reported changes in weight or body mass using a variety
of parameters, and only Range 2005 TZA reported statistically
significant effects (see Table 1).
Range 2005 TZA found that participants receiving multiple mi-
cronutrients had gained significantly more weight at sevenmonths
than those in the placebo group. This was a 2 x 2 factorial study
and the difference in weight was appreciable in both treatment
groups compared to placebo. In the treatment arm that received
both high dose multivitamins and high dose zinc, the weight gain
appeared clinically important (MD2.37 kg, 95%CI 2.21 to 2.53;
one trial, 192 participants, Analysis 3.6). However, in the treat-
ment arm that received high-dose multivitamins alone, the weight
gain was minimal (MD 0.30 kg, 95% CI 0.17 to 0.43; one trial,
198 participants, Analysis 3.6). In Lodha 2014 IND, multi-mi-
cronutrient supplementation with or without zinc did not consis-
tently alter children’s weight, BMI-for-age z score or height-for-
age z score (one trial, 198 participants; Analysis 3.7).
One study, Praygod 2011a TZA, found an appreciable improve-
ment in mean handgrip strength at two months but not five
months (mean difference (change in handgrip strength) 1.22 kg,
95% CI 0.49 to 1.95; one trial, 771 participants; Analysis 3.8).
The clinical importance of this difference is unclear. Consistent
with the change in weight, this increase was only present in HIV-
negative participants.
2.2 Individual micronutrients
Vitamin A (DRI: 900 µg/3000 IU per day)
Supplement dosing regimes
Three trials directly compared vitamin A given alone versus
placebo (Ginawi 2013 IND: vitamin A 5000 IU; Hanekom 1997
ZAF: vitamin A 200,000 IU on Day 0 and Day 1; Pakasi 2010
IDN: vitamin A 5000 IU daily). In addition, seven trials com-
bined vitamin Awith zinc (see Comparison 6: Zinc plus vitamin A
versus placebo), and five studies gave vitamin A as part of a multi-
micronutrient supplement (see Comparison 3: Multivitamin and
trace element tablets versus placebo).
Serum vitamin A concentrations at baseline and follow-up
Seven studies report on measures of vitamin A status, but Pakasi
2010 IDN and Visser 2011 ZAF reported data as median plasma
levels so could not be included in the meta-analysis, and Semba
2007 MWI only presented data graphically (see Table 2). Only
Semba 2007 MWI reports a difference that was statistically sig-
nificant in favour of supplements, but this difference (at eight
months) is unlikely to be of clinical significance.
In four trials in adults and one in children, mean serum vitamin A
level substantially increased in both intervention and control arms
regardless of supplementation, and there was no statistically sig-
nificant difference between the groups (one trial, 85 participants;
Analysis 4.1; three trials, 242 participants; Analysis 4.2; Table 2).
Tuberculosis treatment outcomes
Supplementation with vitamin A alone or in combination with
other micronutrients appears to have little or no effect on mortal-
ity (eight trials, 3308 participants; Analysis 4.3), but these trials,
even the larger ones, were significantly underpowered to rule out
a clinically important effect.
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Only Pakasi 2010 IDN reported on treatment completion and
found no statistically significant effect (one trial, 158 participants,
Analysis 4.4). Hanekom 1997 ZAF reported that more children
in the supplement group remained symptomatic after six weeks of
tuberculosis treatment than in the control group, but this was not
statistically significant (one trial, 76 participants, Analysis 4.5).
The trial authors also reported no statistically significant differ-
ences in respiratory symptoms at three months, or in chest x-ray
resolution; but specific data on these outcomes were not provided.
Supplementation with vitamin A alone had no effect on the num-
ber of participants who were sputum smear negative after two
weeks, one month, or two months (two trials, 224 participants,
Analysis 4.6). Pakasi 2010 IDN reported that all participants in
the vitaminA and placebo armwere smear negative at twomonths.
Nutritional recovery and quality of life
Hanekom1997ZAF reported that themeanweight z score at base-
line was −1.41 (SD 1.41) in the supplement group, and −1.44
(SD 1.34) in the placebo group (it is unclear whether this is weight
for age or weight for height). The trial authors also reported that
no statistically significant differences in change-in-weight z scores
were recorded at any time-point, but the specific data for this out-
come was not provided.
Pakasi 2010 IDN reports that the mean BMI at baseline was 16.5
kg/m² (SD 2.2) in the supplement group and 16.4 kg/m² (SD
2.5) in the placebo group. There was no statistically significant
difference in mean BMI between groups at two or six months
(one trial, 158 participants, Analysis 4.7). Pakasi 2010 IDN also
reported that there were no statistically significant differences in
mid upper arm circumference (MUAC) or percentage body fat
(Analysis 4.8).
Zinc (DRI: 11 mg/day)
Supplement dosing regimes
Five trials directly compared daily zinc given alone versus placebo
(Ginawi 2013 IND: 15mg zinc sulphate; Lodha 2014 IND: 20mg
elemental zinc; Range 2005 TZA: zinc 45 mg daily; Lawson 2010
NGA: 90mg elemental zinc weekly; Pakasi 2010 IDN: 15 mg zinc
sulphate daily). In addition, seven trials combined vitamin A with
zinc (see Comparison 6: zinc plus vitamin A versus placebo), and
four trials gave zinc as part of a multi-micronutrient supplement
(see comparison 3: Multivitamin and trace element tablets versus
placebo).
Serum zinc concentrations at baseline and follow-up
Five studies report mean plasma zinc levels at baseline and during
follow-up (see Table 3). Pakasi 2010 IDN and Armijos 2010MEX
reportmean zinc levelswithin the normal range at baseline.Ginawi
2013 IND and Karyadi 2002 IDN reported that 30% of the
participants had low zinc levels (less than 10.7 µmol/L) and in
Lodha 2014 IND approximately 50% of the participants had zinc
levels greater than 65 µg/dL.
Overall, daily supplementationwith zinc sulphate increased serum
zinc concentrations after two months and six months compared
to placebo (four trials, 472 participants, Analysis 5.1; Table 3),
with more consistent effects at six months.
Tuberculosis treatment outcomes
No effect on mortality has been seen with zinc alone or in combi-
nation with other micronutrients (seven trials, 2862 participants,
Analysis 5.2, Analysis 5.3). These trials, even the larger ones, are
significantly underpowered to rule out a clinically important ef-
fect.
There was no appreciable differences in treatment completion be-
tween the zinc alone and placebo groups (two trials, 353 partic-
ipants, Analysis 5.4), and there were no differences between the
groups in the numbers who remained sputum-culture positive at
four weeks (three trials, 783 participants, Analysis 5.5) or eight
weeks (five trials, 1076 participants, Analysis 5.5). Furthermore,
Lodha 2014 IND reports no difference in chest X-ray clearance
after six months between the zinc and placebo groups (one trial,
201 participants, Analysis 5.6).
Nutritional recovery and quality of life
One trial in children in India found no difference in mean weight
(kg), weight-for-age z score, BMI-for-age z score or height-for-
age z score after two months or six months supplementation with
zinc alone (one trial, 201 participants, Analysis 5.7; Analysis 5.10;
Analysis 5.11; Analysis 5.12). Similarly, Pakasi 2010 IDN found
no difference inBMI or body fat (%) in adults at two or sixmonths
(one trial, 162 participants, Analysis 5.8 and Analysis 5.9; Pakasi
2010 IDN), and Lawson 2010 NGA presented data on changes in
BMI graphically, and BMI appeared to improve at the same rate
in all groups (Lawson 2010 NGA).
Range 2005 TZA reported a very small but statistically signifi-
cant decrease in weight gain with supplementation compared to
placebo (MD −0.21 kg, 95% CI −0.36 to −0.06; one trial 183
participants; Analysis 5.7).
Vitamin A plus zinc (DRI: vitamin A 900 µg/3000 IU, zinc
11 mg per day)
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Supplement dosing regimes
Seven studies in adults with sputum positive pulmonary tuber-
culosis compared the combination of vitamin A and zinc versus
placebo (Ginawi 2013 IND: vitamin A 5000 IU and 15 mg zinc
sulphate; Singh 2013 IND: 25000 IU vitamin A and 50 mg zinc
sulphate, once daily for 10 days and then thrice weekly until six
months; Karyadi 2002 IDN: vitamin A 5000 IU and zinc 15 mg
daily for six months; Armijos 2010 MEX: vitamin A 5000 IU plus
zinc 50 mg daily for four months; Lawson 2010 NGA: vitamin
A 5000 IU/day plus 90 mg elemental zinc/week for six months;
Pakasi 2010 IDN: vitamin A 5000 IU plus 15 mg zinc sulphate
daily for six months; Visser 2011 ZAF: vitamin A 100,000 IU at
baseline plus zinc 15 mg for five days per week for two months).
Tuberculosis treatment outcomes
Four trials reported on deaths that occurred during the trial. In
HIV negative participants there were no statistically significant
differences in risk of death between those who received zinc and
vitamin A or placebo (four trials, 430 participants, Analysis 6.1),
but in HIV-positive participants the effect did reach statistical
significance (RR 5.94, 95% CI 1.07 to 32.96; two trials, 136
participants; Analysis 6.1). However, both of these analyses are
substantially underpowered to have confidence in these effects.
Only Pakasi 2010 IDN reported on treatment completion and
found no statistically significant difference between the groups
(one trial, 152 participants; Analysis 6.2). Overall, there is no
statistically significant difference between supplementation and
placebo in the number of participants who remain sputum-smear
positive at one month or two months (seven trials, 726 partic-
ipants, Analysis 6.3). One study, Armijos 2010 MEX, did find
a statistically significant difference in sputum positivity at three
months in favour of supplementation (RR 0.12, 95% CI 0.02 to
0.84; one trial, 33 participants; Analysis 6.3), but the difference
was not significant at two or four months. Visser 2011 ZAF found
no statistically significant difference in time to smear or culture
conversion (one trial, 154 participants; P = 0.15 and P = 0.38
respectively, authors’ own figures).
Nutritional recovery and quality of life
Karyadi 2002 IDN reported a statistically significant increase in
mean body weight at six months (MD 3.10 kg, 95% CI 0.74 to
5.46; one trial, 80 participants; Analysis 6.4), but there were no
differences in any other nutritional parameters (see Table 4 and
Analysis 6.5; Analysis 6.6; Analysis 6.7; Analysis 6.8; Analysis 6.9;
Analysis 6.10; Analysis 6.11; Analysis 6.12). There was no sta-
tistically significant differences between intervention and control
arms in any of the other three trials that reported changes in BMI
or weight.
Two trials reported on changes in Karnofsy score, a rating scale
of a person’s ability to perform activities of daily living ranging
from 0 (dead) to 100 (normal). Karyadi 2002 IDN reported that
supplementation resulted in a small but statistically significant
difference in Karnofsky score at six months (MD 2.5%, 95%
CI 0.91 to 4.09; one trial 80 participants; Analysis 6.13), while
Lawson 2010 NGA found no difference at two or six months but
only presented data graphically (one trial, 233 participants). A
difference in Karnofsky score of 2.5% is unlikely to be of clinical
significance.
Vitamin D (DRI for adults: 5 to 15 µg/200 to 600 IU per
day)
Supplement dosing regimes
Eight trials evaluated vitamin D supplementation versus placebo:
Morcos 1998 EGY: 1000 IU daily for eight weeks; Nursyam 2006
IDN: 250 µg daily for six weeks; Ralph 2013 IDN: 50,000 IU
daily for eight weeks; Mily 2015 BGD: 5000 IU daily for eight
weeks; Tukvadze 2015 GEO: 50000 IU three times a week for
eight weeks, then every two weeks for eight weeks; Wejse 2008
GNB: 100,000 IU at 0, 5, and 8 months; Daley 2015 IND and
Martineau 2011 GBR: 2.5 mg on days 0, 14, 28, and 42).
In addition, one trial evaluated vitamin D combined with arginine
(Ralph 2013 IDN: 50,000 IU plus arginine 6 g daily for eight
weeks), two trials evaluated vitamin D combined with calcium
(Singh 2013 IND: 250 IU plus calcium 500 mg daily for 10 days
then three times a week; Kota 2011 IND: 60,000 IU per week
plus calcium 1000 mg per day for 3 months), and four trials of
multi-micronutrients included vitamin D in standard daily doses
(see comparison 3).
Vitamin D levels at baseline and follow-up (deficient ≤ 50
nmol/L, and insufficient ≤ 75 nmol/L)
Seven trials reported vitamin D status at baseline and during fol-
low-up, although only four trials provided data that we could in-
clude in a meta-analysis of the effect of Vitamin D supplementa-
tion on Vitamin D levels at follow-up (see Analysis 7.1; Table 5).
In four studies where the mean serum vitamin D levels were in
the deficient range at baseline, there were large improvements at
eight weekswith vitaminDcompared to placebo (Martineau 2011
GBR:MD78.60, 95%CI 54.17 to 103.03; Kota 2011 IND:MD
28.00, 95% CI 20.29 to 35.71; Mily 2015 BGD and Tukvadze
2015 GEO presented graphically, see Table 5). In two additional
studies where themean serum vitamin D levels were in the normal
or insufficient range at baseline, there were no statistically signifi-
cant differences at eight weeks (Wejse 2008 GNB:MD 2.00, 95%
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CI −7.76 to 11.76), or six months (Daley 2015 IND: MD 8.60,
95%CI −6.29 to 23.49).
Tuberculosis treatment outcomes
There were no statistically significant differences in the number
of deaths between those receiving vitamin D (any formulation) or
placebo regardless of HIV status (seven trials, 2649 participants,
Analysis 7.2; Analysis 7.3).
Only Ralph 2013 IDN reported on cure, for which there was no
statistically significant difference between the vitamin D and the
placebo groups (one trial, 76 participants, Analysis 7.4). Wejse
2008 GNB also found no statistically significant difference in re-
covery, as defined by a newly developed tuberculosis scoring sys-
tem (one trial, 348 participants, Analysis 7.5). This system rates
the patient’s condition on a scale of zero to 13, based on signs and
symptoms and anthropometric measurements (Wesje 2008).
Overall, there were no statistically significant differences in the
proportion of people that remained sputum positive at any time
point from four weeks to eight months (seven trials, 1197 partici-
pants, Analysis 7.6). One trial of daily supplementation, Nursyam
2006 IDN, showed a statistically significant difference in the pro-
portion of participants who remained sputum positive at six weeks
(RR 0.06, 95% CI 0.00 to 0.95; one trial, 67 participants, Anal-
ysis 7.6); but the difference was not significant two weeks later.
One additional trial, Kota 2011 IND, also reported finding a sta-
tistically significant difference but only presented the P value (P =
0.067).
Nutritional recovery and quality of life
There were no statistically significant differences in mean BMI
after six to eight weeks of supplementation (four trials, 430 par-
ticipants, Analysis 7.7), or in mean body weight (two trials, 150
participants, Analysis 7.8). Wejse 2008 GNB also reported no sta-
tistically significant difference in weight gain at eight months but
only reported the P value (one trial, 359 participants, P = 0.9, au-
thors’ own figures), and Ralph 2013 IDN reported no statistically
significant difference in the proportions gaining less than 5%, 5%
to 9.9%, or greater than 10% weight.
Daley 2015 IND reported that mean Karnofsky score increased
in both groups, with no statistically significant difference at eight
weeks (one trial, 212 participants, Analysis 7.9).
Adverse events
Five trials reported adverse events, which we have summarized in
Table 6. There were no important differences in reported adverse
events between the supplemented and the placebo groups.
Vitamin E and selenium capsules (DRI: vitamin E 15 mg,
selenium 55 µg per day)
One trial compared a daily vitamin E (140 mg) and selenium
(200 µg) supplement with placebo in adults being treated for spu-
tum-smear positive pulmonary tuberculosis (Seyedrezazadeh 2006
IRN).
The trial authors reported the median plasma vitamin E and se-
lenium levels at baseline and at eight weeks. They reported that
the median level of both micronutrients rose in the supplement
group and decreased in the placebo group. We were unable to
assess whether these differences between groups were statistically
significant (Appendix 8). In addition, one study that gave multi-
micronutrients, including vitamin E (133 mg) and selenium (65
µg), measured the vitamin E and selenium levels at baseline and
during follow-up (Semba 2007 MWI). The trial authors reported
that both vitamin E and selenium levelswere “significantly higher”
in the supplement group after eight months, but only presented
the data graphically.
Tuberculosis treatment outcomes
No deaths were reported and this trial did not report cure or
treatment completion.
There was no statistically significant difference between the sup-
plement and placebo groups in the numbers of participants who
were sputum-smear positive at 15, 30, 45, and 60 days after the
start of antituberculous treatment (one trial, 35 participants, Anal-
ysis 9.1).
Nutritional recovery and quality of life
The trial authors reported a ’constant increment’ in BMI for the
two months of treatment with no statistically significant differ-
ences between the groups, but did not present these data.
Arginine (currently considered a conditionally essential
amino acid, depending on the developmental stage and
health status of the individual)
Four trials compared daily supplementation with arginine (1 mg
daily: Schön 2003 ETH and Schön 2011 ETH; 1000 mg twice
daily for 30 days: Farazi 2015 IRN; and 6mg daily for eight weeks:
Ralph 2013 IDN) with either placebo (Schön 2003 ETH; Ralph
2013 IDN; Farazi 2015 IRN) or a biscuit that contained trace
amounts of arginine (0.1 mg arginine, Schön 2011 ETH). The
trials were all conducted in adults being treated for smear-positive
pulmonary tuberculosis. Farazi 2015 IRN only included HIV-
negative participants. The percentage ofHIV-positive participants
in the other three trials ranged from 13% (Ralph 2013 IDN) to
52% (Schön 2003 ETH).
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Tuberculosis treatment outcomes
The included trials reported a total of 12 deaths. There was no
significant difference in the risk of death between the arginine sup-
plemented group and the placebo group (three trials, 394 partici-
pants, Analysis 8.1). There was also no significant difference in the
proportion of participants who were cured (two trials, 279 partic-
ipants, Analysis 8.2), or sputum smear or culture positive at four
or eight weeks of follow-up (four trials, 464 participants, Analysis
8.3). Schön 2003 ETH reported a statistically significant increase
in sputum-smear conversion in HIV-negative participants receiv-
ing arginine; however, our analysis of the data showed a non-sig-
nificant difference between groups in the numbers of participants
still sputum-smear positive at eight weeks (one trial, 56 partici-
pants, Analysis 8.3).
At two weeks Schön 2003 ETH reported that compared to the
placebo group, fewer HIV-negative participants in the arginine
group reported cough (RR0.71, 95%CI 0.53 to 0.96; one trial, 56
participants, Analysis 8.4). Similarly, at eight weeks significantly
fewer participants in the arginine group reported cough compared
to those in the placebo group (RR 0.78, 95% CI 0.61 to 0.99;
three trials, 348 participants, Analysis 8.4); this difference should
be viewed with caution as only Farazi 2015 IRN provided base-
line data that showed no difference in cough symptoms between
groups.
Nutritional recovery and quality of life
In two studies there was no significant difference in weight gain
(Schön 2003 ETH only presented the data graphically) or the pro-
portion of participants with weight gain greater than 10% (Schön
2011 ETH; one trial, 170 participants, Analysis 8.5) between the
arginine and placebo or low arginine groups. In a recent study,
arginine supplementation significantly reduced the number of par-
ticipants with a BMI of less than 18.5 after one (P = 0.032) and
two (P = 0.04) months of antituberculous treatment compared to
placebo (Farazi 2015 IRN).
3. Other trials
One small trial compared supplementation withC. striata capsules
(6 g per day), for four months, with organoleptically-matched
placebo on sputum and cytokine conversion in 36 HIV-negative
participants with sputum smear positive pulmonary tuberculosis
(Paliliewu 2013 IDN).
Tuberculosis treatment outcomes
This trial did not report on death, cure, or treatment completion.
The rate of sputum smear conversion was greater in the supple-
mented group compared to placebo group. However, these dif-
ferences were not statistically significant at any of the time points
measured.
Nutritional recovery and quality of life
This outcome was not reported.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Multi-micronutrient supplementation compared with placebo for patients with active tuberculosis
Patient or population: adults and children with act ive tuberculosis
Settings: low- and middle-income countries
Intervention: mult i-m icronutrient supplements
Comparison: placebo or no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Multi-micronutrients
Death HIV-negative participants RR 0.86
(0.46 to 1.6)
1219
(4 trials)
⊕⊕©©
low1,2,3
Mult i-m icronu-
trient supplements may
have lit t le or no ef fect
on mortality in HIV-neg-
at ive tuberculosis pa-
t ients
40 per 1000 34 per 1000
(18 to 64)
HIV-positive participants RR 0.92
(0.69 to 1.23)
1429
(3 trials)
⊕⊕⊕©
moderate4,5
Mult i-m icronutrients
probably have lit t le or
no ef fect on mortality in
HIV-posit ive tuberculo-
sis pat ients not on ARV
therapy
357 per 1000 328 per 1000
(246 to 439)
Cure rate - - - (0 trials) - We don’t know if mult i-
m icronutrients improve
cure in tuberculosis pa-
t ients
Treatment completion 970 per 1000 960 per 1000
(920 to 101)
RR 0.99 (0.95 to 1.04) 302
(1 trial)
⊕©©©
very low6,7
We don’t know if mult i-
m icronutrients improve
treatment complet ion
in tuberculosis pat ients
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Remaining sputum
positive
(at 4 weeks)
309 per 1000 312 per 1000
(263 to 371)
RR 0.92
(0.63 to 1.35)
1020
(2 studies)
⊕©©©
very low8,9,10
We don’t know if mult i-
m icronutrients reduce
the proport ion of pa-
t ients st ill sputum posi-
t ive at 4 weeks
Weight gain - - Not pooled 2940
(5 trials)
⊕⊕©©
low11
Mult i-m icronu-
trient supplements may
not improve weight gain
in tuberculosis pat ients
Quality of life - - - (0 trials) - We don’t know if mult i-
m icronutrients improve
quality of lif e in tuber-
culosis pat ients
* The assumed risk is taken f rom the risk in the control groups of the included studies. The corresponding risk (and its 95%CI) is based on the assumed risk in the comparison
group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: CI = conf idence interval; RR = risk rat io; GRADE = Grading of Recommendations Assessment, Development and Evaluat ion
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1Five RCTs comparing mult i-m icronutrient supplementat ion with placebo in adults (Range 2005 TZA; Semba 2007 MWI;
Villamor 2008 TZA) and children (Lodha 2014 IND; Mehta 2011 TZA), reported deaths during treatment. The exact
composit ion of nutrients varied f rom 1 to 10 t imes the DRI. Three studies are f rom Tanzania, 1 f rom Malawi, and 1 f rom
India. There is evidence of part icipants being signif icant ly undernourished at baseline.
2No serious inconsistency: stat ist ical heterogeneity was low. Although the est imate of ef fect is trending towards a benef it
this is due to 1 trial (Villamor 2008 TZA), the remaining trials found non signif icant trends in the opposite direct ion. Not
downgraded.
3Downgraded by 2 for imprecision: the 95% CI of the pooled ef fect crosses 1 and includes a 2% absolute reduct ion in death
which might be considered benef icial given the low cost of the intervent ion. The opt imal information size to reliably detect a
clinically benef icial ef fect if there is 1 is greater than 2000.
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4Downgraded by 1 for indirectness: none of the part icipants in these trials were receiving ant iretroviral therapy (Range 2005
TZA; Semba 2007 MWI; Villamor 2008 TZA). The exact composit ion of nutrients varied f rom 1 to 10 t imes the DRI. Two studies
are f rom Tanzania and 1 in Malawi. There is evidence of part icipants being signif icant ly undernourished at baseline.
5No serious imprecision: the 95%CI of the pooled ef fect crosses 1 and does includes a 5% absolute reduct ion in death which
might be considered benef icial given the low cost of the intervent ion. However, the ef fect est imate is of no dif ference between
the treatments and the opt imal information size to reliably detect a clinically benef icial ef fect is met.
6Downgraded by 2 for indirectness: current evidence is lim ited to 1 small t rial (Lodha 2014 IND) conducted in moderately
undernourished, HIV-negat ive children in India, where treatment complet ion was very high in both groups. The result is not
easily generalized to other sett ings.
7Downgraded by 1 for imprecision: although this trial approaches adequate power to detect a result , the fact that treatment
complet ion was so high in both arm renders the result irrelevant to sett ings where treatment complet ion is lower.
8Downgraded by 1 for inconsistency. Stat ist ical heterogeneity is high; 1 study found a non-signif icant trend in favour of
supplementat ion, and 1 study in favour of placebo.
9Downgraded by 1 for indirectness. Both studies were conducted in Tanzania. Dif ferent populat ions may dif fer in their
m icronutrient def iciency or requirement.
10Downgraded by 1 for imprecision. The 95%CI is wide and includes what may be clinically important ef fects.
11Downgraded by 2 for inconsistency: Stat ist ical heterogeneity is very high. Four studies f rom Tanzania and India found
no evidence of improved weight gain with supplements, while 1 study f rom Tanzania found large increases in weight with
micronutrients at 8 months.
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D I S C U S S I O N
Summary of main results
Macronutrient supplementation
The included trials were too small to reliably prove or exclude
clinically important benefits on mortality, cure, or treatment com-
pletion (very low quality evidence). One small trial from India did
find a statistically significant benefit on treatment completion, and
clearance of the bacteria from the sputum, but these findings have
not been confirmed in larger trials elsewhere.
The provision of free food or high-energy nutritional products
probably does produce a modest increase in weight gain during
treatment for active tuberculosis, although this was not consistent
across all included trials (moderate quality evidence). Two small
studies provide some evidence that quality of life may also be
improved but the trials were too small to have much confidence
in the result (low quality evidence).
Micronutrient supplementation
Multi-micronutrients may have little or no effect on mortality in
HIV-negative people with tuberculosis (low quality evidence), and
probably have little or no effect on mortality in HIV-positive pa-
tients who are not taking anti-retroviral therapy (moderate quality
evidence). There is insufficient evidence to know if multi-micronu-
trients improve cure, treatment completion, or the proportion of
tuberculosis patients remaining sputum positive during the first
eight weeks (very low quality evidence).
Multi-micronutrients may have little or no effect on weight gain
during treatment (low quality evidence), although one of the three
studies did find a substantial benefit in one study arm. No stud-
ies assessed the effect of multi-micronutrient supplementation on
quality of life.
Individual micronutrients
Although low vitaminA levels are common in tuberculosis, plasma
levels probably increase following initiation of tuberculosis treat-
ment regardless of supplementation. There is no evidence that
supplementation in doses up to three times the DRI has a ben-
eficial effect on tuberculosis treatment outcomes, or nutritional
recovery.
B vitamins have been given in doses up to 10 times theDRI as part
of multi-micronutrient supplementation. There is no evidence of
an effect on mortality from tuberculosis. Due to the paucity of
trials we cannot make any further conclusions about the effect of
this vitamin on other tuberculosis outcomes.
Vitamin C has only been evaluated as part of multi-micronutrient
supplements. Doses of vitamin C up to five times the DRI had
no effect on tuberculosis mortality. Due to the paucity of trials
we cannot make any further conclusions about the effect of this
vitamin on other tuberculosis outcomes.
Vitamin D supplementation appears to improve plasma levels
compared to placebo when participants are deficient at the start
of supplementation, but may not have any clinically important
effects on early sputum conversion.
Vitamin E has only been assessed in combination with other vi-
tamins or selenium. The dose used was up to 10 times the DRI.
None of these trials show any significant benefit or harmwith sup-
plementation, but supplementation probably does improve blood
levels of both vitamin E and selenium.
There is some evidence that plasma zinc levels increase during the
first six months of supplementation, but no convincing evidence
of other benefits.
Overall completeness and applicability of
evidence
The included studies were generally too small and too limited to
make broad conclusions on the presence or absence of clinically
important benefits of nutritional supplementation on tuberculosis
treatment outcomes.
Although the included studies are from low- and middle-income
countries, they may not reflect the food-insecure settings where
most supplementation programmes take place, and where the ben-
efit may plausibly be greatest.
Where a supplement has so far not shown any benefit, this may
also be an issue relating to the dose used as people recovering
from tuberculosis may havemicronutrient requirements which are
higher than healthy people, however there is currently no evidence
to support this.
In addition, it should be noted that most of the HIV-positive
participants in these trials were not taking antiretroviral therapy.
Quality of the evidence
We assessed the quality of evidence using the GRADE method-
ology, and displayed the results in two ’Summary of findings’ ta-
bles (Summary of findings for the main comparison; Summary of
findings 2). ’Moderate’ quality evidence implies we can have some
confidence in the result, but further research evidence would still
be helpful. ’Low’ and ’very low’ quality reflect decreasing levels of
confidence in the result.
The quality of evidence was mainly downgraded under ’directness’
and ’precision’. Directness is an assessment of how well the evi-
dence matches the PICO question being asked (population, in-
tervention, control, outcome). Because nutritional deficiencies are
likely to differ widely among populations, it is difficult to gener-
alize the results of one or two trials to other settings or subgroups.
Precision involves an assessment of the statistical and clinical sig-
nificance of the result, and also whether the sample size of the
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trials is adequate to reliably detect an effect. Most of these trials
were small and well below the optimal information size for the
outcomes that were being measured.
Potential biases in the review process
We minimized biases in the review process by performing a com-
prehensive search of the literature for relevant published, unpub-
lished, and ongoing trials and by independently selecting and ap-
praising the studies, and extracting the data in duplicate. Where
data was missing, we sought additional information and data di-
rectly from the study authors where this was possible to do so.
We did not conduct an extensive hand-search for grey literature.
Therefore, the review is at risk of publication bias from less promi-
nent trials. We attempted to reduce this risk by identifying rele-
vant conference abstracts and registered ongoing trials. The search
of the trials registry to identify trial protocols and ongoing trials
yielded 16 potentially relevant trial protocols. These will require
further assessment and exploration to either: 1) link them to trials
already included in the review; or 2) if not included, to attempt
to obtain the completed trial reports. This task is time-consuming
and has to be balanced against feasibility and time constraints.
Agreements and disagreements with other
studies or reviews
Nutritional supplementation in HIV-positive patients without
tuberculosis has been assessed by two further Cochrane reviews
(Irlam 2010; Grobler 2013).
Grobler 2013 found 14 small trials that compared macronutrient
supplementation with no supplementation and concluded that
although there was evidence that supplementation increased both
energy and protein intake, there was no evidence of a clinical
benefit on either nutritional- or HIV-related outcomes.
Irlam 2010 assessed 30 trials that compared micronutrients with
placebo from both developed and developing countries. The au-
thors concluded that multi-micronutrient supplements have sig-
nificant benefits in HIV-positive pregnant women and children.
In children there was also evidence of a reduction inmortality with
vitamin A, and a reduction in diarrhoeal morbidity with zinc.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is insufficient research to know whether routinely provid-
ing free food or energy supplements results in better tuberculo-
sis treatment outcomes, but limited evidence suggests it probably
improves weight gain.
Although blood levels of some vitamins may be low in patients
starting treatment for active tuberculosis, there is currently no re-
liable evidence that routinely supplementing above recommended
daily amounts has clinical benefits.
Implications for research
High quality studies of food provision to tuberculosis patients in
food-insecure settings are urgently needed to support the con-
tinued expenditure on food support to tuberculosis programmes.
In designing these studies, researchers, and programme managers
need to be clear about the aim of food provision. Whilst an ef-
fect on mortality would provide strong advocacy for continued
financial support, if the primary aim is to promote adherence, or
to mitigate the catastrophic financial consequences of the illness,
then these are the outcomes that should be measured, and appro-
priate comparison interventions should be selected. If the primary
aim is to reduce mortality, then future trials must be large enough
to reliably detect or exclude an effect.
The failure to demonstrate a beneficial effect with micronutrient
supplementation does not imply that one does not exist. Further
studies, perhaps using higher doses, would still be beneficial but
should have adequate sample sizes to reliably detect or exclude
clinically important benefits. It would also be useful if some stan-
dardization of outcome measurements could be made.
For nutritional recovery it seems important to assess changes in
weight and lean body mass during the first two months of treat-
ment rather than as a single measure at the end of treatment. It is
also essential that measures of how this translates into improved
quality of life and physical functioning are made, as weight gain
on its own is of little interest.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Armijos 2010 MEX
Methods Study design: randomized controlled trial (RCT).
Study dates and duration: recruited August 2005 to July 2006, follow-up 6 months
Standard care: all participants received directly observed antituberculous therapy, per
InstitutoMexicano del Seguro Social (IMSS) guidelines: 2months of isoniazid/rifampin/
pyrazinamide/ethambutol followed by 4 months of isoniazid and rifampin
Participants Number: 39 enrolled; 33 analysed.
Inclusion criteria: adults aged 18 to 65 years, smear positive pulmonary tuberculosis,
informed consent
Exclusion criteria: pregnancy, breast feeding, used corticosteroids, human immunodefi-
ciency virus (HIV), diabetes, or another serious co-morbidity
Baseline characteristics
• Nutritional status: mean body mass index (BMI) (standard deviation (SD)): 20.4
kg/m² (5.0) treatment group versus 22.6 kg/m² (4.2) control group.
• HIV status: all negative.
• Multidrug-resistant/extensively drug-resistant tuberculosis (MDR/XDR-TB): not
described.
• Vitamin A status µg/dL (SD): 29.4 (13.3) supplement group versus 29.8 (13.8)
placebo group; normal range.
• Zinc status µg/L (SD): 738 (168) supplement group versus 764 (137) placebo
group; normal range.
Interventions Group 1: vitamin A 5000 IU/day (as retinyl acetate) plus zinc 50 mg/day (as zinc chelate)
for 4 months
Group 2: placebo with identical appearance.
Outcomes • Deaths during study.
• Percentage remaining smear positive at 1, 2, 3, 4, and 5 months.
• Mean zinc, retinol, and albumin levels at 0, 2, and 6 months.
Not included in review:meanmonthly intake of zinc and vitaminA,measures of immune
response at 0, 2, and 6 months
Notes Location: Ciudad Juárez, México.
Setting: IMSS outpatient services.
Funding: Center for Border Health Research, UTEP-UTSPH Hispanic Health Dispar-
ities Research Center
Risk of bias
Bias Authors’ judgement Support for judgement
32Nutritional supplements for people being treated for active tuberculosis (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Armijos 2010 MEX (Continued)
Random sequence generation (selection
bias)
Unclear risk The trial authors described it as “ran-
domised”, but gave no further details
Allocation concealment (selection bias) Unclear risk “A co-investigator not involved in data col-
lection or analysis maintained the study
codes and allocated the supplements”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Placebo group
subjects received organoleptically identical,
matched placebo...Subject codes remained
sealed until after data analysis”
Incomplete outcome data (attrition bias)
All outcomes
Low risk The analysis included 33/39 (85%) ran-
domized participants. The trial authors
clearly stated the reasons for drop-out
Selective reporting (reporting bias) Unclear risk We could not retrieve the trial protocol.
Trial participants were followed-up to 6
months but treatment completion and cure
were not reported
Other bias Low risk We did not identify any other sources of
bias.
Daley 2015 IND
Methods Study design: RCT.
Study dates and duration: January 2010 to August 2011 (enrolment), follow-up com-
pleted by February 2012
Standard care: both groups received standard category 1 tuberculosis treatment according
to Indian national guidelines
Participants Number: 247 randomized (121 to vitamin D group, 126 to placebo)
Vitamin D group: 101/121 included in primary analysis.
Placebo group: 110/126 included in primary analysis.
Inclusion:HIV-negative participants aged 18 to 75 years with pulmonary tuberculosis (at
least 1 documentedpositive sputum smear)who had received 1dose or less of tuberculosis
treatment
Exclusion: participants with multidrug-resistant tuberculosis, pre-existing liver or kidney
disease, concurrent steroid or cytotoxic drug treatment, metastatic malignant disease,
pregnancy or lactation, active diarrhoea, hyper-calcaemia (corrected serum calcium > 2.
62 mmol/L), or those who were not expected to survive for 180 days
Baseline characteristics
• Nutritional status: mean BMI ± SD: 18.2 ± 2.9 kg/m² vitamin D group versus
17.8 ± 3.0 kg/m² placebo.
• HIV status: all negative.
• MDR/XDR-TB: excluded.
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Daley 2015 IND (Continued)
• Mean vitamin D status ± SD (mmol/L): 63.1 ± 46.6 vitamin D group versus 62.2
± 51.0 placebo group.
Interventions Both groups received antituberculous treatment and were not provided with any advice
about changing their diet or sun exposure
Vitamin D group: 4 doses of tasteless, odourless 2.5 mg vitamin D3 oil (100,000 IU per
dose) orally once every 2 weeks for 8 weeks
Placebo group: identical Miglyol (the dosing regime is not clearly stated but we assume
that it was identical to that of the vitamin D)
Outcomes Primary outcome: time to sputum culture conversion (time to first negative culture)
Secondary outcome: time to sputum culture conversion (time to first of 2 consecutive
negative cultures), time to smear conversion (time to first negative smear and time to first
of 2 consecutive negative smears), proportion of participants who had positive cultures
at 56 days, Karnofsky performance status and body mass index (BMI) at 56 days, rate of
rise in time to detection in culture and 25-hydroxyvitamin-D concentration at day 180
Primary safety outcome: incidence of hypercalcaemia (corrected serum calcium > 2.62
mmol/L)
Secondary safety outcome: rate of serious adverse events (death, admission to hospital,
life-threatening illness, persistent disability, congenital anomaly, or predefined disease-
related complications of tuberculosis infection), and adverse events (any untoward med-
ical occurrence after study drug)
Notes Baseline characteristics:mostly similar between groups, but the placebo grouphad slightly
more men than the vitamin D group, and there were slightly more participants with
isoniazidmonoresistance in the vitaminDgroup (14/121; 12%) compared to the placebo
group (8/126; 6%). It is unclear whether these differences were appreciably different or
not
Setting: 13 clinics in Vellore and Krishnagiri districts of Tamil Nadu, India
Funding: Dalhousie University and Infectious Diseases Training and Research Centre
Trial registration: NCT00366470.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Bottles containing vitamin D or placebo
were randomized by computer into per-
muted blocks of 4 without stratification,
then labelled with serial study numbers in
their randomized order. The randomiza-
tion code was maintained in Canada and
only after the database was locked was the
code broken
Allocation concealment (selection bias) Low risk The trial authors stated that neither the
participant nor the clinical and laboratory
investigators and personnel in India were
aware of treatment assignment. As each
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Daley 2015 IND (Continued)
participant was recruited, the next serially
numbered bottle was assigned to the partic-
ipant by study personnel. Both treatments
were stored in identical dark glass dropper
bottles at room temperature and protected
from light
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial authors state that neither the pa-
tient nor the clinical and laboratory inves-
tigators and personnel in India were aware
of treatment assignment. The randomiza-
tion code was maintained in Canada by 1
investigator. After the database was locked,
the code was broken and analysis was done
with knowledge of assignment. Both treat-
ments were stored in identical dark glass
dropper bottles at room temperature and
protected from light. Both treatments were
oil-based and were tasteless and odourless
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants receiving 1 dose of interven-
tion and with at least 2 sputum culture re-
sults were included in the primary analysis.
Participants with only 1 culture result were
excluded: Vitamin D group = 8/121 (7%)
and placebo group = 5/126 (4%)
Selective reporting (reporting bias) Low risk Primary and secondary outcomes reported
in the publication match those set out in
the protocol
Other bias Low risk Baseline and demographic characteristics
were mostly similar between groups, but
the placebo group had slightly more men
than the vitamin D group, and there were
slightly more participants with isoniazid
mono-resistance in the vitamin D group
Funding source: Dalhousie University and
Infectious Diseases Research and Training
Center
Conflict of interest: Reinhold Vieth co-
ownsDdrops a company that promotes and
sells Vitamin D. All other trial authors de-
clared no conflicts of interest
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Farazi 2015 IRN
Methods Study design: RCT.
Study dates and duration: recruited December 2012 to May 2014, follow-up 4 weeks
Standard care: all participants received directly observed antituberculous therapy (isoni-
azid, pyrazinamide, rifampicin, and ethambutol for 2 months followed by isoniazid and
ethambutol for 6 months)
Participants Number: 63 randomized (32 in arginine group, 31 in placebo group)
Sex: arginine group 46.9% male; placebo group 51.6% male.
Inclusion: new cases smear-positive pulmonary TB 15 years or older
Exclusion: hospitalization, pregnancy, clinical signs of comorbidity (diabetes, malig-
nancy, hepatic/renal failure, HIV-positive), L-arginine supplementation during the past
month, and allergic reactions to L-arginine
Baseline characteristics
• Nutritional status (BMI < 18.5 kg/m²): arginine 46.9%; placebo 45.2%.
• HIV status: all HIV-negative.
• MDR/XDR-TB: not reported on.
Interventions Both groups received anti-TB treatment.
Arginine group: 1000 mg pure L-arginine hydrochloride; twice daily for 30 days
Placebo group: 1000 mg sugar (capsules identical to L-arginine capsule); twice daily for
30 days
Outcomes • Treatment success.
• Sputum conversion.
• Weight gain.
• Clinical symptoms at 1 and 2 months.
Not included in review: ESR, CRP.
Notes Location: Markazi Province, Iran.
Setting: clinics.
Funding: Arak University of Medical Science.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “random number tables”.
Allocation concealment (selection bias) Low risk “Preparation of the randomization en-
velopes was performed by a member of the
staff who was not directly involved in the
study and a sealed copy of the treatment
code was kept by the project leader until all
data had been collected and analyzed”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “identical capsules of L-arginine...or
placebo”.
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Farazi 2015 IRN (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Supplement: 2/34 (6%).
Placebo: 3/34 (9%).
Selective reporting (reporting bias) Low risk Primary and secondary outcomes reported
in the publication match those set out in
the protocol
Other bias Low risk Baseline and demographic characteristics
were similar between groups
Funding source: Arak University of Medi-
cal Sciences.
Conflicts of interest: all trial authors de-
clared no conflict of interest
Ginawi 2013 IND
Methods Study design: RCT.
Study dates and duration: not stated.
Standard care: not stated.
Participants Number: 178 randomized, 127 analysed.
Inclusion criteria: category 1pulmonary tuberculosis patients attending theDOTS centre
Exclusion criteria: those who did not take medication regularly (missing even 1 dose in
the first 2 months), had severe adverse reactions, or drug-resistant tuberculosis
Baseline characteristics
• Nutritional status: not stated.
• HIV status: not stated.
• MDR/XDR-TB: excluded.
• Vitamin A status µg/dL (SD): unclear if it is baseline data or % increase from
baseline.
• Zinc status µg/L (SD): unclear if it is baseline data or % increase from baseline.
Interventions Placebo group: lactose only.
Vitamin A group: 1500 retinol equivalents (5000 IU) vitamin A (as retinyl acetate)
Zinc group: 15 mg zinc (as zinc sulfate).
Vitamin A and zinc group: 1500 retinol equivalents (5000 IU) vitamin A (as retinyl
acetate) and 15 mg zinc (as zinc sulfate)
Supplement and placebo were given to the participants with the antituberculous drugs
on DOTS day.
Outcomes • Sputum positivity: sputum smear negative for tubercle bacilli at 2 months.
• Blood chemistry: haemoglobin, white blood cell count, erythrocyte sedimentation
rate (ESR), serum albumin, serum retinol, and serum zinc concentration at 2 and 6
months.
Notes Location: Lucknow, North India.
Setting: not stated.
Funding: not stated.
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Ginawi 2013 IND (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial authors described the trial as a
double blind, placebo-controlled trial. Sup-
plement and placebo capsules were indis-
tinguishable in appearance both externally
and internally
Incomplete outcome data (attrition bias)
All outcomes
High risk The trial authors stated that they excluded
non-compliant participants, participants
who experienced severe adverse reactions,
and participants with drug-resistant tuber-
culosis from the analysis. The trial authors
did not describe reasons for loss to follow-
up of 51 participants
178 participants randomized.
127 participants completed the trial.
28.6% loss to follow-up (> 10% therefore
high risk of bias).
Selective reporting (reporting bias) Unclear risk We were unable to obtain the trial protocol
so it is unclear if there is selective outcome
reporting in this instance.
Other bias Unclear risk Baseline comparability: no significant dif-
ference in biochemical status at baseline.
No information on age, gender, or nutri-
tional status at baseline
Conflicts of interest: not reported.
Funding: no information provided on
funding resources.
Hanekom 1997 ZAF
Methods Study design: RCT.
Study dates and duration: dates not stated, follow-up 3 months
Standard care: all participants received directly observed antituberculous therapy,without
any routine multivitamin preparations
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Hanekom 1997 ZAF (Continued)
Participants Number: 110 enrolled; 85 analysed.
Inclusion criteria: children aged under 15 years with pulmonary tuberculosis
Exclusion criteria: HIV-positive.
Baseline characteristics
• Nutritional status: mean weight z score (SD): −1.41 (1.41) treatment group
versus −1.44 (1.34) control group.
• HIV status: all negative.
• MDR/XDR-TB: not described.
• Vitamin A status µg/dL (SD): 17.6 (10.1) supplement group versus 18.6 (10.6)
placebo group; normal range 20 to 80.
Interventions Group 1: vitamin A 200,000 IU; 2 doses before beginning antituberculous therapy
Group 2: placebo with identical appearance.
Outcomes • Resolution of respiratory symptoms at 6 weeks and 3 months.
• Change-in-weight z scores.
• Vitamin A levels at baseline, 6 weeks, and 3 months.
Not included in review: chest X-ray changes, retinol binding protein, and prealbumin
levels: at baseline, 6 weeks, and 3 months
Notes Location: Cape Town, South Africa.
Setting: children’s hospital (outpatient or inpatient not stated in report)
Funding: the Glaxo ’Action TB’ International Research Initiative, Medical Research
Council of South Africa
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors described the trial as “ran-
domised”; but did not provide any further
details
Allocation concealment (selection bias) Unclear risk None described.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial authors described the trial as “dou-
ble blind”, with an “identical appearing
placebo”. No comment on outcome asses-
sors
Incomplete outcome data (attrition bias)
All outcomes
High risk The trial enrolled 110 participants, of
which 15 were later excluded for not at-
tending the last follow-up appointment
and 10 for not meeting the inclusion crite-
ria. The trial authors presented data for 76
of the remaining 85 (85%) participants
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Hanekom 1997 ZAF (Continued)
Selective reporting (reporting bias) Unclear risk We were unable to retrieve the trial proto-
col. There was no evidence of selective re-
porting
Other bias Low risk We did not identify any other sources of
bias.
Jahnavi 2010 IND
Methods Study design: RCT.
Study dates and duration: August to December 2005, follow-up 1-year
Standard care: all participants received directly observed antituberculous therapy accord-
ing to the Revised National Tuberculosis Control Programme, India, without any rou-
tine multivitamin preparations
Participants Number: 100 participants randomized.
Inclusion criteria: adults aged 18 to 65 years; with active tuberculosis; pulmonary or
extrapulmonary smear/culture positive, BMI < 20 kg/m²
Exclusion criteria: HIV-positive, diabetes, other severe underlying disease
Baseline characteristics
• Nutritional status: mean weight kg (SD):43.0 (8.2) treatment group versus 44.2
(8.2) control group; mean BMI (SD): 17.1 kg/m² (2.8) treatment group versus 17.9
kg/m² (2.1) control group.
• HIV status: all negative.
• MDR/XDR-TB: unknown.
• Micronutrient status: not assessed at baseline.
Interventions Group 1: Control group: standard tuberculosis treatment as per the Revised National
Tuberculosis Control Programme. A general instruction to “increase food intake”
Group 2: targeted dietary advice to reach 35 kcal/kg/day and food supplements that
consisted of “sweet balls” made of wheat flour, caramel, groundnuts, vegetable ghee,
sprouted gram, and nuts - each containing 6 g protein and 600 kcal - consumed daily
under supervision for 3 months
Outcomes • Body weight at baseline and 3 months.
• Maximum grip strength and timed stand test at baseline and 3 months.
• Quality of life at baseline and 3 months.
• Sputum conversion at 2, 4, and 6 months.
• Completion of the entire course of treatment.
• Deaths during study.
Notes Location: Krishna district, Andhrapradesh, India.
Setting: community-based catchment area of 1 medical college and 1 DOTS centre
Funding: University of Padova, Italy.
Risk of bias
Bias Authors’ judgement Support for judgement
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Jahnavi 2010 IND (Continued)
Random sequence generation (selection
bias)
High risk “randomisation performed by randomly
shuffling the envelopes that contained the
study codes”
Allocation concealment (selection bias) Unclear risk The trial did not describe this, but given
that the envelopes with codes were shuffled
it would seem adequate
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial did notmake any attempt to blind
the participants; the trial report does not
mention whether or not the outcome asses-
sors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There were no apparent losses to follow-up.
Selective reporting (reporting bias) High risk Despite 1 year of follow-up, the trial au-
thors only reported outcomes at 3 months,
and incompletely reported sputum conver-
sion
Other bias Low risk We did not identify any other sources of
bias.
Jeremiah 2014 TZA
Methods Study design: open label RCT.
Study dates and duration: September 2010 to August 2011.
Standard care: treatment was given as FDC tablets, each contained Isoniazid (75 mg)
, rifampin (150 mg), pyrazinamide (400 mg), and ethambutol (275 mg) during the
intensive phase, and for continuation phase the tablet contained isoniazid (75 mg) and
rifampicin (150 mg) only. If body weight < 50 kg then 3 tablets, and > 50 kg 4 tablets
Participants Number: 469 screened, 100 randomized (by HIV status).
Inclusion criteria: sputum smear positive pulmonary tuberculosis patients 15 years or
older, regardless of HIV status, with written informed consent
Exclusion criteria: HIV-positive participants on ART, pregnant women, terminally sick
patients unlikely to survive > 48 hrs, and non-residents of Mwanza City
Baseline characteristics
• Nutritional status: median BMI (kg/m²) pulmonary tuberculosis-positive/HIV-
positive supplement group: 19.4; 18.3, 20.5 pulmonary tuberculosis positive/HIV-
positive no supplement group: 18.8; 17.4, 20.1, pulmonary tuberculosis positive/HIV-
negative supplement group: 18; 16.9, 19.7. Pulmonary tuberculosis positive/HIV-
negative no supplement group: 18.6; 17.3,19.6. Median weight (kg): pulmonary
tuberculosis positive/HIV-positive supplement group: 52.3; 49.9, 56.6. pulmonary
tuberculosis positive/HIV-positive no supplement group: 51.9; 49.2, 56.1. Pulmonary
tuberculosis positive/HIV-negative supplement group: 50.7; 48.2, 57.7. Pulmonary
tuberculosis positive/HIV-negative no supplement group: 52; 44.6, 58.8.
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Jeremiah 2014 TZA (Continued)
• HIV status: median CD4 cell count; IQR cells/µL pulmonary tuberculosis-
positive/HIV-positive supplement: 243.5; 140.5, 337.5 pulmonary tuberculosis-
positive/HIV-positive no supplement: 168; 64, 338 pulmonary tuberculosis positive/
HIV-negative supplement: 611; 457; 726 pulmonary tuberculosis positive/HIV-
negative no supplement: 637; 433, 812.
• MDR/XDR-TB: not described.
Interventions • Group 1: pulmonary tuberculosis-positive/HIV-positive and Group 2: pulmonary
tuberculosis positive/HIV-negative: no supplement.
• Group 3: pulmonary tuberculosis-positive/HIV-positive and Group 4: pulmonary
tuberculosis positive/HIV-negative: daily 5 high energy and vitamin/mineral enriched
biscuit bars containing about 1000 kcal and additional vitamins and minerals
(including zinc and selenium). Produced by Compact A/S. Supplement provided
during first 2 months of tuberculosis treatment. Intake monitored by patient treatment
supporter.
Basic biscuit (30 g): 4.5 g protein, 615 kJ energy, 120 mg phosphorous, 120 mg calcium,
36 mg magnesium, 70 mg sodium, 150 mg potassium, and traces < 1 mg of iron and
zinc
Biscuit with additional micronutrients: as above plus 1.5 mg vitamin A, 20 mg thiamin,
20mg riboflavin, 25 mg vitamin B6, 50 µg vitamin B12, 0.8 mg folic acid, 40mg niacin,
200 mg vitamin C, 60 mg vitamin E, 5 µg vitamin D, 0.2 mg selenium, 5 mg copper,
30 mg zinc
Outcomes • Mortality at 2 months.
• Median weight gain at 2 months.
• Sputum culture at 2 months.
Not included in review: pharmacokinetics of rifampin and genotype of organic anion-
transporting polypeptide encoded by SLCO1B1 rs149032 responsible for hepatic drug
disposition
Notes Location: Mwanza, Tanzania.
Setting: urban and suburban clinics.
Funding: Danish Ministry of Foreign Affairs (DANIDA, DFC file no. 09-026RH)
through Denmark’s International Development Cooperation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial authors stated that simple
randomization, stratified by HIV sta-
tus, was computed using the website
www.randomization.com.
Allocation concealment (selection bias) High risk This was an open-label trial, therefore it
is likely that the people allocating the
treatment where aware of which treatment
group they were allocating the participants
to
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Blinding (performance bias and detection
bias)
All outcomes
High risk This was an open-label trial, therefore
the participants and personnel were not
blinded to the treatment. It is unclear if
the outcome assessors were blinded to the
treatment
Incomplete outcome data (attrition bias)
All outcomes
High risk The trial authors stated that they analysed
all available data
Intervention arm: 2/51 (4%) lost to follow-
up (died or defaulted); no supplement arm:
6/49 (12%) lost to follow-up (died or de-
faulted)
Selective reporting (reporting bias) Low risk We obtained the protocol obtained. The
primary and secondary outcomes reported
in the publication are in line with those set
out in the protocol
Other bias Low risk We did not identify any other sources of
bias.
Karyadi 2002 IDN
Methods Study design: RCT.
Study dates and duration: December 1997 to December 1998, follow-up 6 months
Standard care: all participants received directly observed antituberculous therapy in line
with WHO recommendations: 2RHZE/4HR
Participants Number: 110 enrolled; 80 analysed.
Inclusion criteria: adults aged 15 to 55 years, 3 positive sputum smears, clinical and
radiological signs consistent with pulmonary tuberculosis
Exclusion criteria: previous antituberculous therapy, drug resistance, extra-pulmonary
tuberculosis, pregnancy, lactation, use of corticosteroids, vitamin A, zinc, or iron in the
previous month, moderate to severe injury or surgery in the previous month, diabetes,
renal failure, liver disease, neoplasm, or congestive heart failure
Baseline characteristics
• Nutritional status: BMI < 18.5 kg/m²: 25/40 treatment group versus 26/40
placebo group.
• HIV status: not mentioned.
• MDR/XDR-TB: excluded.
• Vitamin A status: mean plasma retinol µmol/L (SD): 0.82 (0.04) supplement
group versus 0.90 (0.04) placebo group; normal range > 0.7.
• Zinc status: mean plasma zinc µmol/L (SD): 11.52 (0.26) supplement group
versus 11.15 (0.28) placebo group; normal range > 10.7.
Interventions Group 1: daily capsules of vitamin A 5000 IU and zinc 15 mg (as zinc sulphate) for 6
months
Group 2: placebo (lactose).
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Outcomes • Sputum-culture positive at 0, 2, and 6 months.
• Body weight at 0, 2, and 6 months.
• BMI at 0, 2, and 6 months.
• MUAC, body fat percentage.
• Karnofsky score at 0, 2, and 6 months.
• Blood retinol and zinc levels.
Not included in the review: biceps, triceps, subscapular, and supra-iliac skinfold thick-
ness; blood haemoglobin, zinc protoporphyrin, x-ray changes
Notes Location: Jakarta, Indonesia.
Setting: pulmonary outpatient clinics of 1 public hospital and 3 health centres
Funding: Gesellschaft fur Technische Zusammenarbeit (GTZ) GmbH, Eschborn, Ger-
many; the Neys-van Hoogstraten Foundation; the Directorate General of Communi-
cable Disease Control and Environmental Health, Indonesia; the Integrated Excellent
Research Project, Ministry of Research and Technology Indonesia; PT Kimia Farma,
Indonesia provided the supplements and placebo; PT Indo Farma provided the tuber-
culosis drugs
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “We used a table with randomly assorted
digits to allocate patients into 2 groups”
Allocation concealment (selection bias) Unclear risk The trial authors did not describe the
method of allocation concealment but
seems likely given the description of blind-
ing
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Supplements and placebo were indistin-
guishable”. “The authors, health staff, and
patients were unaware of the treatment
code until the study was completed”
Incomplete outcome data (attrition bias)
All outcomes
High risk The trial authors appear to have added 2 ex-
clusion criteria post-hoc: participants who
missed even 1 day of treatment during the
first 2months, andparticipantswhohad se-
vere adverse drug effects. The trial authors
analysed 80/110 (72%) participants
Selective reporting (reporting bias) Unclear risk We were unable to retrieve the trial proto-
col. Although cure is a standard outcome
for tuberculosis programmes, this was not
reported
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Other bias Low risk We did not identify any other sources of
bias.
Kota 2011 IND
Methods Study design: RCT.
Study dates and duration: not stated.
Standard care: all participants received intensive phase antimicrobial treatment com-
prising of isoniazid, rifampicin, pyrazinamide, and ethambutol. All participants were
adjusted for oral hypoglycaemic agents and insulin for glycaemic control
Participants Number: 45 enrolled, (15 excluded), 30 randomized and included in the final analysis
Inclusion criteria: older than 15 years, newly diagnosed pulmonary tuberculosis patients,
poorly controlled Type 2 diabetes mellitus (HbA1C > 7%) and serum 25(OH) D < 20
ng/mL. Pulmonary tuberculosis diagnosis based on 1 of the following criteria: at least 2
positive sputum smears (from 3), 1 positive smear and typical picture of lung infiltration
on chest X-ray
Exclusion criteria: younger than 15 years, patients already on ATT, serum 25(OH) D >
20ng/mL, diseases affecting vitamin D metabolism such as malabsorption, renal failure,
or with prolonged immobilization
Baseline characteristics
• Nutritional status: mean weight (kg ± SD) supplement group: 49.1kg ± 4.5,
control: 44.6 ± 5.6.
• HIV status: not stated.
• MDR/XDR-TB: not stated.
• Vitamin D 25-(OH) D (ng/mL) status: supplement group 12.8 ± 4.5, control
group: 11.1 ± 4.7.
• Vitamin A and zinc status: not reported.
Interventions Group 1: vitamin D supplement along with intensive phase ATT. Oral cholecalciferol
sachets (60,000 IU/week) and calcium carbonate (1000 mg/day)
Group 2: no vitamin D supplement just intensive phase ATT.
The trial authors did not state the duration of the intervention
Outcomes • Vitamin D levels every 4 weeks for 12 weeks.
• Sputum smear conversion every 4 weeks for 12 weeks.
• Fasting blood sugar and post lunch blood sugar monthly.
• HbA1C monthly.
• ESR monthly.
Notes Location: Medwin Hospital, Hyderabad, India.
Setting: hospital setting (inpatient).
Funding: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk The trial authors did not describe the ran-
domization process
Allocation concealment (selection bias) Unclear risk The trial authors did not mention whether
treatment allocation was concealed or not
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The trial authors did not describe any as-
pect of blinding in the paper
Incomplete outcome data (attrition bias)
All outcomes
Low risk According to data provided, the trial au-
thors included all of the participants ran-
domized at baseline in the final analysis at
12 weeks
Selective reporting (reporting bias) Unclear risk We were unable to obtain the study pro-
tocol so it is unclear if all of the proposed
outcomes have been reported on
Other bias Low risk We did not identify any other sources of
bias.
Lawson 2010 NGA
Methods Study design: RCT.
Study dates and duration: September 2003 to June 2005, follow-up 6 months
Standard care: all participants received standard National Tuberculosis Programme treat-
ment for tuberculosis: 2RHZE/4HE
Participants Number: 350 enrolled.
Inclusion criteria: adults aged > 15 years with sputum positive pulmonary tuberculosis
Exclusion criteria: previous antituberculous therapy, pregnancy, lactation, use of corti-
costeroids or zinc in the previous month, major surgery in the previous month, diabetes,
severe cardiovascular/renal or hepatic disease, currently taking oral contraceptives, un-
able to return
Baseline characteristics
• Nutritional status: mean BMI (SD):19.8 kg/m² (3.3) placebo group, 21.3 kg/m²
(4.7) zinc plus placebo group, 19.6 (3.5) zinc plus vitamin A group.
• HIV status: 45% HIV-positive placebo group, 49% zinc plus placebo group, 42%
zinc plus vitamin A group.
• MDR/XDR-TB: not mentioned.
• Vitamin A status: not reported.
• Zinc status: not reported.
Interventions Group 1: placebos (similar in appearance to zinc and vitamin A tablets)
Group 2: 90 mg of elemental zinc per week plus daily placebo
Group 3: 90 mg of elemental zinc per week plus 1500 mcg retinol equivalents (5000IU
vitamin A) weekly
Supplements were observed for 2 months then given as monthly supplies for the next 4
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months
Outcomes • Time to sputum smear conversion.
• Chest X-ray scores at 2 and 6 months.
• Clinical symptoms (cough, fever and night sweats) at 2 and 6 months.
• BMI at 2 and 6 months.
• Karnofsky score at 2 and 6 months.
• Deaths during the trial.
Not included in the review: ESR and haemoglobin values.
Notes Location: Abuja, Nigeria.
Setting: 8 district hospitals.
Funding: no sources stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Prepared the allocation sequence using
random numbers generated in Minitab...
using permuted block randomisation with
four different black sizes”
Allocation concealment (selection bias) Low risk “One of the investigators who was not
on the site prepared the allocation se-
quence...and the randomisation sequence
was kept at the Liverpool School ofTropical
Medicine Treatment...allocation was des-
ignated by a lettered code and concealed
from the investigators and subjects until
data analysis was completed”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Placebo tablets resembled the supplement
tablets”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were 14 of 116 in the placebo group,
15 of 117 in the zinc group, and 21 of 117
in the zinc and vitamin A group lost to
follow-up
Selective reporting (reporting bias) Unclear risk We were unable to retrieve the trial proto-
col. There was no evidence of selective re-
porting
Other bias Low risk We were unable to identify any other
sources of bias.
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Lodha 2014 IND
Methods Study design: RCT.
Study dates and duration: January 2008 to June 2012.
Standard care: all children had 2 months intensive phase that used 3 or 4 drugs (iso-
niazid, rifampicin, pyrazinamide, and ethambutol) followed by 4 months of isoniazid
and rifampicin. Category 3 treatment was isoniazid, rifampicin, and pyrazinamide for 2
months followed by 4 months of rifampicin and isoniazid
Daily doses were based on weight: 5 to 7 mg isoniazid/kg; 10 to 13 mg rifampicin/kg;
35 to 40 mg pyrazinamide/kg; 20 to 25 mg ethambutol/kg
In case of non-response (clinical or radiological) antituberculous therapywas changed to 2
months streptomycin, isoniazid, rifampicin, pyrazinamide, and ethambutol; followed by
1month of isoniazid, rifampicin, and ethambutol; and 5months of isoniazid, rifampicin,
and ethambutol. Any child who did not respond on this regimen and for whom an
alternative diagnosis was ruled out was started on 2nd line antituberculous therapy, which
included an injection of kanamycin, ofloxacin, and ethionamide and an additional drug
(cycloserine or co-amoxiclav)
Participants were followed up every 2 weeks in the first 2months, and then every 4 weeks
for the remaining 4 months of ATT treatment
Participants Number: 403 randomized. At 2 months: data on 393 children; at 6 months: data on
381 children
Inclusion criteria: children 6 months to 15 years who presented with any of the following
symptoms were considered tuberculosis suspects and screened: cough > 2 weeks with no
improvement after 7 to 10 days amoxicillin, fever > 2 weeks with no improvement during
7 to 10 days amoxicillin, recent unexplained weight loss or failure to thrive, unusual or
unexplained fatigue or lethargy or subtle clinical symptoms and history of close contact
with adult tuberculosis patient. All had chest X-ray and tuberculin skin test. If the chest
X-ray was consistent with intrathoracic tuberculosis, the child was considered to have
tuberculosis. The trial enrolled children with newly diagnosed probable intrathoracic
tuberculosis with or without extrapulmonary lesions.
Exclusion criteria: bilateral pedal oedema; known HIV infection; history of antitubercu-
lous therapy or isoniazid prophylaxis > 4 weeks; signs of upper airway obstruction; O2
saturation < 92%; signs of renal, hepatic, or cardiovascular disease; inability to attend
follow-up session for reading of the skin test; documented intake of zinc continuously
> 2 weeks in the 4 weeks preceding enrolment; CNS, osteoarticular, pericardial or renal
tuberculosis; history of contact with a documented case of drug-resistant tuberculosis;
or were non-residents of Delhi
Baseline characteristics
• Nutritional status (weight-for-age z score): MN+Z group −2.72 ± 1.85; MN
group −2.8 ± 1.6; zinc group −2.5 ± 1.5; placebo −2.8 ± 1.6.
• HIV status: HIV-negative only.
• MDR/XDR-TB (n/N tested): MN+Z group 1/18 (5.6%); MN group 1/29 (3.
4%); zinc group 1: 1/21 (4.8%), placebo group 2/26 (7.9%).
• Serum zinc concentration < 65 µg/dL (n/N): MN + Z 60/102; MN 51/100; zinc
53/101; placebo 55/100.
Interventions All children received antituberculous therapy.
Supplemented daily for 6 months.
Zinc group: zinc (20 mg elemental zinc).
Micronutrient group: micronutrients (vitamin A, thiamine, riboflavin, vitamins B6 and
B12, folic acid, niacin, vitamin C, vitamin E, vitamin D, selenium, and copper) without
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zinc
Micronutrient + zinc group: micronutrients (as above) in combination with zinc (20 mg
elemental zinc)
Placebo group: placebo.
Outcomes • Change in weight-for-age z score at 6 months and resolution of pulmonary lesions
using chest X-ray at 6 months.
• Height-for-age z score.
• Mid upper arm circumference.
• Triceps skin fold thickness.
• BMI-for-age z score at 2 and 6 months.
• Resolution of symptoms at 2 months (as reported by parents).
• Proportion of children requiring extension of intensive phase of therapy at 2
months.
• Improvement in chest X-ray at 2 months.
Notes Location:Delhi, India. All India Institute ofMedical Sciences&Kalawati SaranChildren
Hospital associated with Lady Hardinge Medical College
Setting: urban, hospital.
Funding: Norwegian Programme for Development, Research and Education and Re-
search council of Norway and Global Health and Vaccination Research GLOBVAC
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Adequate randomization described: a sci-
entist who was not involved in the data col-
lection and analysis, generated random-al-
location sequences in permuted blocks of
variable sizes separately for the 2 sites. Sep-
arate sequences were generated for the age
groups 6 months to 3 years, 4 to 6 years, 7
to 9 years, and 10 to 15 years
Allocation concealment (selection bias) Low risk Bottles that contained the micronutrient
supplements were serially numbered for
each stratum for the 2 sites. The 4 study
syrup preparations had a similar packag-
ing, appearance, and smell. The partici-
pant, physician, and laboratory personnel
were blinded to the intervention.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The 4 study syrup preparations had a
similar packaging, appearance, and smell.
The participant, physician, and laboratory
personnel were blinded to the interven-
tion. They maintained masking during the
data analysis by coding treatment alloca-
49Nutritional supplements for people being treated for active tuberculosis (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Lodha 2014 IND (Continued)
tion with 4 letters
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up overall
2 months: 10/403 (2.5%); 6 months: 22/
403 (5.5%)
6 month loss to follow-up per group:
Micronutrient + zinc group: 8/102 (8%)
Micronutrient group: 4/100 (4%)
Zinc group: 7/101 (7%)
Placebo group: 3/100 (3%)
Selective reporting (reporting bias) Low risk We obtained the study protocol and the
trial authors reported all outcomes in the
paper that they listed in the protocol. Five
additional outcomes were listed in the pro-
tocol and will likely be reported in future
papers
• Interferon gamma responses toM.
tuberculosis antigens ESAT6 and CF10 by
quantiferon assay at baseline, 2 months,
and 6 months of treatment.
• To study effect of zinc
supplementation on ocular toxicity in
children receiving ethambutol by VER.
• To document drug resistance (S, I,
R, E) patterns among children with
culture confirmed tuberculosis.
• To document genotypic strain
diversity among children with culture
confirmed tuberculosis, also associations
between strain type and disease severity
and drug resistance.
• To document the spectrum of
mycobacterial species by culture in
children clinically suspected of having
pulmonary tuberculosis.
Other bias Low risk Baseline characteristics: most demographic
and clinical profiles were comparable at
baseline. However, there were some differ-
ences regarding sex distribution, parental
educational level, diagnosis, and energy and
zinc intakes before enrolment
Fundings: non-biased source of funding.
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Martineau 2011 GBR
Methods Study design: RCT.
Study dates and duration: January 2007 to July 2009, follow-up 8 weeks
Standard care: All participants received directly observed antituberculous therapy:
2RHZE
Participants Number: 146 enrolled; 128 in primary analysis.
Inclusion criteria: adults aged over 18 years, newly diagnosed sputum positive pulmonary
tuberculosis
Exclusion criteria: known intolerance to vitamin D or antituberculous therapy, sarcoido-
sis, hyperparathyroidism, nephrolithiasis, HIV infection, pulmonary silicosis, malig-
nancy, renal or hepatic failure, oral corticosteroids, cytotoxic drugs or other immuno-
suppressant therapy in the last month, antituberculous therapy for > 7 days in the pre-
ceding 6 months, currently taking antituberculous therapy other than RHZE, known
rifampicin resistance, serum corrected calcium > 2.65 mmol/L, aspartate transaminase
or alanine transaminase > 120 IU/L, total serum bilirubin > 40 µmol/L, serum creatinine
> 250 µmol/L, pregnant or breastfeeding
Baseline characteristics
• Nutritional status: mean BMI (SD): 20.1 kg/m² (3.1) supplement group versus
20.2 kg/m² (2.7) placebo group.
• HIV status: 5% positive supplement group versus 3% positive placebo group.
• MDR/XDR-TB: rifampicin resistant isolate: 0% supplement group versus 4%
placebo group.
• Vitamin D status: mean serum 25-hydroxyvitamin D nmol/L (SD): 21.1 (20.0)
supplement group versus 21.3 (19.0) placebo group; normal range > 75 nmol/L.
Interventions Group 1: 4 oral doses of 2.5 mg vitamin D3 (Viganol oil, Merck Serono) on or before
day 7 after the start of tuberculosis treatment, day 14, day 28, and day 42.
Group 2: an organoleptically identical placebo (Miglyol Oil, Caesar and Loretz) given
as above
Outcomes • Median time to sputum conversion.
• Serious adverse events.
• Other adverse events.
• Death.
• Mean serum 25-hydroxyvitamin D at baseline and day 56.
Not included in the review: haemoglobin level, mean corpuscular volume, total white
blood cell count, lymphocyte count, monocyte count, neutrophil count, platelet count,
erythrocyte sedimentation rate,C-reactive protein levels, chest radiography zones affected
Notes Location: London, UK.
Setting: 10 National Health Service Trusts.
Funding: British Lung Foundation.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “generated a random sequence using a com-
puter program that assigned the term active
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or placebo to the numbers 1 to 200 by per-
muted block randomisation with blocks of
10”
Allocation concealment (selection bias) Low risk “The packs were then assigned a ran-
domisation number according to this com-
puter generated randomisation sequence”,
“Study staff who assigned patients to the
active drug or placebo had no knowledge
of the next assignment in the sequence, be-
cause they did not have access to the study
code”, “Treatment allocationwas concealed
from patients and study staff ”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “organoleptically identical placebo”.
“adverse events judged to be potentially re-
lated to vitamin D by physicians unaware
of allocation”
“Those analysing the data were not masked
to group assignment”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The trial authors reported outcomes on
an intention-to-treat basis. The number
of participants lost to follow-up (3 in the
placebo group and 6 in the placebo group)
and the reasons were clearly reported for
each group
Selective reporting (reporting bias) Unclear risk We were unable to retrieve the trial proto-
col. There was no evidence of selective out-
come reporting
Other bias Low risk We did not identify any other sources of
bias.
Martins 2009 TLS
Methods Study design: RCT.
Study dates and duration: March 2005 to November 2005, follow-up 8 months
Standard care: all participants received routine care including drugs (DOTS), default
tracing, and clinical monitoring according to National TB Control Program guidelines:
2RHZE/6HE
Participants Number: 270 enrolled; numbers presented varies for each outcome
Inclusion criteria: adults aged > 18 years, pulmonary tuberculosis diagnosed by positive
sputum criteria or NTP guidelines, willingness to receive treatment from the clinic for
8 months
Exclusion criteria: pregnancy, previous treatment for tuberculosis for > 1 month, unable
to agree to complete treatment, unwilling to attend for a daily meal, chose community
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DOT
Description: adults aged > 18 years.
Baseline characteristics
• Nutritional status: BMI < 18.5 kg/m²: 108/137 treatment group versus 105/133
control group.
• HIV status: not mentioned.
• MDR/XDR-TB: not mentioned.
• Described as poor; 80% had no formal income, food was readily available but
expensive.
Interventions Group 1: a daily meal (intensive phase; week 1 to 8) followed by a food parcel (contin-
uation phase; week 9 to 32). The meal consisted of a bowl of meat, kidney beans, and
vegetable stew with rice. The food parcel contained unprepared red kidney beans, rice,
and oil adequate for 1 meal per day
Group 2: verbal and written nutritional advice concerning locally available food that
would constitute a balanced diet
Outcomes • Treatment completion at 8 months.
• Mean weight gain (%) at 8 weeks and 32 weeks.
• Cough clearance at 4, 8, and 32 weeks.
• Sputum clearance.
• Adverse events.
• Deaths during study.
Not included in review: mean compliance, default rate.
Notes Location: Dili, Timor-Leste.
Setting: 3 primary care clinics.
Funding: the UNICEF/UNDP/World Bank/WHO Special Programme for Research
and Training in Tropical Diseases, Australian National Health and Research Council
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “An independent statistician computer
generated a random allocation sequence
with randomly varying block sizes in Stata
(version 8)”
Allocation concealment (selection bias) Low risk “The sequence was concealed from all
investigators with sequentially numbered
opaque sealed envelopes prepared distant
from the study site”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Both participants and treatment providers
were aware of an individual’s allocation sta-
tus after randomisation. An independent
observer, who was blinded to the interven-
tion received by the patients, however, de-
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termined the primary outcome”
Incomplete outcome data (attrition bias)
All outcomes
High risk High levels of missing data for the out-
comes of cough clearance (28% interven-
tion versus 27% control at 8 weeks) and
weight gain (12% intervention versus 9%
control at 8 weeks, 29% intervention ver-
sus 33% control at 32 weeks). These could
significantly affect the result
Selective reporting (reporting bias) Low risk We were unable to retrieve the trial proto-
col. There was no evidence of selective re-
porting
Other bias Low risk We did not identify any other sources of
bias.
Mehta 2011 TZA
Methods Study design: RCT.
Standard care: all participants received antituberculous therapy (6 months DOT: isoni-
azid 50 mg, rifampicin 200 mg, ethambutol 10 to 15 mg/kg, and pyrazinamide 20 to 30
mg/kg daily for 2 months; isoniazid 50 mg and rifampicin 200 mg daily for 4 months)
and were visited at home by the study nurse every 2 weeks
Study dates and duration: May 2005 to September 2007. Follow-up 8 weeks
Participants Number: 255 enrolled and randomized; outcomes presented for 237
Inclusion criteria: aged 6 weeks to 5 years; loss of > 10% maximum weight or failure
to gain weight for 2 months; cough with wheeze for ≥ 4 weeks; history of household
contact with a probable or confirmed tuberculosis case in the past 6 months; pyrexia
of unknown origin; painless swelling in a group of cervical lymph nodes; children who
were diagnosed with tuberculosis in the past 5 years and have received antituberculous
therapy for a period < 4 weeks. Positive TST (≥ 10 mm induration in HIV-negative
and ≥ 5 mm in HIV-positive; after 48 to 72 hours) or with chest X-ray indicative of
tuberculosis (based on unequivocal lymphadenopathy or military tuberculosis) eligible
for enrolment
Exclusion criteria: children who had been treatedwith antituberculous therapy exceeding
4 weeks in the past 1 year
Baseline characteristics
• Nutritional status: median (IQR) MUAC cm: 13.0 (11.9 to 14.25) multivitamin
group versus 13.0 (11.2 to 14.0) placebo group; weight (kg): 8.48 multivitamin group
versus 7.95 placebo group.
• HIV status: 39.1% HIV-positive in the multivitamin group, 29.1% HIV-positive
in the placebo group.
• MDR/XDR-TB: not mentioned.
• Micronutrient status: not documented.
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Interventions Group 1: multivitamin supplements daily for the first 2 months. Composition: vitamin
B1 0.5 mg, vitamin B2 0.6 mg, niacin 4 mg, vitamin B6 0.6 mg, folate 130 µg, vitamin
B12 1 µg, vitamin C 60 mg, and vitamin E 8 mg
• Age < 6 months: 1 capsule daily.
• Age 7 to 36 months: 2 capsules daily.
• Age > 36 months: 3 capsules daily.
Group 2: placebo daily for the first 2 months.
Outcomes • Weight gain at 2 months.
• Deaths during treatment.
Not included in this review: height, MUAC, and triceps skin-fold thickness changes at
2 months, clearance on chest x-ray at 2 months, immunological outcomes
Notes Location: Dar Es Salaam, Tanzania.
Setting: hospital paediatric clinic.
Registration number: NCT00145184.
Source of funding: National Institutes of Health Grant, the Harvard School of Public
Health
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk An off-site statistician generated the ran-
domization sequence; a list from 1 to 400
was prepared according to this randomiza-
tion sequence in blocks of 20
Allocation concealment (selection bias) Low risk At enrolment, the trial staff assigned each
eligible child to the next numbered bottle
of regimen at the site. The statistician kept
the randomization list confidential, with
the exception of the pharmaceutical com-
pany that prepared the blinded treatment
Blinding (performance bias and detection
bias)
All outcomes
Low risk To minimize the risk of loss of blinding,
the regimen bottles, with no visual differ-
ence between active regimen and placebo,
were received from the manufacturer with-
out any identification; the study staff then
labelled the bottles with the participant’s
initials and identificationnumber. Both the
clinicians and the participants were blinded
to the study regimen
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up were low: 2.3% supple-
ment group versus 1.6% placebo group
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Selective reporting (reporting bias) Low risk Although we were unable to retrieve the
trial protocol, there was no evidence of se-
lective reporting
Other bias High risk There was a large difference in HIV sta-
tus between the intervention and control
groups at baseline
Mily 2015 BGD
Methods Study design: RCT.
Standard care: all participants received antituberculous therapy (isonizaid 75 mg, ri-
fampicin 150 mg, pyrazinamide 400 mg, and ethambutol 275 mg for 2 months, fol-
lowed by rifampicin 150 mg plus isonizaid 75 mg for 4 months), given under direct
observation
Study dates and duration: December 2010 to December 2013. Follow-up 24 weeks
Participants Number: 288 enrolled and randomized.
Inclusion criteria: age > 18 years, newly diagnosed sputum smear-positive tuberculosis,
consent
Exclusion criteria: pregnancy and lactation, relapse tuberculosis, HIV infection, hyper-
calcaemia, regular intake of vitamin D, diabetes, cardiovascular, hepatic and renal dis-
eases and malignancy, suspicion of prolonged drug abuse
Baseline characteristics
• Nutritional status: mean weight (kg): males: 47.9 vitamin D group versus 46.3
placebo group; females: 38.4 vitamin D group versus 39.8 placebo group.
• HIV status: excluded.
• MDR/XDR-TB: not mentioned.
• Micronutrient status: mean plasma 25(OH)D3 level: 28.0 vitamin D group
versus 28.1 placebo group.
Interventions Group 1: vitamin D 5000 IU daily for 8 weeks.
Group 2: placebo.
Not included in the review:
Group 3: 4-phenylbutyrate 500 mg twice daily.
Group 4: vitamin D plus 4-phenylbutyrate.
Outcomes • Culture conversion at 4 weeks.
• Time to sputum conversion.
• Vitamin D levels.
• Weight gain.
• Adverse events.
Not included in this review: Cough remission, CXR changes, normalization of fever,
immunological measures
Notes Location: Dhaka, Bangladesh.
Setting: National Institute of the Diseases of the Chest Hospital (NIDCH)
Registration number: NCT01580007.
56Nutritional supplements for people being treated for active tuberculosis (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Mily 2015 BGD (Continued)
Source of funding: International Centre for Diarrheal Disease Research, Bangladesh,
Sida Agreement support Grant 384, and Swedish Strategic Foundation, and the Swedish
Heart-Lung Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer-generated randomization se-
quence”.
Allocation concealment (selection bias) Low risk “Independent assistants from the Hospital
pharmacy prepared the study medication
packs (PBA and placebo tablets; with iden-
tical appearance, colour and taste), and la-
belled these tablets with a randomization
number”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “placebo with identical appearance, colour
and taste”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up in the first 8 weekswere
low.
Selective reporting (reporting bias) Low risk We were unable to retrieve the trial proto-
col. There was no evidence of selective re-
porting
Other bias Low risk We did not identify any other sources of
bias.
Morcos 1998 EGY
Methods Study design: RCT.
Study dates and duration: not stated.
Standard care: all participants received standard anti-tuberculous therapy: HRS for 2
months (beyond 2 months therapy is not described)
Participants Number: 24 enrolled; outcomes presented for 24.
Inclusion criteria: children with active tuberculosis; pulmonary or extrapulmonary
Exclusion criteria: none stated.
Baseline characteristics
• Nutritional status: not stated.
• HIV status: not mentioned.
• MDR/XDR-TB: not mentioned.
• Vitamin D1: the mean vitamin D level at baseline is not given for the separate
groups.
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Interventions Group 1: usual treatment plus vitamin D (1000 IU/day) for 8 weeks
Group 2: usual treatment.
Outcomes • Body weight before and after treatment.
• Vitamin D levels.
Notes Location: Cairo, Egypt.
Setting: inpatients and outpatients at a children’s hospital
Funding: not stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly divided into 2 groups”. The trial
authors did not provide any further details
Allocation concealment (selection bias) Unclear risk The trial authors did not describe any allo-
cation concealment
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial authors did not describe any
blinding and did not use a placebo
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up: 24/24 (100%) anal-
ysed.
Selective reporting (reporting bias) Unclear risk We were unable to retrieve the trial proto-
col.
Other bias High risk The trial authors did not state important
baseline characteristics
Nursyam 2006 IDN
Methods Study design: RCT.
Study dates and duration: January 2001 to August 2001, follow-up 8 weeks
Standard care: all participants received antituberculous therapy in accordance with
DOTS program, first category: 2RHZE/4RH
Participants Number: 67 enrolled; outcomes presented for 67.
Inclusion criteria: adults aged 15 to 59 with sputum-culture positive pulmonary tuber-
culosis and moderately advanced lesion
Exclusion criteria: corticosteroids or immunosuppressive treatment, AIDS, renal failure,
diabetes mellitus, liver cirrhosis, measles, malignancies, leprosy, or severe nutritional
deficiency
Baseline characteristics
• Nutritional status: mean BMI (SD): 16.87 kg/m² (2.06) treatment group versus
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17.68 kg/m² (2.54) placebo group.
• HIV status: negative.
• MDR/XDR-TB: not described.
• Described as: 67.2% had low income, 71.6% were low in nutritional status.
• Vitamin D status at baseline not described.
Interventions Group 1: vitamin D (0.25 mg/day for the first 6 weeks).
Group 2: placebo.
Outcomes • Sputum-culture positive at 6 weeks.
• BMI at 0 and 6 weeks.
Outcomes not included in this review: x-ray improvement at 6 weeks, default rate
Notes Location: Jakarta, Indonesia.
Setting: outpatients at a pulmonary clinic.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors described it as “ran-
domised”; but gave no further details
Allocation concealment (selection bias) Unclear risk The trial authors did not describe alloca-
tion concealment.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial authors described the trial as “dou-
ble blind” and stated “the placebo were
manufactured in the same shape and size”.
They did no provide any further details
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up. The trial
authors analysed 67/67 (100%) for sputum
conversion at 6 weeks
Selective reporting (reporting bias) Unclear risk We were unable to retrieve the trial proto-
col. There was no evidence of selective re-
porting
Other bias Low risk We did not identify any other sources of
bias.
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Pakasi 2010 IDN
Methods Study design: RCT.
Study dates and duration: January 2004 to December 2005, follow-up 6 months
Standard care: all participants received antituberculous therapy in accordance with
DOTS program; 2RHZE (daily)/4HR (thrice weekly), given by a treatment partner who
was paid if the participant successfully completed treatment
Participants Number: 300 enrolled; 76 zinc; 72 vitamin A; 66 vitamin A + zinc; 86 placebo - 255
completed 6 months and were analysed
Inclusion criteria: adults aged 15 to55, newly diagnosed sputumAFBpositive pulmonary
tuberculosis
Exclusion criteria: pregnancy, lactation, underlying chronic, or degenerative diseases
Baseline characteristics
• Nutritional status: mean BMI (SD): 16.5 kg/m² (2.2) Zinc; 16.5 kg/m² (2.2) Vit
A; 16.6 kg/m² (2.1) zinc + vitamin A, and 16.4 kg/m² (2.5) in the placebo group.
• HIV status: not mentioned.
• MDR/XDR-TB: not mentioned.
• Vitamin A status: median plasma retinol µmol/L (IQR): 0.75 (0.5 to 1.0) zinc; 0.
7(0.5 to 1.5) vitamin A; 0.7(0.4 to 1.1) zinc + vitamin A and 0.7(0.5 to 1.0) placebo
group.
• Zinc status: mean plasma zinc µmol/L (SD): 11.6(2.2) zinc; 11.9(3.0) vitamin A;
12.1(3.0), zinc + vitamin A and 11.8(2.4) placebo group.
Interventions Zinc group: 15 mg zinc sulphate daily for 6 months as a capsule
Vitamin A group: 5000 IU (1500 retinol equivalents) daily as a capsule
Zinc + vitamin A group: both the above capsules for 6 months
Placebo group: lactose capsule daily for 6 months.
Outcomes • Sputum smear conversion weekly for 8 weeks.
• Anthropometry: weight, BMI, skin folds, percentage body fat.
• Blood tests: plasma zinc, vItamin A.
• Deaths during study.
Not included in this review: chest X-ray cavity size, C-reactive protein, ESR,
Hemoglobin, leukocyte count, and serum albumin
Notes Location: Nusa Tenggara Timur Province, Indonesia.
Setting: community-based trial.
Funding: Canadian International Development Agency through World Vision Interna-
tional Indonesia:Food integrated to Hinder TB Project (WVI-FIGHT Project)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomisationwas done using a computer
program”.
Allocation concealment (selection bias) Unclear risk “a treatment code was given to each sub-
ject”. The trial authors did not provide any
further details
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Pakasi 2010 IDN (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk “All capsules were identical in shape ,colour
and size”.
Incomplete outcome data (attrition bias)
All outcomes
High risk There was greater than 10% loss to follow-
up in each group.
Selective reporting (reporting bias) Unclear risk We were unable to retrieve the trial proto-
col. There was no evidence of selective re-
porting
Other bias Low risk We did not identify any other sources of
bias.
Paliliewu 2013 IDN
Methods Study design: RCT.
Study dates and duration: not described.
Standard care: short course directly observed antibiotic therapy. Intensive 60-day treat-
ment with isoniazid (300 mg/day), rifampicin (600 mg/day), pyrazinamide (1600 mg/
day), and ethambutol (1200 mg/day) followed by a sustained 45-dose therapeutic phase
with isoniazid (800 mg/dose) and rifampicin (600 mg/dose)
Participants Number: 36 enrolled.
Inclusion criteria: 14 to 50 years, ≥ 2 sputum smear positive, minimal-medium radio-
logical lesion, 16 to 23 mg/kg² (BMI), ≥ 2.5 to 4.5 g/dL albumin levels and no prior
history of tuberculosis or tuberculosis treatment
Exclusion criteria: pregnant, breast feeding, used corticosteroids, had HIV, diabetes or
another serious co morbidity
Baseline characteristics
• Nutritional status: not stated.
• HIV status: not stated.
• MDR/XDR-TB: not stated.
• Micronutrient levels not stated.
• Sputum positivity: 18 (100%) in intervention group, 18 (100%) in placebo group.
Interventions Channa striata group: C. striata capsules, 4 months supplementation with 2 g/day, 3
times/day of C. striata for 12 weeks.
Placebo group: organoleptically matched placebo with identical dosage regime
Outcomes • Percentage sputum conversion.
• Disease signs & symptoms - cough, haemoptysis, dyspnoea, fever, night sweats,
fatigue.
• Laboratory indicators- AST, ALT, creatinine, uric acid, albumin.
• TNF-α, IFN-γ , and IL-10 levels.
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Paliliewu 2013 IDN (Continued)
Notes Location: Indonesia.
Setting: clinic, patients attending Department of Internal Medicine, University of Sam
Ratulangi, Manado, North Sulawesi, Indonesia
Funding: research grant from PT. Royal Medicalink Pharmalab, Makassar South Su-
lawessi, Indonesia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors did not describe how the
random sequence was generated
Allocation concealment (selection bias) Unclear risk The trial authors did not explicitly describe
this process.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Participants were blinded to the treatment
allocation as organoleptically identical cap-
sules were provided to both groups at sim-
ilar times. Blinding of study personnel and
outcome assessors was not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The trial authors did not provide any infor-
mation on the number of participants lost
to follow-up
Selective reporting (reporting bias) Unclear risk We were unable to obtain a copy of the
trial protocol so it is unclear if the authors
presented data on all of the stipulated out-
comes
Other bias Low risk Baseline comparability: figure in paper pro-
vides information on the sex, clinical signs,
and symptoms and lab indicators at base-
line. There was no difference in any of these
variables at baseline
Funding source: research grant from PT.
Royal Medicalink Pharmalab
Conflict of interest: not stated.
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Paton 2004 SGP
Methods Study design: RCT.
Study dates and duration: November 2000 to July 2002. Follow-up 24 weeks
Standard care: all participants received combination antituberculous drug treatment,
ancillary care, and follow-up according to standard protocols of the Tuberculosis Control
Unit
Participants Number: 36 enrolled; outcomes presented for 34.
Inclusion criteria: adults aged 18 to 69 years, with pulmonary tuberculosis and a body
mass index < 20 kg/m²
Exclusion criteria: diabetes or other severe underlying disease, concomitant corticosteroid
or immunosuppressive therapy, HIV-positive or considered to be at risk of HIV and
refused testing, history of non-compliance to tuberculosis therapy, unable to tolerate
conventional regimen, required inpatient care
Baseline characteristics
• Nutritional status: mean BMI (SD): 16.7 kg/m² (1.5) supplement group versus
17.9 kg/m² (1.9) control group.
• HIV status: all negative.
• MDR/XDR-TB: not mentioned.
• Description: no comment on the social economic status of participants.
Interventions Group 1: a target energy intake was calculated for each participant and advice given
to them on how to reach this target based on a 24-hour food diary; participants were
also supplied with high-energy oral nutritional supplements (6.25 g protein, 20.2 g
carbohydrate, 4.29 g fat, 150 kcal/100 mL) and advised to consume 2 packets/day
between meals (600 kcal total), which increased to 3 packets/day if tolerated, until they
reached a body mass index of 20 or usual body weight
Group 2: participants were advised to increase their food intake and given advice to
address any imbalances in their diet based on a 24-hour food diary
Outcomes • Body weight, total lean mass, and total fat mass.
• Change in maximum grips strength and time stands test.
• Change in quality of life score.
Not included in the review: total energy intake; total energy intake from normal diet
Outcomes measured at 6, 12, and 24 weeks.
Notes Location: Singapore.
Setting: outpatients attending a tuberculosis control unit.
Funding: National Medical Research Council of Singapore, Ensure donated by Abbott
Laboratories
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomisation was 1:1 for the 2
groups and was performed by randomly
shuffling opaque envelopes containing
study codes. Preparation of the randomisa-
tion envelopes was performed by amember
of the staff who was not directly involved
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Paton 2004 SGP (Continued)
in the study”
Allocation concealment (selection bias) Unclear risk See above. The trial authors did not report
any further details
Blinding (performance bias and detection
bias)
All outcomes
High risk None described. Given the nature of the
intervention, only outcome assessors could
reasonably have been blinded but the trial
authors did not describe this
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses to follow-up were low at 6 weeks
(3%), but high at 24 weeks: 21% in the
supplement group versus 35% in the advice
only group
Selective reporting (reporting bias) Unclear risk We were unable to retrieve the trial proto-
col. There was no evidence of selective re-
porting
Other bias Low risk We did not identify any other sources of
bias.
Praygod 2011a TZA
Methods Study design: RCT.
Study dates and duration: April 2006 to March 2009, follow-up 5 months
Standard care: all participants received standardized antituberculous drug treatment for
6 to 8 months according to national guidelines: 2RHZE/6HE
Participants Number: 865 enrolled.
Inclusion criteria: adults aged > 15 years, with new or relapse pulmonary tuberculosis
Exclusion criteria: extra-pulmonary tuberculosis, terminal illness, pregnancy, sputum-
positive patients with HIV co-infection
Note: the trial included patients with sputum-negative pulmonary tuberculosis and HIV
co-infection
Baseline characteristics
• Nutritional status: mean BMI (SD): 18.9 kg/m² (2.8) intervention group versus
18.9 kg/m² (3.1) control group.
• HIV status: 27% HIV-positive intervention group versus 29% control group.
• MDR/XDR-TB: not mentioned.
• Description: no comment on the social economic status of participants.
• Micronutrient status: at baseline not reported.
Interventions Group 1: the intervention group received a daily energy-protein similar to the control
biscuit but with additional: 1.5 mg vitamin A, 20 mg thiamin, 20 mg riboflavin, 25 mg
vitamin B6, 50 µg vitamin B12, 0.8 mg folic acid, 40 mg niacin, 200 mg vitamin C, 60
mg vitamin E, 5 µg vitamin D, 0.2 mg selenium, 5 mg copper, 30 mg zinc
Group 2: the control group received a daily energy-protein biscuit for the first 60 days
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Praygod 2011a TZA (Continued)
of treatment. Composition: 4.5 g protein, 615 kJ energy, 120 mg phosphorous, 120 mg
calcium, 36 mg magnesium, 70 mg sodium, 150 mg potassium, and traces < 1 mg of
iron and zinc
Outcomes • Body weight, arm fat area, arm muscle area at 0, 2, and 5 months.
• Maximum hand grips strength at 0, 2, and 5 months.
Notes Location: Mwanza, Tanzania.
Setting: 4 tuberculosis clinics serving urban and suburban patients
Funding: the Danish Council for Independant Research, Danida and the University of
Copenhagen
Clinical trial registry number: NCT00311298.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Allocation to treatment arms followed
a computer-generated randomisation se-
quence using permuted blocks of ten”
Allocation concealment (selection bias) Low risk “The random sequence was used by a des-
ignated research staff member who was not
involved in any clinical work in TB clinics
to arrange and label the supplement packs
with identity numbers ranging from 1 to
1500. During the study, the randomisa-
tion sequence and code were kept in a safe
cabinet and were accessible only to the re-
search staff. Recruitment of study partic-
ipants was done by clinic staff. Then the
same designated research staff assigned the
recruited patient an identity number and
sent the corresponding nutritional supple-
ment pack to the respective clinic”.
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Both control and experimental supple-
ments were of the same size and colour
but had slightly different tastes and were
wrapped in grey-coloured paper box with
6 bars each”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up at 2 months and 5
months were 10.2% and 18.0% respec-
tively. However, the proportion lost to fol-
low-up did not differ significantly between
the groups
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Praygod 2011a TZA (Continued)
Selective reporting (reporting bias) Unclear risk Outcomes reported in the publication
match those set out in the protocol. How-
ever, mortality, a secondary outcome was
not reported on
Other bias Low risk The baseline characteristics of the 2 arms
were comparable.
Funding: Danish council for indepen-
dent research - Medical sciences; Danida
throughConsultative ResearchCommittee
for Development Research; University of
Copenhagen
Conflict of interest: all trial authors re-
ported no conflicts of interest
Praygod 2011b TZA
Methods Study design: RCT.
Study dates and duration: April 2006 to March 2009, follow-up 5 months
Standard care: all participants received standardized antituberculous drug treatment for
6 to 8 months according to national guidelines: 2RHZE/6HE
Participants Number: 377 randomized.
Inclusion criteria: adults aged > 15 years, with new or relapse sputum-positive pulmonary
tuberculosis with HIV co-infection
Exclusion criteria: extra-pulmonary tuberculosis, terminal illness, pregnancy
Baseline characteristics
• Nutritional status: mean BMI (SD): 18.7 kg/m² (2.9) intervention group versus
18.5 kg/m² (2.8) control group.
• HIV status: all HIV positive.
• MDR/XDR-TB: not mentioned.
• Description: no comment on the social economic status of participants.
Interventions Group 1: the intervention group received 6 daily energy-protein biscuits for the first 60
days of treatment, of which 1 contained the additional micronutrients
Group 2: the control group received 1 daily energy-protein biscuit with additional mi-
cronutrients
Basic biscuit: composition: 4.5 g protein, 615 kJ energy, 120 mg phosphorous, 120 mg
calcium, 36 mg magnesium, 70 mg sodium, 150 mg potassium, and traces < 1 mg of
iron and zinc
Biscuit with additional micronutrients: as above plus 1.5 mg vitamin A, 20 mg thiamin,
20mg riboflavin, 25 mg vitamin B6, 50 µg vitamin B12, 0.8 mg folic acid, 40mg niacin,
200 mg vitamin C, 60 mg vitamin E, 5 µg vitamin D, 0.2 mg selenium, 5 mg copper,
30 mg zinc
Outcomes • Body weight, arm fat area, arm muscle area at 0, 2, and 5 months.
• Maximum hand grips strength at 0, 2, and 5 months.
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Notes Location: Mwanza, Tanzania.
Setting: 4 tuberculosis clinics serving urban and suburban patients
Funding: The Danish Council for Independant Research, Danida and the University of
Copenhagen
Clinical trial registry number: NCT00311298.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer-generated randomisation se-
quence, using permuted blocks of ten”
Allocation concealment (selection bias) Low risk “The allocation sequence was used by des-
ignated research staff to sequentially ar-
range and label supplement packs with
identity numbers ranging from 1 to 500.
During the study the randomisation se-
quence and code were kept in a safe cab-
inet only accessible by designated research
staff. Recruitment was done by clinic staff.
The same designated research staff not em-
ployed at the study clinics assigned an iden-
tity number to the recruited patient and
sent the corresponding nutritional pack to
the respective clinic”
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding was not possible due to the nature
of the intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk At 2 and 5 months, 12.2% and 19.1% of
participants were lost to follow-up. How-
ever, the proportions lost to follow-up were
similar across the intervention and control
arms of the study
Selective reporting (reporting bias) Low risk Outcomes reported in the publication
match those set out in the protocol. How-
ever, mortality, a secondary outcome was
not reported on
Other bias Low risk The baseline characteristics of the 2 arms
were comparable.
Funding: Danish council for Indepen-
dent Research - Medical sciences; Danida
throughConsultative ResearchCommittee
for Development Research; University of
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Copenhagen
Conflict of interest: all trial authors re-
ported no conflicts of interest
Pérez-Guzmán 2005 MEX
Methods Study design: RCT.
Study dates and duration: March 2001 to January 2002, follow-up 8 weeks
Standard care: all participants received a short-course regimen with 4 antituberculous
drugs under the DOTS strategy according to WHO guidelines
Participants Number: 21 enrolled; outcomes presented for 21.
Inclusion criteria: adults aged 17 to 60 years with sputum-culture positive pulmonary
tuberculosis
Exclusion criteria: diabetes mellitus; HIV-positive; signs of coronary heart disease
Baseline characteristics
• Nutritional status: mean BMI (SEM): 19.9 kg/m² (1.2) intervention group versus
19.2 kg/m² (0.8) normal diet group.
• HIV status: excluded.
• MDR/XDR-TB: not reported
Interventions Group 1: normal diet containing 2500 calories a day, 16% protein, 54% carbohydrate,
and 30% lipids for 8 weeks; included 250 mg cholesterol/day
Group 2: high cholesterol diet containing 2500 kcal per day, 16% protein, 54% carbo-
hydrate, and 30% lipids for 8 weeks; included 850 mg cholesterol/day
Outcomes • Sputum-culture positive at end of weeks 2, 4, and 8.
Not included in the review: mean number of colony-forming units and acid-fast bacilli
in sputum smear; self reported severity of cough, sputum production, and dyspnoea
Outcomes measured at weeks 1, 2, 3, 4, 5, 6, 7, and 8.
Notes Location: Mexico City, Mexico.
Setting: hospital inpatients.
Funding: none declared.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors described the trial as “ran-
domised”; but did not provide any further
details
Allocation concealment (selection bias) Unclear risk The trial authors did not describe alloca-
tion concealment.
Blinding (performance bias and detection
bias)
Unclear risk “Patients were unaware of the group to
which they had been assigned”
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All outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up. 21/21 (100%).
Selective reporting (reporting bias) Unclear risk We were unable to retrieve the trial proto-
col. There was no evidence of selective re-
porting
Other bias Low risk We did not identify any other sources of
bias.
Ralph 2013 IDN
Methods Study design: RCT.
Study dates and duration: June 2008 to February 2010.
Standard care: participants received directly observed antituberculous therapy: weight-
dosed rifampicin, isoniazid, pyrazinamide, ethambutol daily for 2 months; then ri-
fampicin, isoniazid 3 times a week for 4 months
Participants Number: 548 assessed for eligibility; 200 randomized (45% of planned sample size); 155
analysed
Inclusion criteria: consecutive patients referred to Timika tuberculosis clinic with newly
diagnosed with pulmonary tuberculosis (≥ 2 direct sputum specimens positive for acid
fast bacilli (AFB)) were assessed for eligibility: sputum smear positive, > 15 years, not
pregnant, without hypercalcaemia (ionized calcium ≤ 1.32 mmol/L), not previously
treated for tuberculosis, agreeing to stay in Timika for 6 months and providing written
informed consent
Exclusion criteria: not specified.
Baseline characteristics
• Nutritional status: arginine + vitamin D group 49 ± 8.9 kg; arginine group 47.9 ±
9 kg; vitamin D group 48.1 ± 6.6 kg; placebo group 48.7 ± 5.5 kg.
• HIV status: arginine + vitamin D group 28% HIV-positive; arginine group 6%
HIV-positive; vitamin D group 15% HIV-positive; placebo group 5% HIV-positive.
• MDR/XDR-TB: not reported.
• Vitamin D levels: not reported.
• Arginine levels: not reported.
Difference in sex, HIV status, and X-ray severity at baseline
Interventions L-Arginine + vitamin D group: active L-arginine (L-arginine hydrochloride, Argimax®)
6 g (6 tablets) daily for 8 weeks and active cholecalciferol (vitamin D3, Calciferol
Strong®) 50,000 IU (1250 mcg, 1 tablet) at baseline and on day 28
L-Arginine + placebo vitamin D group: active L-arginine (L-arginine hydrochloride,
Argimax®) 6 g (6 tablets) daily for 8 weeks and placebo cholecalciferol: 1 tablet at
baseline, 1 tablet at 28 days
Placebo L-arginine + vitamin D group: placebo L-arginine: 6 tablets daily for 8 weeks
and active cholecalciferol (vitamin D3, Calciferol Strong®) 50,000 IU (1250 mcg, 1
tablet) at baseline and on day 28
Placebo group: placebo L-arginine: 6 tablets daily for 8weeks and placebo cholecalciferol:
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1 tablet at baseline, 1 tablet at 28 days
Outcomes • Proportion of participants with negative sputum culture on liquid medium at 4
weeks.
• Composite clinical severity score at week 8 (points allocated on weight change,
forced expiratory value (FEV1), cough and presence/absence of sputum and
haemoptysis.
• Safety (death, hospitalization, hypercalcaemia).
• Sputum smear conversion time (≥ 2 consecutive negative smears without a
subsequent positive).
• Change in 6 minute walk test.
• Modified St George’s respiratory questionnaire.
• Chest X-ray severity score (0, 8, and 24 weeks).
• FEV1.
• Primary endpoint stratified by HIV and ethnicity.
• Serious adverse events: death, hospitalization, and life-threatening conditions.
• Adverse events: new symptoms or hypercalcaemia.
Notes Location: Timika, Indonesia.
Setting: Timika tuberculosis clinic and community hospital.
Funding: Australian Respiratory Council, Royal Australasian College of Physicians Co-
vance Award (APR), National Health and Medical Research Council of Australia
Trial registration: NCT00677339.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block random allocation sequence strati-
fied by ethnicity (Papuan/non-Papuan)was
generated and remained concealed from
all investigators throughout study. Inde-
pendent assistants prepared packs labelling
themwith a code corresponding to the ran-
domization sequence
Allocation concealment (selection bias) Low risk Participants were assigned the next sequen-
tial code and dispensed an opaque enve-
lope containing study medication. Active
and placebo medications appeared identi-
cal
Blinding (performance bias and detection
bias)
All outcomes
Low risk Randomization sequence was unknown to
all investigators. Independent assistants la-
belled medication packs with codes corre-
sponding to random sequence. Active and
placebo medications appeared identical
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Incomplete outcome data (attrition bias)
All outcomes
Low risk The trial authors stated that they con-
ducted a modified intention-to-treat anal-
ysis. They kept participants in the arm to
which they were randomized, but excluded
protocol violators and participants lost to
follow-up from the final analysis
Loss to follow-up per arm at end of 4 weeks
(primary outcomes time point)
• L-arginine + vitamin D: 4/50 (8%).
• L-arginine: 3/50 (6%).
• Vitamin D: 3/50 (6%).
• Placebo: 2/50 (4%).
(Loss to follow-up < 10%).
Selective reporting (reporting bias) Unclear risk We were unable to retrieve the trial proto-
col. There was no evidence of selective re-
porting
Other bias High risk Baseline comparability: there were differ-
ences in sex, HIV status, and X-ray severity
between groups at baseline
Funding sources: non-commercial funding
sources.
Conflict of interest: the trial authors stated
there were no competing interests
Other: grouping the data could lead to con-
founders.
Range 2005 TZA
Methods Study design: RCT with 2 x 2 factorial design.
Study dates and duration: August 2001 to July 2002, follow-up 7 months
Standard care: all participants received antituberculous therapy according to WHO
guidelines
Participants Number: 530 enrolled; 31 later found ineligible and excluded; number with available
outcomes data varied by outcome
Inclusion criteria: adults aged > 15 years, sputum-culture or sputum-smear positive
pulmonary tuberculosis
Exclusion criteria: returning to treatment after default or previous treatment failure;
thought unlikely to survive; pregnant or lactating
Baseline characteristics
• Nutritional status: mean BMI (SD): 18.3 kg/m² (2.5) zinc + multivitamins group
versus 18.0 kg/m² (2.5) multivitamin + placebo group versus 17.8 kg/m² (2.5)
zinc+placebo group versus 18.7 kg/m² (2.7) placebo group.
• HIV status: 39% zinc + multivitamins group versus 46% multivitamin + placebo
group versus 47% zinc + placebo group versus 38% placebo group.
• MDR/XDR-TB: not mentioned.
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Range 2005 TZA (Continued)
• Zinc or micronutrient status at baseline not given.
Interventions Factorial design, giving daily supplements or placebo for 8 months
Group 1: zinc 45 mg plus placebo.
Group 2: multivitamin andmineral tablet (vitamin A 1.5mg, vitamin B1 20mg, vitamin
B2 20 mg, vitamin B6 25 mg, vitamin B12 50 µg, folic acid 0.8 mg, niacin 40 mg,
vitamin C 200 mg, vitamin D3 5 µg, vitamin E 60 mg, selenium 0.2 mg, and copper
5 mg) plus placebo
Group 3: zinc 4 mg plus multivitamin and mineral tablet (as above)
Group 4: placebo plus placebo.
Outcomes • Death before 8 months.
• Sputum positive at weeks 2, 4, and 8.
• Weight gain at 8 weeks and 7 months.
Not included in the review: HIV viral load and CD4 count at baseline and 8 weeks
Notes Location: Mwanza region, Tanzania.
Setting: outpatients at 5 health facilities.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Before recruitment of patients, all the let-
ters on the containers were replaced with
study serial numbers from 1 to 550 based
on the computer-generated random se-
quences, using permuted blocks of four”
Allocation concealment (selection bias) Unclear risk “The codes for the MVM and Zn tablets
remained in a sealed envelope, and were
only broken after completion of the initial
data analysis”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Placebo tablets were identical in colour,
shape and size to the corresponding white
Zn and green MVM tablets”
Incomplete outcome data (attrition bias)
All outcomes
High risk Loss to follow-up: mortality: 9% zinc
group versus 14% placebo group, weight
gain: 22% zinc group versus 22% placebo
group. These could significantly alter the
result
Selective reporting (reporting bias) Unclear risk We were unable to retrieve the trial proto-
col. There was no evidence of selective re-
porting
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Range 2005 TZA (Continued)
Other bias Low risk We did not identify any other sources of
bias.
Schön 2003 ETH
Methods Study design: RCT.
Study dates and duration: recruited December 2000 to December 2001. Follow-up 8
weeks
Standard care: all participants receivedDOTS in line with EthopianNational Guidelines
Participants Number: 120 enrolled, outcomes presented for 115.
Inclusion criteria: adults aged 15 to 60 years, smear positive pulmonary tuberculosis
Exclusion criteria: admitted to hospital; pregnant; signs of any concomitant disease other
than HIV; or lived too far away to take part in the directly observed therapy short Direct
Observed Treatment Short-Course (DOTS) programme
Baseline characteristics
• Nutritional status: Mean weight in HIV-negative group: 47.8 kg intervention
group versus 45.3 kg control group, mean weight in HIV-positive group: 45.0 kg
intervention group versus 45.3 kg control group.
• HIV status: 52% HIV-positive.
• MDR/XDR-TB: not mentioned.
Interventions Group 1: arginine capsules (1 g arginine) daily for 4 weeks.
Group 2: placebo.
Outcomes • Death during 8 weeks follow-up.
• Sputum positive at week 8.
• Cough at weeks 2 and 8.
• Weight gain at 1, 2, 4, and 8 weeks.
Not included in the review: serum arginine, citrulline, and nitric oxide metabolite levels
at weeks 0, 2, and 8
Notes Location: Ethiopia.
Setting: Outpatient DOTS programme.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomized in blocks of six (performed
by the state pharmacy of Sweden)”
Allocation concealment (selection bias) Low risk “The studywas double blinded and a sealed
copy of the treatment code was kept by the
project leader until all data had been col-
lected and analysed”
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Schön 2003 ETH (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Described as “double blind” and placebos
were used: the trial authors did not give any
further details
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were 115/120 included in the fi-
nal analysis(96%). Three of these died, 2
moved out of the study area
Selective reporting (reporting bias) Unclear risk We were unable to retrieve the trial proto-
col. There was no evidence of selective re-
porting
Other bias Low risk We did not identify any sources of bias.
Schön 2011 ETH
Methods Study design: RCT.
Study dates and duration: recruited February 2004 to December 2006. Follow-up until
August 2007
Standard care: all participants receivedDOTS in line with EthopianNational Guidelines
Participants Number randomized: 80.
Inclusion criteria: newly diagnosed sputum smear positive older than 15 years
Exclusion criteria: admitted to hospital; peanut allergy, pregnant; signs of any concomi-
tant disease other than HIV; previous treatment for tuberculosis
Baseline characteristics
• Nutritional status: high arginine group - mean BMI: 16.9 95% CI 16.4 to 17.4;
low arginine group - mean BMI 16.4 95%CI 16 to 16.8.
• HIV status: high arginine group - 37% HIV-positive; low arginine group - 32%
HIV-positive.
• MDR/XDR-TB: not mentioned.
Interventions All participants received antituberculous therapy.
High arginine group: 30 g peanuts (1 g arginine, 750 kJ) daily for 4 weeks
Low arginine group: 30 g wheat cracker (0.1 g arginine, 623 kJ) daily for 4 weeks
Outcomes Primary outcome: cure rate (smear positive at start of Rx, completed Rx, and smear
negative at end of Rx and 1 previous occasion)
Secondary outcomes: sputum smear conversion, weight gain, sedimentation rate, reduc-
tion of cough, and chest X-ray improvement at 2 months
Not eligible for review: levels of nitric oxide (NO) metabolites in urine and NO in
exhaled air at 2 weeks and 2 months
Notes Location: Gondar, Ethiopia.
Setting: DOTS clinic at Gondar University Hospital.
Funding: Swedish Heart and Lung Foundation.
Trial number: NCT00857402.
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The Department of Epidemiology at the
Karolinska Institute, Sweden performed
randomization in blocks of 6
Allocation concealment (selection bias) Low risk The randomization code was concealed in
180 sealed individual envelopes. The en-
velopes were only opened when the person
was enrolled in the study
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding was not possible due to the nature
of the intervention (wheat cracker versus
peanuts)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Regarding loss to follow-up, 7/180 (4%)
did not complete the supplement
Selective reporting (reporting bias) Low risk Outcomes reported on in the published
study match those set out in the study pro-
tocol
Other bias Low risk There were no differences in baseline char-
acteristics between the 2 groups
Funding: Swedish Heart and Lung Foun-
dation, The Swedish SAREC/SIDA Foun-
dation and the Swedish Research Council
Conflict of interest: the trial authors had
no conflicts of interest
Semba 2007 MWI
Methods Study design: RCT.
Study dates and duration: July 1999 to February 2005, follow-up 24 months
Standard care: all participants received standard antituberculous therapy as recommended
by the Malawi NTP: 2RHZE/6HE
Participants Number: 1148 enrolled; number with available outcomes data varied by outcome
Inclusion criteria: adults aged 18 to 60 years, sputum positive pulmonary tuberculosis
Exclusion criteria: planning to move away from the study area within the next 2 years;
already taking vitamin supplements; already being treated for tuberculosis; previously
treated for tuberculosis
Baseline characteristics
• Nutritional status: geometric mean BMI (SD): HIV-positive participants 18.3 kg/
m² (2.5) supplement group versus 18.1 kg/m² (2.5) placebo group; HIV-negative
participants 18.5 kg/m² (2.6) supplement group versus 18.8 kg/m² (2.9) placebo
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Semba 2007 MWI (Continued)
group.
• HIV status: 71% HIV-positive supplement group versus 74% placebo group.
• MDR/XDR-TB: not mentioned.
Interventions Group 1: daily micronutrient supplementation for 24 months; supplement consisted of
vitamins A (8000 IU), C (500 mg), D (400 IU), E (200 IU), B6 (2 mg), B12 (6 µg)
, riboflavin (1.7 mg), thiamin (1.5 mg), niacin (20 mg), folate (0.4 mg), zinc (10 mg),
iodine (175 µg), and selenium (65 µg)
Group 2: daily placebo.
Outcomes • Death after 8 months follow-up.
• Vitamin A, vitamin E, and selenium levels at 8 months.
Notes Location: Zomba and Blantyre, Malawi.
Setting: participants diagnosed at a hospital clinic and treated at a community clinic near
where they lived
Funding: the National Institutes of Health; the Fogarty International Centre
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A computer random number generator
was used to generate a random allocation
schedule in permuted blocks of 10”
Allocation concealment (selection bias) Low risk “Treatment assignment was concealed by
pre-packing study supplements in sequen-
tially numbered series according to the al-
location schedule”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Both the study staff and the participants
were blinded to the treatment assignment”
“The placebo and active supplements were
of identical appearance in size, shape and
colour. The placebo and active supple-
ments were packed in identical opaque,
white plastic bottles with sealed caps”
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses to follow-up were high: 13.2% in
the supplement group and 12.9% in the
placebo group
Selective reporting (reporting bias) Unclear risk We were unable to retrieve the trial proto-
col. There was no evidence of selective re-
porting
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Other bias Low risk We did not identify any other potential
sources of bias identified
Seyedrezazadeh 2006 IRN
Methods Study design: RCT.
Study dates and duration: recruited April 2003 to May 2004. Follow-up 60 days
Standard care: all participants received the same antituberculous standard therapy in
accordance with the DOTS strategy
Participants Number: 42 enrolled; outcomes data available for 37.
Inclusion criteria: adults (age range not stated), with sputum positive tuberculosis
Exclusion criteria: previous antituberculous treatment; concurrent use of supplements
containing selenium and vitamin E; illicit drug addiction; signs of severe effects of
antituberculous drug treatment during treatment
Baseline characteristics
• Nutritional status: median BMI (IQR): men 19.6 kg/m² (16.0 to 27.1)
supplements group versus 21.0 kg/m² (16.8 to 23.1) placebo group; women 19.5 kg/
m² (16.6 to 25.8) supplements group versus 22.0 kg/m² (17.0 to 26.7) in placebo
group.
• HIV status: not mentioned.
• MDR/XDR-TB: not mentioned.
Interventions Group 1: daily supplements containing vitamin E (140 mg) and selenium (200 µg) for
4 months
Group 2: placebo.
Outcomes • Sputum positive at days 15, 30, 45, and 60.
• Change in body mass index at 2 months.
Not included in the review: number of lung cavities; cavity surface area; and mean lesion
area at 0, 2, and 6 months
Notes Location: Tabriz, Iran.
Setting: outpatient clinic at research centre.
Funding: the Tuberculosis and Lung Disease Research Centre.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors described the sequence
generation as “randomised”, but did not
provide any further details
Allocation concealment (selection bias) Unclear risk The trial authors did not describe any allo-
cation concealment
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Seyedrezazadeh 2006 IRN (Continued)
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial authors described the trial as dou-
ble blind, and capsules as being “similar in
size and red in colour”, which makes true
blinding unlikely
Incomplete outcome data (attrition bias)
All outcomes
Low risk Regarding losses to follow-up, 37/37
(100%) participants were eligible
Selective reporting (reporting bias) Unclear risk We were unable to retrieve the trial proto-
col. There was no evidence of selective re-
porting
Other bias Low risk We did not identify any other sources of
bias.
Singh 2013 IND
Methods Study design: RCT.
Study dates and duration: September to October 2010 (enrolment), 6 months study
period (Oct 2010 to March 2011)
Standard care: initial 2-month phase of antituberculous therapy. The trial authors did
not describe the precise content of the tuberculosis treatment
Participants Number: 40 enrolled and randomized. 37 included in the final analysis (3 excluded
because of poor compliance)
Inclusion criteria: newly diagnosed sputum smear positive pulmonary tuberculosis pa-
tients taking not more than 7 days of antituberculous therapy aged 18 to 60 years.
Exclusion criteria: known history of drug resistant tuberculosis and renal disease
Baseline characteristics
• Nutritional status: mean BMI kg/m² placebo group: 17.7; vitamin D and calcium
group: 16.37, vitamin A and zinc group: 17.52 (no SDs provided).
• HIV status: not reported.
• MDR/XDR-TB: not mentioned.
• Micronutrient status at baseline not described.
Interventions All groups received antituberculous therapy.
Control group: antituberculous therapy only.
Vitamin D and calcium group: tablet containing vitamin D and calcium (250 IU of
vitamin D3, and 500 mg as calcium carbonate). One tablet per day for first 10 days,
then 3 tablets per week for the remainder of the 2 months
VitaimnA and zinc group: zinc tablet (50mg elemental zinc as zinc sulphate) and vitamin
A tablet (25,000 IU vitamin A as vitamin A palmitate). One vitamin A tablet and 1 zinc
tablet per day for first 10 days, then 3 tablets of each per week for the remainder of the
2 months
Outcomes Sputum smear conversion rates every 20 days from enrolment.
Time to sputum smear conversion.
Weight gain at enrolment and 60 days (no SDs provided).
78Nutritional supplements for people being treated for active tuberculosis (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Singh 2013 IND (Continued)
BMI at enrolment and 60 days (no SDs provided).
Not relevant to review: neutrophil count at enrolment and 60 days; lymphocyte count
at enrolment and 60 days; serum alanine transaminase and aspartate transaminase at
enrolment and 60 days; serum haemoglobin at enrolment and end of 2 months (60 days)
Notes Location: India, HNB hospital attached to the Veer Chandra Singh Garhwali Govt.
Medical Science and Research Institute, Srinagar - Pauri Garhwal (Uttarakhand)
Setting: hospital.
Funding: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors did not describe this and
simply stated randomly assigned
Allocation concealment (selection bias) Unclear risk The trial authors did not describe this.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The trial authors did not describe blinding
of participants, personnel, and outcome as-
sessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were 40 patients randomized to the 3
groups. The trial excluded 3 patients due to
non-compliance and excluded them from
the analysis (8% loss to follow-up)
Selective reporting (reporting bias) Unclear risk We were unable to obtain the study pro-
tocol, and therefore there is unclear risk of
selective outcome reporting. In the abstract
the trial authors stated that the aim of the
study was to assess sputum conversion and
blood profiles during the initial phase of
tuberculosis treatment. They reported on
these outcomes
Other bias Unclear risk The trial authors did not report baseline
characteristics. There was no description of
funding sources or conflict of interest state-
ment
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Sudarsanam 2010 IND
Methods Study design: RCT.
Study dates and duration: recruitment January to Nov 2005, follow-up 1 year
Standard care: All participants received the same antituberculous standard therapy in
accordance with the DOTS strategy
Participants Number: 103 enrolled, 99 analysed at 6 months, 91 at 1 year.
Inclusion criteria: age > 12 years, either sputum positive tuberculosis or clinical and
radiological evidence of pulmonary tuberculosis or biopsy proven extra pulmonary tu-
berculosis, informed consent
Exclusion criteria: relapse of previous antituberculous treatment, end stage renal or liver
disease, CD4 count > 200 (if HIV-positive), BMI < 19 kg/m², patients not from Vellore
Baseline characteristics
• Nutritional status: mean BMI supplement: 17.2 kg/m²; mean BMI no
supplement: 18.2 kg/m².
• HIV status: 20 out of 103 were HIV co-infected.
• MDR/XDR-TB: not mentioned.
• All participants belonged to lower socioeconomic strata.
• Micronutrient status at baseline not described.
Interventions Group 1: macronutrient and micronutrient supplementation for 6 months. The
macronutrient was a ready-to-serve powder, given as monthly rations to supply 930 kcal
and 31.5 g protein per day 3 divided servings. The micronutrient as a once-a-day mul-
tivitamin tablet containing: copper sulphate 0.1 mg, D-pantheol 1 mg, dibasic calcium
phosphate 35 mg, folic acid 500 µg, magnesium oxide 0.15 mg, manganese sulphate 0.
01 mg, nicotinamide 25 mg, potassium iodide 0.025 mg, vitamin A 5000 IU, vitamin
B1 2.5 mg, vitamin B12 2.5 µg, vitamin B2 2.5 mg, vitamin B6 2.5 mg, vitamin C 40
mg, vitamin D3 200 IU, vitamin E 7.5 mg, zinc sulphate 50 mg
Group 2: dietary advice alone.
Outcomes • Death.
• Cure.
• Treatment completion.
• Weight gain.
Not included in the review: adherence.
Notes Location: Vellore, India.
Setting: tuberculosis clinics.
Funding: The Fogarty AIDS International Research and Training Program
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “a computer generated randomisation
code”.
Allocation concealment (selection bias) Low risk “Allocation was concealed, the randomi-
sation codes were in opaque envelopes
opened by the dietician after dietary coun-
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Sudarsanam 2010 IND (Continued)
selling”
Blinding (performance bias and detection
bias)
All outcomes
High risk “There were no attempts made to blind any
of the study team or participants”
Incomplete outcome data (attrition bias)
All outcomes
High risk 3.9% were lost to follow-up at 6 months
and 11.7% at 1 year.
Selective reporting (reporting bias) Unclear risk We were unable to retrieve the trial proto-
col. There was no evidence of selective re-
porting
Other bias Low risk We did not identify any other sources of
bias.
Tukvadze 2015 GEO
Methods Study design: RCT.
Standard care: all participants received antituberculous therapy (isonizaid, rifampicin,
pyrazinamide, and ethambutol - no further details given), given under direct observation
Study dates and duration: July 2009 to April 2012. Follow-up 16 weeks
Participants Number: 199 enrolled and randomized.
Inclusion criteria: age > 18 years, newly diagnosed pulmonary tuberculosis disease with
a positive AFB sputum smear, < 7 days of antituberculous drug therapy before entry,
informed consent.
Exclusion criteria: previous tuberculosis, extrapulmonary tuberculosis, pregnancy or lac-
tation, a history of hypercalcaemia, nephrolithiasis, hyperparathyroidism, sarcoidosis,
organ transplant, hepatic cirrhosis, seizures, or cancer in the past 5 years, baseline plasma
calcium concentration > 2.6 mmol/L, creatinine concentration > 250 mmol/L, or aspar-
tate aminotransferase concentrations > 3 times the upper limit of normal, renal replace-
ment therapy, corticosteroid use in the past 30 days, current use of cytotoxic or immuno-
suppressive drugs, known MDR-TB before study enrolment, current imprisonment
Baseline characteristics
• Nutritional status: BMI < 18.5 kg/m²: 18% vitamin D group versus 28 %
placebo group.
• HIV status: 191/199 were tested. 1% HIV positive in the vitamin D group versus
3% HIV positive in the placebo group.
• MDR/XDR-TB: isoniazid and rifampicin resistance: 12% vitamin D group
versus 11% placebo group.
• Micronutrient status: plasma 25(OH)D3 below 30 nmol/L: 92% vitamin D
group versus 92% placebo group.
Interventions VitaminDgroup: 50,000 IU vitaminD3 3 times aweek for 8 consecutive weeks followed
by 50,000 IU every 2 weeks for a further 8 weeks
Placebo group: placebo tablet for similar dosing regime.
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Tukvadze 2015 GEO (Continued)
Outcomes • Time to sputum culture conversion.
• Culture conversion at 8 weeks.
• Vitamin D levels at baseline and every 2 weeks of follow-up.
• Adverse effects.
Not included in this review: calcium level every 4 weeks, multiple subgroup analyses
looking at predictors of culture conversion
Notes Location: Tbilisi, Georgia.
Setting: National Centre for TB and Lung Disease and affiliated clinics
Registration number: NCT00918086.
Source of funding: National Institutes of Health Grant, the Emory University Global
Health Institute
Additional publications: Frediani JK, et al (2015) Macronutrient intake and body com-
position changes during antituberculous therapy in adults, Clinical Nutrition, http://
dx.doi.org/10.1016/j.clnu.2015.02.007
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Treatment assignments were generated
by the Emory University-based study
biostatistician and implemented locally
through a distributed study database with
the use of a randomized permuted block
algorithm stratified by clinical center site”
Allocation concealment (selection bias) Low risk “All study medication bottles had a unique
bottle number to allow for blinded dispens-
ing”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “The study drugs vitamin D3 and the
placebo were identical in shape and
colour”. The trial authors did not report
blinding of outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
High risk 20/100 (20%)were lost to follow-up or dis-
continued intervention in the vitamin D
group versus 30/99 (30%) in the placebo
group
Selective reporting (reporting bias) Low risk We were unable to retrieve the trial proto-
col. There was no evidence of selective re-
porting
Other bias Low risk We did not identify any other sources of
bias.
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Villamor 2008 TZA
Methods Study design: RCT.
Study dates and duration: April 2000 to April 2005, follow-up 24 months
Standard care: all participants received standard antituberculous treatment following the
DOTS scheme: 2RHZE/6HE
Participants Number: 887 enrolled, number with available outcomes data varied by outcome
Inclusion criteria: adults aged 18 to 65 years, sputum positive pulmonary tuberculosis
Exclusion criteria: Karnofsky score < 40%; pregnant; received more than 4 weeks of
antituberculous therapy in the past year; plans to move away from the study area within
the next 2 years
Baseline characteristics.
• Nutritional status: mean BMI (SD): 18.9 kg/m² (2.5) in HIV-negative placebo
group versus 18.9 kg/m² (2.5) in HIV-negative supplement group, 19.6 kg/m² (2.9) in
HIV-positive placebo group versus 19.3 kg/m² (2.8) in HIV-positive supplement
group.
• HIV status: 53% HIV-positive in supplement group versus 53% in placebo group.
• MDR/XDR-TB: not mentioned.
• Description: > 85% had primary school education.
• Micronutrient status at baseline not described.
Interventions For 24 months
Group 1: daily oral dose in tablet form of mixed micronutrients containing retinol (5000
IU), vitamin B1 (20 mg), vitamin B2 (20 mg), vitamin B6 (25 mg), niacin (100 mg)
, vitamin B12 (50 µg), vitamin C (500 mg), vitamin E (200 mg), folic acid (0.8 mg),
and selenium (100 µg)
Group 2: placebo.
Outcomes • Sputum-culture positive at 1 month.
• Recurrence of positive culture between 1 and 8 months.
• Mortality within 2 years.
• Nutritional parameters: body weight, mid-upper arm circumference, fat-mass, fat-
free mass.
Not included in the review: CD4, CD8, CD3 count and HIV viral load, haemoglobin,
albumin levels, peripheral neuropathy, and genital ulcers
Notes Location: Dar es Salaam, Tanzania.
Setting: 5 outpatient clinics.
Funding: The National Institute of Allergy and Infectious Diseases, US Department of
Agriculture
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Consenting subjects were randomly as-
signed in computer-generated permuted
blocks of 20”
Allocation concealment (selection bias) Unclear risk The trial authors did not describe any allo-
cation concealment
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Blinding (performance bias and detection
bias)
All outcomes
Low risk “Active tablets and placebo were indistin-
guishable in size, taste, and colour. All clin-
ical and research staff were unaware of the
subjects’ treatment assignment”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There were 628/725 (85%) for sputum-
culture positive at 1 month; for mortality
the trial authors included all participants in
the analysis up to the point of loss to fol-
low-up if before end of trial, and presented
hazard ratios
Selective reporting (reporting bias) Unclear risk We were unable to retrieve the trial proto-
col. There was no evidence of selective re-
porting
Other bias Low risk We did not identify any other sources of
bias.
Visser 2011 ZAF
Methods Study design: RCT.
Study dates and duration: May 2005 to August 2008, follow-up 8 weeks
Standard care: all participants received antituberculous therapy: 2RHZE plus pyridoxine
25 mg/day
Participants Number: 154 enrolled; 124 completed study.
Inclusion criteria: 18 to 60 years old, 2 positive sputum smears for acid-fast bacilli or 1
positive plus suggestive chest X-ray findings, written informed consent to a HIV test
Exclusion criteria: previous treatment of tuberculosis, known or suspected multidrug
resistant tuberculosis, clinical evidence of extrapulmonary tuberculosis or liver disease,
renal failure, congestive heart failure or neoplasm, pregnancy
Baseline characteristics
• Nutritional status: mean BMI (SD): males; supplement group 18.9 kg/m² (2.7)
versus 19.0 kg/m² (2) placebo group, females; supplement group 23.0 kg/m² (4.3)
versus 21.6 kg/m² (4.8) placebo group.
• HIV status: 9% HIV positive supplement group versus 11% HIV-positive
placebo group.
• MDR/XDR-TB: excluded.
• Median retinol (range): 21.1 µg/dL (15.1 to 27.8) supplement group versus 21.2
(15.7 to 28.9) placebo group (normal range: > 20 µg/dL).
• Median Zinc (range): 62 µg/dL (53 to 71.8) supplement group versus 59 (51.8 to
65.3) placebo group (normal range: > 70 µg/dL).
Interventions Group 1: a single capsule that contained 200,000 IU vit A (retinyl palmitate) within 24
hours of starting tuberculosis treatment plus 15 mg zinc (zinc gluconate) daily for 5 days
per week for 8 weeks
Group 2: placebo capsule (sunflower oil) within 24 hours of starting tuberculosis treat-
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Visser 2011 ZAF (Continued)
ment plus placebo tablet (starch/gelatin base) daily for 5 days per week for 8 weeks
Outcomes • Death.
• Sputum-smear positive at baseline and 8 weeks.
• Adverse events.
• Weight gain at 2 months.
• Arm muscle circumference at 2 months.
• Vitamin A and zinc status at 2 and 8 weeks.
Outcomes not included in review: adherence, lung cavities at 2 months, copper, CRP,
albumin, haemoglobin, WBC, and neutrophil levels at 2 and 8 weeks
Notes Location: Cape Town, South Africa.
Setting: primary care tuberculosis clinics.
Funding: research grants from the National Research Foundation South Africa, the Nor-
wegian Programme for Development, Research and Higher Education, the Research
Council of Norway, the National Research Foundation, the South African Sugar Associ-
ation, and the Fogarty International Centre. The South African Department of Health
and Pharma Natura Pty donated the vitamin A and placebo capsules respectively
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer-generated permuted blocks of
8, generated by an independent epidemiol-
ogist”
Allocation concealment (selection bias) Low risk “Treatment allocations was concealed by
prepackaging supplements in sequentially
numbered packets according to the alloca-
tion schedule”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Active and placebo capsules and tablets for
both groups were identical in size, shape
and colour. All research team members as
well as laboratory staff involved in the trial
were blinded”
Incomplete outcome data (attrition bias)
All outcomes
High risk Loss to follow-up was high in both groups:
12/77 (16%) supplement group versus 19/
77 placebo group (25%)
Selective reporting (reporting bias) Unclear risk We were unable to retrieve the trial proto-
col. There was no evidence of selective re-
porting
Other bias Low risk “Because of a change in national policy
in April 2008 15 participants received TB
treatment 7 days per week with unsuper-
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vised weekend doses”
Comment: this was unlikely to introduce
significant bias.
Wejse 2008 GNB
Methods Study design: RCT.
Study dates and duration: November 2003 to December 2005, follow-up 12 months
Standard care: all participants received antituberculous therapy: 2RHZE/6HE
Participants Number: 367 enrolled; number with available outcomes data varied by outcome
Inclusion criteria: adults aged > 15 years, diagnosis of tuberculosis by smear positive
(pulmonary tuberculosis) or WHO clinical criteria (extrapulmonary tuberculosis)
Exclusion criteria: none stated.
Baseline characteristics
• Nutritional status: mean BMI (range): 18.8 kg/m² (12 to 33) treatment group
versus 18.5 kg/m² (12 to 27) placebo group.
• HIV status: 39% HIV-positive supplement group versus 33% HIV-positive
placebo group.
• MDR/XDR-TB: not mentioned.
• Mean serum 25-hydroxyvitamin D3 nmol/L (SD): 77.5 (23.8) supplement group
versus 79.1 (21.8) placebo group (normal range: > 75 nmol/L).
• Described as a poor urban population.
Interventions Vitamin D group: 3 doses cholecalciferol (100,000 IU) in drinkable ampoules; given at
start of treatment, 5 months, and 8 months
Placebo group: vegetable oil without cholecalciferol.
Outcomes • Death at 12 months in HIV-positive and HIV-negative participants.
• Sputum-smear positive at baseline, 2 weeks, 4 weeks, 6 weeks, 2 months, 5
months, and 8 months.
• Adverse events.
• Weight gain at 8 months.
• Changes in tuberculosis score at 2, 5, and 8 months.
• Vitamin D status at 2 and 8 months.
Outcomes not included in review: change in CD4 count at 8 months
Notes Location: Guinnea-Bassau.
Setting: 3 health centres and a tuberculosis hospital in a demographic surveillance area
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The random allocation sequence was
computer generated; a list of continuous
study numbers was generated with a ran-
dom allocation to treatment 1 or 2”
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Allocation concealment (selection bias) Low risk “Study numbers were consecutive and
given to patients by the field assistant at
inclusion, and patients were recorded in a
book with pre-written study numbers and
allocation sequence number 1 or 2”, “A
physician gave the trial information and
obtained consent...a trial nurse adminis-
tered studymedicine according to sequence
number”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Study medicine was provided in identical
containers labelled lot 204 (allocation se-
quence number 1) or lot 205 (allocation
sequence number 2)”
“Patients, staff, and researchers assessing
outcome were blinded”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Imbalanced attrition: 20/187 (11%) sup-
plement group versus 10/180 placebo
group (6%)
Selective reporting (reporting bias) Unclear risk We were unable to retrieve the trial proto-
col. There was no evidence of selective re-
porting
Other bias Low risk We did not identify any other sources of
bias.
Abbreviations: RCT = randomised controlled trial; AIDS = acquired immune deficiency syndrome; HIV = human immunodeficiency
virus; E = ethambutol; H = isoniazid; R = rifampicin; S = streptomycin; Z = pyrazinamide; CRP = C-reactive protein; CD4/CD8/
CD3 = a measure of immunological function in HIV-positive people; MDR = multidrug-resistant TB; XDR = extensively drug-
resistant TB; DOTS = directly observed therapy short course; TST = tuberculin skin testing; BMI = body mass index; CXR = chest
X-ray; ESR = erythrocyte sedimentation rate; WBC = white blood cell count; 2RHZE/4HE = 2 months of isoniazid, rifampin,
prazinamide, and ethambutol followed by 4 months of ethambutol and isoniazid; 2RHZE/4HR = 2 months of isoniazid, rifampin,
prazinamide, and ethambutol followed by 4 months of rifampin and isoniazid; INH = isoniazid; 2RHZE/6HE = 2 months of
isoniazid, rifampin, prazinamide, and ethambutol followed by 6 months of ethambutol and isoniazid.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Denti 2015 Ineligible outcomes: pharmacokinetics.
Dibari 2013 Ineligible intervention. Looks at acceptability of ready to eat foods
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Gwinup 1981 Outcomes were irrelevant to this Cochrane review’s objectives (assessed effect of vitamin supplementation on
serum calcium levels in people with tuberculosis)
Hasan 2015 Ineligible intervention: propolis.
Kawai 2014 Ineligible outcomes: linked to Villamor 2008 TZA.
Khandelwal 2014 Ineligible study design: cohort study.
Lin 2014 Ineligible intervention; no relevant outcomes.
Lutge 2013 Ineligible intervention; food vouchers.
Martineau 2009 Excluded as evaluates a single dose of vitamin D.
Mbala 1998 Outcomes were not relevant to review’s objectives (assessed neurological and neuropsychiatric symptoms in
children being treated for tuberculosis using isoniazid with or without vitamin B6 supplementation)
Narang 1984 Groups were not randomly allocated, participants not being treated for active tuberculosis, and outcomes were
not relevant to review’s objectives
Oluboyede 1978 It was unclear whether the groups were randomized; we were unable to contact the trial authors
Permatasari 2014 Ineligible intervention: propolis.
Ramakrishnan 1961 Groups were not randomized to different dietary interventions
Samsidi 2013 Ineligible control/comparison; the control group received milk-based protein supplement
Shi 2001 The study authors assessed only partial parenteral nutrition, which we excluded from this Cochrane review
Srivastava 2011 The study only provided vitamin D for 5 days.
Characteristics of studies awaiting assessment [ordered by study ID]
Al Mamun 2014
Methods RCT
Participants Smear-positive tuberculosis participants (N = 111)
Interventions Vitamin A (5000 IU daily) + zinc (15 mg daily)
Placebo
Outcomes Smear conversion, radiology, haemoglobin, erythrocyte sedimentation rate, C-reactive protein
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Notes The abstract does not provide any data for any of the measured outcomes. We contacted the study authors but did
not receive a response
Chandra 2004
Methods RCT
Duration: not described
Participants Number: 44 enrolled (28 men and 16 women)
Interventions Group 1: 3 tablets 3 times weekly of multiple micronutrients
Group 2: placebo
Outcomes Sputum-smear test positive at 2, 3, 5, and 6 months
Chest x-ray findings positive at 3 and 6 months
Notes Location: India
Setting: unclear
Information still pending: Ranjit Kumar Chandra is a researcher in the field of nutrition and immunology who has
been accused of committing scientific fraud by the British Medical Journal. A jury trial in July 2015 concluded that
the allegations of fraud were truthful. Due to these allegations, a number of his scientific articles have been subject
to retraction (see https://en.wikipedia.org/wiki/Ranjit Chandra).
Guzman-Rivero 2013
Methods RCT (pilot study)
Participants Pulmonary tuberculosis patients
Interventions Antituberculous treatment combined with zinc (45 mg/day) or placebo for 3 months
Outcomes Clinical outcomes, sputum clearance, radiological improvement and nutritional status
Notes Conference abstracts (2)
Information still pending:
Neither of the abstracts provides data for any of the measured outcomes. We contacted the authors for information
but have not received a response
Nagrale 2013
Methods RCT
Participants Newly diagnosed sputum positive pulmonary tuberculosis
Interventions Antituberculous treatment with N-acetylcysteine (600 mg, 2 tablets daily ) or placebo for 2 months
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Outcomes Sputum conversion, radiological improvement, DTH response, glutathione peroxidase levels
Notes Conference abstract
Information still pending:
The abstract does not provide any data for any of the measured outcomes. We contacted the study authors in May
2015 for full text but did not receive a response
Nawas 2013
Methods RCT; November 2010 to October 2011
Participants 100 newly diagnosed sputum positive pulmonary tuberculosis
Interventions Antituberculous treatment (fixed-dose combination) withMorinda citrifolia (125 mg) and Zinger officinale (125 mg)
extract or placebo
Outcomes Sputum conversion at 6 months
Notes Conference abstract
Information still pending: the abstract does not provide any data for any of the measured outcomes. We contacted
the study authors in May 2015 for the full-text article but did not receive a response
Abbreviations: RCT = randomised controlled trial; N = number of participants.
Characteristics of ongoing studies [ordered by study ID]
ChiCTR-IPR-15006395
Trial name or title The influence and mechanism of vitamin D3 supplementation on the treatment outcomes of tuberculosis
patients of different glucose tolerance
Methods RCT.
Participants Inclusion criteria: new diagnosed tuberculosis, sputum smear positive, aged ≥ 18, stable address.
Exclusion criteria: HIV-positive, tumour, pregnant or lactating women, injured lately, adjusted calcium
concentration > 2.65 mmol/L.
Gender: both.
Interventions NTB: vitamin D3; HTB: vitamin D3; NTB: control; HTB: control
Outcomes Primary: treatment outcomes; CD4+/CD8+; quantity of life (SF-36v2)
Secondary: oxidative stress; serum 25(OH)D.
Starting date 25 May 2015.
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Contact information kevin 1971@126.com
Notes China.
ChiCTR-TRC-12002546
Trial name or title The effect and mechanism of retinol and vitamin A supplementation in patients with diabetes and pulmonary
TB
Methods RCT.
Participants Inclusion criteria: participants with pulmonary tuberculosis and diabetes, aged 18 to 75 years, diagnosed by
the golden criteria of pulmonary tuberculosis and diabetes; no vitamin or mineral supplement 1month before
the screening.
Exclusion criteria: no severe complications of diabetes including diabetic eye diseases, renal disease and foot
disease, etc; pregnancy or lactation women; cancer; coronary heart disease; recent suffered trauma or recent
surgery
Interventions Vitamin D (400 IU/d).
Vitamin A (2000 IU/d).
Vitamin D (400 IU/d) + vitamin A (2000 IU/d).
Placebo control.
Outcomes Retinol; vitamin D; fasting glucose; fasting insulin; CD4+/D8+; protein kinase C (PKC); blood lymphocyte
proliferation
Starting date 20 October 2012.
Contact information kevin 1971@126.com; maiguo@public.qd.sd.cn
Notes China.
ChiCTR-TRC-14005241
Trial name or title A prospective study of oral nutritional supplement in perioperative application with pulmonary TB patients
Methods RCT.
Participants Inclusion criteria: diseases mainly included tuberculosis cavity, tuberculous bronchiectasis disease, pulmonary
tuberculosis and pneumothorax, tuberculosis and pulmonary bulla, tuberculous pyothorax, who were all the
hospitalized patients with video assisted thoracoscopic surgery; by NRS2002 screening score greater than or
equal to 3 points to consider the risk of malnutrition in this study; ranging in age from 18 to 80
Exclusion criteria: pregnancy and lactation women; having the injection contraindication; having nutrition
agent or medication allergy or a history of asthma; diabetes medication; fat metabolism, liver and kidney
dysfunction; on the day of surgery transfusion volume above 800 mL; unstable endocrine disease; unstable
vital signs
Interventions Nutrison Fibre + normal diet or normal diet.
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Outcomes Serum albumin and pre-albumin, weight, T cell subset.
Starting date From 01 October 2014 to 01 October 2016.
Contact information daoren 000113@126.com
Notes Shenzhen, China.
Hospital setting.
IRCT201112178429N1
Trial name or title Effect of zinc supplementation in improving pulmonary TB patients in Qom
Methods RCT.
Participants Inclusion criteria: active tuberculosis and filling the informed consent.
Exclusion criteria: diseases such as cancer, stroke, immunosuppressive diseases, and not agreeing to take
mineral supplement or placebo
Interventions Intervention 1: zinc supplement (30 mg zinc) every second day for 6 months
Intervention 2: placebo every second day for 6 months.
Outcomes Radiological signs: timepoint: at baseline, 2 months, and 6 months later. Method of measurement: chest
radiology
Smear negative: timepoint: at baseline, 2 months, and 6 months later. Method of measurement: smear
Stop coughing: timepoint: at baseline, 2 months and 6 months later. Method of measurement: physical exam
Stop fever: timepoint: at baseline, 2 months and 6 months later. Method of measurement: physical exam
Starting date 21 January 2012.
Contact information fpourfallah@pasteur.ac.ir
Notes Recruitment complete.
Iran.
IRCT201211179855N2
Trial name or title Randomized, double-blind, placebo-controlled trial of L-arginine supplementation for the treatment of pul-
monary TB
Methods RCT.
Participants Inclusion criteria: adults over 15 years; new cases of positive sputum smear.
Exclusion criteria: pregnant women; aged under 15 years; patients who during the past month received L-
arginine; sensitivity to L-arginine
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Interventions Intervention 1: standard antituberculous treatment for 6 months plus L-arginine, 2 g daily in first month.
Intervention 2: standard 6-month antituberculous treatment plus placebo 2 g daily in first month
Outcomes Improved para-clinical tests. Timepoint: day 14, 28, 42, and 56. Measurement method: check of CRP
Improved para-clinical tests. Timepoint: day 14, 28, 42, and 56. Measurement method: check of ESR
Improved para-clinical tests. Timepoint: day 14, 28, 42, and 56. Measurement method: check of CBC
Weight gain: timepoint: 0 and 56. Measurement method: weight measurement
Improve of life quality: timepoint: 0 and 56. Measurement method: standard questionnaire of GHQ-28
Starting date 21 December 2012.
Contact information farazialiasghar@yahoo.com
gakbarifard@yahoo.com
Notes Recruitment complete.
Iran.
ISRCTN16469166
Trial name or title Nutrition and wasting in TB: Can nutritional supplementation in TB patients improve body weight gain,
body composition and treatment outcome?
Methods RCT.
Participants Expected enrolment: adults > 18 years with sputum positive pulmonary tuberculosis
Interventions • Standard treatment plus nutritional supplementation (supplements containing 450 kcal energy plus a
wide range of vitamins and minerals in doses of approximately half the required daily intakes (but no iron)).
• Standard treatment only.
Outcomes Primary: body weight gain and body composition.
Secondary: micronutrient status and production of inflammatory cytokines
Starting date 15 May 2007.
Anticipated end date: 1 January 2008.
Contact information Dr Frank Wieringa (wieringa@tiscali.nl), Dept. of Internal Medicine, Hasan Sadikin Hospital, Bandung,
Indonesia
Notes We attempted to contact the author for results on 25 January 2010 and 05 May 2010 with no reply
Location: Indonesia.
Registration number: ISRCTN16469166.
Source of funding: Netherlands Organisation for Scientific Research (The Netherlands)
We contacted the trial authors for information on 20 July 2015
There was no sign of publication of the data (PubMed search)
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NCT00507000
Trial name or title Role of oral vitamin D as an adjunct therapy in Category I pulmonary TB along with assessment of immuno-
logical parameters
Methods RCT.
Participants Adults aged 18 to 60 years with newly diagnosed sputum-smear positive pulmonary tuberculosis
Interventions • Cholecalciferol (vitamin D) and calcium carbonate.
• Placebo (lactose granules).
Outcomes Primary: time to becoming sputum-smear negative.
Secondary: relapse rate; safety assessment; immune function.
Starting date May 2008.
Anticipated end date: September 2010.
Contact information DrRavinderGoswami (gosravinder@hotmail.com),Department of Endocrinology andMetabolism, All India
Institue of Medical Sciences, New Delhi, India
Notes Location: India.
Registration number: NCT00507000.
Source of funding: Indian Council of Medical Research; Ministry of Science and Technology, India
We contacted the trial authors for information.
There was no sign of publication of the data (PubMed search)
NCT00698386
Trial name or title Efficacy of oral zinc administration as an adjunct therapy in new pulmonary TB (Category I) patients
Methods RCT.
Participants Adults with newly diagnosed smear positive pulmonary tuberculosis
Interventions 50 mg zinc as zinc sulphate daily for 6 months during DOTS versus placebo
Outcomes Time to sputum conversion, cure rate, relapse, adverse events, patient and physician global assessment of cure
Starting date February 2008.
Contact information Surendra K Sharma, MD, PhD, All India Institute of Medical Sciences, New Delhi
surensk@gmail.com, sksharma@aiims.ac.in
Notes Location: India.
Registration number: NCT0069386.
Source of funding: Ministry of Science and Technology, India
We contacted the trial authors for information.
No sign of publication of the data (PubMed search).
94Nutritional supplements for people being treated for active tuberculosis (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
NCT00788320
Trial name or title Antimicrobial peptide LL-37 (cathelicidin) production in activeTBdisease: role of vitaminDsupplementation
Methods RCT.
Participants Adults aged > 18 years with newly diagnosed pulmonary tuberculosis
Interventions Drug: vitamin D3.
Drug: placebo.
Outcomes LL-37 level, time to sputum conversion, vitamin D and calcium levels
Starting date October 2008.
Contact information Not stated.
Notes Location: USA.
Registration number: NCT00788320.
Source of funding: Emory University.
This study has been withdrawn prior to enrolment (inadequate enrolment). See https://clinicaltrials.gov/ct2/
show/NCT00788320 for details.
NCT01635153
Trial name or title Effects of a protein calorie supplement in HIV-infected women with TB DarDar
Methods RCT.
Participants Inclusion criteria: female, HIV, age > 18, CD4 > 50, BMI > 16 new tuberculosis diagnosis, not on anti-
retroviral therapy, residence in Dar es Salaam.
Exclusion Criteria: current anti-retroviral therapy, serious co-morbidities
Interventions Group 1: micronutrient supplement.
Group 2: protein calorie supplement.
Outcomes Primary outcomes: change in CD4 count (time frame: baseline to 8 months)
Secondary outcomes: body mass index at 6 months (time frame: baseline to 6 months); proportion of subjects
who achieve 100 cell count increase in CD4 cell count (Time frame: baseline to 8 months)
Starting date May 2012.
Contact information Charles F von Reyn, MD, Geisel School of Medicine at Dartmouth
Notes Active, not recruiting.
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NCT01657656
Trial name or title Vitamin D supplementations as adjunct to anti-TB drugs in Mongolia
Methods RCT.
Participants Inclusion criteria: sputum positive tuberculosis patients.
Exclusion criteria: abnormal LFTs at baseline (2.5 times upper limit of normal), as they will be at higher risk
of developing drug-induced hepatitis
Interventions Vitamin D (does not state what comparator group receiving).
Outcomes The primary endpoint will be time to sputum culture conversion from positive to negative (time frame: 8
weeks)
Starting date October 2012.
Contact information gdavaasa@hsph.harvard.edu (Ganmaa Davaasambuu).
Notes Study status: completed.
Mongolia.
NCT01722396
Trial name or title Pharmacogenetics of Vitamin D Supplementation in TB.
Methods Open label study of vitamin D supplementation.
Participants Patients with active or latent tuberculosis.
Interventions Active tuberculosis patients take 100,000 units of vitamin D every 8 weeks during their tuberculosis treatment
Outcomes • Ex vivo responses of monocytes to vitamin D (time frame: 0 and 8 weeks).
• Ex vivo responses of T cells to vitamin D (time frame: 0 and 8 weeks).
Starting date March 2011.
Contact information Alice Turner, University of Birmingham.
Notes Status: completed.
NCT01992263
Trial name or title A trial of vitamin D supplementation among TB patients in South India
Methods RCT.
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Participants Inclusion criteria: 18 to 60 years old, active tuberculosis diagnosis by GeneXpert®; HIV infection status
(according to AMC HIV clinic medical records of enzyme-linked immunosorbent assay (ELISA) results).
Exclusion criteria: children (< 18 years of age) and older than 60 years, pregnant at baseline, other severe
complications or illnesses requiring hospitalisation, received tuberculosis treatment for greater than 4 weeks
in the past 5 years, refused to participate, residing in a geographic location > 1 hour from AMC (by public
transit)
Interventions Vitamin D (2000 IU/4000 IU/600 IU) or placebo.
Outcomes Primary outcomes
• Cell-mediated immunological markers (T cells) (time frame: 1 year).
• Immune function (time frame: 1 year).
• Serum 25(OH)D concentrations (time frame: 1 year).
Secondary outcomes
• HIV disease progression (time frame: 1 year).
• tuberculosis treatment outcomes (time frame: 1 year).
Starting date January 2015.
Contact information smehta@cornell.edu
Notes Not yet recruiting.
NCT02169570
Trial name or title Effect of supplementary vitamin D in patients with diabetes mellitus and pulmonary TB (EVIDENT)
Methods RCT.
Participants Inclusion criteria: 30 to 60 years; patients having both tuberculosis and type 2 DM; consenting to participate;
no history of previous ATT; plan to have ATT and DM treatment.
Exclusion criteria: pregnant women; patients with extra-pulmonary tuberculosis or multi-drug resistant
(MDR)-tuberculosis or relapse cases, hepatic or renal diseases or HIV infection, hypo- or hyper-parathy-
roidism; patients on corticosteroids, or immunosuppressive, or thiazides diuretics, or any other drugs known
to interfere with vitamin D levels
Interventions Calcium; placebo calcium; placebo vitamin D; vitamin D.
Outcomes Primary outcomes
• Change acid fast bacilli (AFB) smear (sputum) (time frame: 0, 4, 8, 12, 16, and 24 weeks, and 6
months).
• Change in chest X-ray (time frame: 0, 8, 16, and 24 weeks, and 6 months).
• Change in tuberculosis score (time frame: 0, 4, 8, 12, 16, 20, and 24 weeks, and 6 months).
• Change in weight (time frame: 0, 4, 8, 12, 16, 20, and 24 weeks, and 6 months).
Secondary outcomes
• Change haemoglobin A1c (HbA1c) (time frame: 0, 8, 16, and 24 weeks, and 6 months).
• Change in fasting blood test (FBS) (time frame: 0, 8, 16, and 24 weeks, and 6 months).
• Change in random blood sugar (RBS) (time frame: 0, 8, 16, and 24 weeks, and 6 months).
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Starting date December 2014.
Contact information nadia.shah@live.com
Notes Pakistan.
Status: not yet recruiting.
NCT02464683
Trial name or title Effect of vitamin D as adjunctive therapy in patients with pulmonary evolution TB (Vitamin D)
Methods RCT.
Participants Inclusion criteria: men and women over 18 and under 65 years old, with tuberculosis confirmed by positive
smear and positive culture, without documented evidence of previous treatment for tuberculosis, with hae-
moglobin values greater than 10 g/dL, and written consent
Exclusion criteria: HIV-positive, no written consent, chronic lung disease, clinical evidence of infectious or
chronic inflammatory disease processes such as: rheumatoid arthritis, systemic lupus erythematosus (SLE),
Sjögren Sx, dermatomyositis, scleroderma, seronegative arthritis, gout, inflammatory bowel disease, chronic
active hepatitis, glomerulonephritis, rheumatic fever and cardiac disease, cancer, and history of alcohol or
drug abuse
Interventions Vitamin D (200 IU) or placebo daily for 60 days.
Outcomes Determination of cytokines.
Starting date April 2014.
Contact information Martha Torres Rojas, PhD marthatorres98@yahoo.com
Notes Mexico.
NCT02554318
Trial name or title The effect of fermented soybean supplementation on the body weight and physical function of TB patients
with standard therapy in Indonesia
Methods RCT.
Participants Inclusion criteria: newly diagnosed adult male and female tuberculosis active patients with clinical evidences
of active tuberculosis symptoms (positive or negative sputum smears, positive chest X-ray that compatible
with a diagnosis of tuberculosis); no history of previous antituberculous treatment.
Exclusion criteria: heavy smoker (> 20 cigarettes per day); pregnancy and lactation; extrapulmonary tubercu-
losis; known allergy to soybean; clinical evidences of any underlying disease
Interventions Fermented soybean.
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Outcomes Body weight, body mass index, handgrip strength, 6-minute walk test
Starting date October 2013.
Contact information Michael B Krawinkel, Prof Dr University of Gleesen.
Notes Uncertain what the comparison group received.
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D A T A A N D A N A L Y S E S
Comparison 1. Macronutrient supplementation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death (1 year of follow-up) 4 567 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.10, 1.20]
1.1 HIV-positive 2 72 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.12, 3.01]
1.2 HIV-negative 3 230 Risk Ratio (M-H, Fixed, 95% CI) 0.18 [0.02, 1.48]
1.3 Unknown HIV status 1 265 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Cured (at 6 months) 1 102 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.59, 1.41]
2.1 HIV-positive 1 22 Risk Ratio (M-H, Random, 95% CI) 1.38 [0.46, 4.14]
2.2 HIV-negative 1 80 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.53, 1.35]
3 Treatment completion 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 HIV-negative 1 100 Risk Ratio (M-H, Random, 95% CI) 1.20 [1.04, 1.37]
3.2 Unknown HIV status 1 265 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.86, 1.12]
4 Sputum negative at 8 weeks 3 222 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.86, 1.37]
5 Mean weight gain 5 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 After 6 weeks 1 34 Mean Difference (IV, Random, 95% CI) 1.73 [0.81, 2.65]
5.2 After 8 weeks 3 689 Mean Difference (IV, Random, 95% CI) 0.78 [-0.05, 1.60]
5.3 After 12 weeks 1 100 Mean Difference (IV, Random, 95% CI) 2.6 [1.74, 3.46]
5.4 After 20 weeks (12 weeks
post supplementation)
1 306 Mean Difference (IV, Random, 95% CI) -0.20 [-1.34, 0.94]
5.5 After 24 weeks 1 26 Mean Difference (IV, Random, 95% CI) 1.78 [-0.25, 3.81]
5.6 After 32 weeks 1 265 Mean Difference (IV, Random, 95% CI) 2.60 [0.52, 4.68]
6 Change in maximum grip
strength (kg)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 At 6 weeks 1 34 Mean Difference (IV, Random, 95% CI) 3.44 [0.78, 6.10]
6.2 At 8 weeks 1 332 Mean Difference (IV, Random, 95% CI) 0.50 [-0.63, 1.63]
6.3 At 12 weeks 1 100 Mean Difference (IV, Random, 95% CI) 1.50 [1.08, 1.92]
6.4 At 20 weeks 1 303 Mean Difference (IV, Random, 95% CI) 1.30 [-0.11, 2.71]
6.5 At 24 weeks 1 26 Mean Difference (IV, Random, 95% CI) 0.39 [-3.05, 3.83]
7 Change in quality of life score 1 Mean Difference (IV, Random, 95% CI) Totals not selected
7.1 At 6 weeks 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 At 24 weeks 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. High cholesterol (850 mg/day) versus low cholesterol (250 mg/day) diet
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Sputum-culture positive 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 At baseline 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 At 2 weeks 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 At 4 weeks 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 At 8 weeks 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 3. Multivitamin and trace element tablets versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death during follow-up in adults
and children
5 2902 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.79, 1.18]
1.1 HIV-negative individuals 4 1218 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.46, 1.60]
1.2 HIV-positive individuals 3 1429 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.69, 1.23]
1.3 HIV-positive and HIV-
negative individuals
1 255 Risk Ratio (M-H, Random, 95% CI) 1.59 [0.53, 4.72]
2 Tuberculosis treatment
completion
1 302 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.95, 1.04]
3 Sputum-smear or sputum-
culture positive at 1 month
2 1020 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.63, 1.35]
3.1 Mixed HIV-positive and
HIV-negative
1 392 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.99, 1.45]
3.2 HIV-negative individuals
only
1 306 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.47, 1.13]
3.3 HIV-positive individuals
only
1 322 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.45, 1.31]
4 Sputum-smear or sputum-
culture positive at 2 months
2 731 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.59, 1.35]
5 Clearance of chest X-ray at 6
months
2 497 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.90, 1.18]
6 Weight 3 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 After 2 months of
supplementation
2 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 After 5 months
follow-up (3 months post
supplementation)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 After 6 months
supplementation (children)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.4 After 7 months of
supplementation
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Anthropometrical changes at
follow-up
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 Weight-for-age z score at
2 months
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 Weight-for-age z score at
6 months
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 Weight (kg) at 2 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.4 Weight (kg) at 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.5 Height-for-age z score at 2
months
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.6 Height-for-age z score at 6
months
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.7 BMI z score at 2 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.8 BMI z score at 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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8 Mean change in handgrip
strength (kg)
1 1480 Mean Difference (IV, Fixed, 95% CI) 1.16 [0.50, 1.81]
8.1 At 2 months 1 771 Mean Difference (IV, Fixed, 95% CI) 1.22 [0.49, 1.95]
8.2 At 5 months 1 709 Mean Difference (IV, Fixed, 95% CI) 0.90 [-0.56, 2.36]
Comparison 4. Vitamin A versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Children: mean serum retinol
(normal range > 20 µg/L)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 At baseline 1 85 Mean Difference (IV, Fixed, 95% CI) -1.0 [-5.38, 3.38]
1.2 At 6 weeks 1 85 Mean Difference (IV, Fixed, 95% CI) 1.30 [-3.91, 6.51]
1.3 At 3 months 1 85 Mean Difference (IV, Fixed, 95% CI) 0.70 [-3.85, 5.25]
2 Adults: mean serum retinol
(normal range > 70 µmol/L)
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 At baseline 3 242 Mean Difference (IV, Fixed, 95% CI) -0.06 [-0.13, 0.01]
2.2 At 2 months 3 242 Mean Difference (IV, Fixed, 95% CI) 0.05 [-0.03, 0.14]
2.3 At 6 months 3 242 Mean Difference (IV, Fixed, 95% CI) 0.07 [-0.02, 0.16]
3 Death 8 3308 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.84, 1.12]
3.1 Vitamin A alone 1 115 Risk Ratio (M-H, Fixed, 95% CI) 1.79 [0.19, 16.69]
3.2 Vitamin A plus zinc 4 535 Risk Ratio (M-H, Fixed, 95% CI) 2.38 [0.87, 6.53]
3.3 Vitamin A as part
of a multi-micronutrient
supplement
4 2658 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.81, 1.09]
4 Treatment completion 1 158 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.80, 1.04]
5 Symptomatic at 6 weeks 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Sputum-smear and sputum-
culture positive during follow-
up
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Baseline 1 158 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.98, 1.03]
6.2 2 weeks 1 158 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.50, 1.28]
6.3 1 month 1 148 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.33, 1.48]
6.4 2 months 2 199 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.23, 4.73]
7 BMI (kg/m²) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 Baseline 1 158 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.63, 0.83]
7.2 2 months 1 148 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.44, 1.04]
7.3 6 months 1 136 Mean Difference (IV, Fixed, 95% CI) -0.30 [-1.15, 0.55]
8 Body fat (%) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 Baseline 1 158 Mean Difference (IV, Fixed, 95% CI) -0.90 [-2.80, 1.00]
8.2 2 months 1 148 Mean Difference (IV, Fixed, 95% CI) -0.90 [-2.84, 1.04]
8.3 6 months 1 136 Mean Difference (IV, Fixed, 95% CI) -1.80 [-3.96, 0.36]
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Comparison 5. Zinc versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Serum zinc level (normal range >
10.7 µmol/L)
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 At baseline 4 472 Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.36, 0.30]
1.2 At 2 months 4 452 Mean Difference (IV, Fixed, 95% CI) 0.59 [0.24, 0.93]
1.3 At 6 months 4 440 Mean Difference (IV, Fixed, 95% CI) 0.60 [0.31, 0.88]
2 Death by 6 to 8 months 7 2862 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.82, 1.13]
2.1 Zinc alone 4 714 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.70, 2.22]
2.2 Zinc plus vitamin A 4 477 Risk Ratio (M-H, Fixed, 95% CI) 2.08 [0.65, 6.64]
2.3 Zinc as part of a multi-
micronutrient supplement
3 1671 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.77, 1.07]
3 Death by 6 to 8 months
(subgrouped by HIV status)
4 815 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.75, 2.09]
3.1 HIV-negative individuals 3 442 Risk Ratio (M-H, Fixed, 95% CI) 1.92 [0.53, 6.98]
3.2 HIV-positive individuals 2 211 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.59, 1.91]
3.3 HIV status unknown 1 162 Risk Ratio (M-H, Fixed, 95% CI) 1.70 [0.29, 9.89]
4 Treatment completion at 6
months
2 353 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.92, 1.04]
5 Sputum-smear or sputum-
culture positive during follow-
up
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 At baseline 3 596 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.92, 1.03]
5.2 At 2 weeks 3 806 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [1.02, 1.17]
5.3 At 4 weeks 3 783 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.93, 1.20]
5.4 At 8 weeks 5 1076 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.72, 1.28]
6 Clearance of chest X-ray at 6
months
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7 Weight at follow-up 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 Baseline: weight (kg) 2 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 2 months: weight (kg) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 6 months: weight (kg) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.4 7 months: weight (kg) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 BMI (kg/m²) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 Baseline 1 162 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.62, 0.82]
8.2 2 months 1 151 Mean Difference (IV, Fixed, 95% CI) 0.20 [-0.55, 0.95]
8.3 6 months 1 140 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.70, 0.90]
9 Body fat (%) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 Baseline 1 162 Mean Difference (IV, Fixed, 95% CI) -0.90 [-2.51, 0.71]
9.2 2 months 1 151 Mean Difference (IV, Fixed, 95% CI) -1.30 [-3.07, 0.47]
9.3 6 months 1 140 Mean Difference (IV, Fixed, 95% CI) -1.5 [-3.51, 0.51]
10 Weight-for-age z score 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10.1 Baseline: weight-for-age
z score
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 2 months: weight-for-age
z score
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.3 6 months: weight-for-age
z score
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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11 BMI-for-age z score 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11.1 Baseline: BMI-for-age z
score
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.2 2 months: BMI-for-age z
score
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.3 6 months: BMI-for-age z
score
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Height-for-age z score at
follow-up
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12.1 Baseline: height-for-age z
score
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.2 2 months: height-for-age
z score
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.3 6 months: height-for-age
z score
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 6. Zinc plus vitamin A versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death by 6 months 4 578 Risk Ratio (M-H, Fixed, 95% CI) 2.33 [0.90, 6.07]
1.1 HIV-negative individuals 4 430 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.31, 3.99]
1.2 HIV-positive individuals 2 136 Risk Ratio (M-H, Fixed, 95% CI) 5.94 [1.07, 32.96]
1.3 Unknown HIV status 1 12 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Treatment completion at 6
months
1 152 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.84, 1.07]
3 Sputum-smear and sputum-
culture positive during follow-
up
7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 At baseline 5 652 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.99, 1.01]
3.2 1 month 4 485 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.86, 1.17]
3.3 2 months 7 726 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.71, 1.15]
3.4 3 months 2 266 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.61, 1.49]
3.5 4 months 2 266 Risk Ratio (M-H, Fixed, 95% CI) 1.51 [0.86, 2.65]
3.6 5 months 1 33 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.7 6 months 2 113 Risk Ratio (M-H, Fixed, 95% CI) 0.2 [0.01, 4.04]
4 Body weight (kg) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Baseline 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 2 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 BMI (kg/m²) 2 664 Mean Difference (IV, Fixed, 95% CI) -0.09 [-0.45, 0.28]
5.1 Baseline 2 232 Mean Difference (IV, Fixed, 95% CI) -0.00 [-0.62, 0.61]
5.2 2 months 2 219 Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.65, 0.58]
5.3 6 months 2 213 Mean Difference (IV, Fixed, 95% CI) -0.24 [-0.91, 0.43]
6 Mid upper arm circumference
(cm)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 Baseline 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 2 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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6.3 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Biceps skinfold thickness (mm) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 Baseline 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 2 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Triceps skinfold thickness (mm) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 Baseline 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 2 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.3 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Subscapular skinfold thickness
(mm)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 Baseline 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 2 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.3 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Suprailiac skinfold thickness
(mm)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10.1 Baseline 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 2 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.3 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Body fat (%) 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11.1 Baseline 2 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.2 2 months 2 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.3 6 months 2 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Fat mass (kg) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12.1 Baseline 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.2 2 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.3 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Karnofsky score 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
13.1 Baseline 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.2 2 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.3 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 7. Vitamin D versus placebo or no supplement
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Serum vitamin D levels (nmol/
L)
5 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 At baseline 5 894 Mean Difference (IV, Random, 95% CI) -0.10 [-3.01, 2.82]
1.2 At 8 weeks 3 460 Mean Difference (IV, Random, 95% CI) 33.68 [3.99, 63.37]
1.3 At 6 to 8 months 2 376 Mean Difference (IV, Random, 95% CI) 7.90 [0.52, 15.28]
2 Death during follow-up (2 to 12
months)
7 2649 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.81, 1.12]
2.1 Vitamin D alone 4 814 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.79, 2.02]
2.2 Vitamin D plus arginine 1 75 Risk Ratio (M-H, Fixed, 95% CI) 1.53 [0.06, 36.25]
2.3 Vitamin D as part
of a multi-micronutrient
supplement
3 1760 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.77, 1.08]
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3 Death during follow-up (2 to 12
months)
7 2649 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.83, 1.13]
3.1 HIV-positive individuals 3 1089 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.80, 1.09]
3.2 HIV-negative individuals 6 1403 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.72, 2.21]
3.3 HIV status mixed or
unknown
2 157 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.30, 7.38]
4 Cure at 6 months 1 151 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.75, 1.31]
5 Tuberculosis score 1 1142 Mean Difference (IV, Fixed, 95% CI) -0.13 [-0.32, 0.06]
5.1 At baseline 1 348 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.52, 0.31]
5.2 2 months 1 297 Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.47, 0.42]
5.3 5 months 1 271 Mean Difference (IV, Fixed, 95% CI) -0.16 [-0.51, 0.19]
5.4 8 months 1 226 Mean Difference (IV, Fixed, 95% CI) -0.19 [-0.52, 0.14]
6 Sputum-smear or sputum-
culture positive
7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 At baseline 5 1022 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.92, 1.03]
6.2 4 weeks 5 929 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.74, 1.03]
6.3 6 weeks 4 656 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.55, 1.03]
6.4 8 weeks 6 856 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.54, 1.20]
6.5 5 months 1 148 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.32, 28.18]
6.6 6 months 1 247 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.37, 1.47]
6.7 8 months 1 147 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Body mass index 4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 At baseline 4 464 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.71, 0.30]
7.2 At 6 to 8 weeks 4 430 Mean Difference (IV, Fixed, 95% CI) -0.19 [-0.70, 0.32]
8 Body weight (kg) 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 Before treatment 2 150 Mean Difference (IV, Fixed, 95% CI) 0.20 [-2.43, 2.83]
8.2 At 8 weeks 2 150 Mean Difference (IV, Fixed, 95% CI) 1.08 [-1.61, 3.77]
9 Karnofsky score at 8 weeks 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 At baseline 1 247 Mean Difference (IV, Fixed, 95% CI) -1.47 [-3.42, 0.48]
9.2 At 8 weeks 1 212 Mean Difference (IV, Fixed, 95% CI) 0.85 [-1.33, 3.03]
Comparison 8. Arginine versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death during treatment 3 394 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.21, 2.09]
1.1 HIV-negative 1 56 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 HIV-positive 1 59 Risk Ratio (M-H, Fixed, 95% CI) 1.58 [0.15, 16.44]
1.3 HIV-negative and positive 2 279 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.13, 1.94]
2 Cured at 6/8 months 2 279 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.90, 1.22]
3 Sputum-smear or sputum-
culture positive
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 At baseline 4 464 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.98, 1.02]
3.2 At 4 weeks 2 162 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.51, 1.12]
3.3 At 8 weeks 3 351 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.41, 1.42]
3.4 At 8 weeks (HIV-negative
only)
1 56 Risk Ratio (M-H, Random, 95% CI) 0.12 [0.01, 2.07]
4 Cough 3 404 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.62, 0.93]
4.1 At 2 weeks 1 56 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.53, 0.96]
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4.2 At 8 weeks 3 348 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.61, 0.99]
5 Weight gain > 10% 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 HIV-positive and HIV-
negative
1 170 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.74, 1.84]
5.2 HIV-positive 1 65 Risk Ratio (M-H, Fixed, 95% CI) 2.15 [0.96, 4.78]
Comparison 9. Vitamin E plus selenium versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Sputum-smear positive at follow-
up
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 15 days 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 30 days 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 45 days 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 60 days 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
A D D I T I O N A L T A B L E S
Table 1. Effect of multi-micronutrient supplementation on nutritional recovery
Trial ID Population Weight
measurement
Baseline nutritional status Duration of
supplement and
follow-up
Comment
Supplement Placebo
Mehta 2011
TZA
HIV-pos-
itive and HIV-
negative children
Weight gain me-
dian (IQR)
MUAC (cm)
13.0 (11.9 to 14.
25)
Weight: 8.48kg
(NR)
MUAC (cm)
13.0 (11.2 to 14.
0)
Weight kg: 7.95
kg (NR)
Supplement and
follow-up 2
months
The trial authors
reported no ef-
fect of supple-
ment on median
weight,
height, or mid-
upper arm cir-
cumference at 2
months
Lodha 2014
IND
HIV-negative
children
Change in
weight-for-age z
score
Weight-for-age z
score (SD):
−2.72 (1.85,
MN+Z group);
−2.8 (1.6, MN
group)
Weight-for-age z
score (SD):−2.8
(1.6)
Supplement and
follow-up 6
months
The trial authors
reported no dif-
ference in weight
(kg), weight-for-
age z score,
height-for-age z
score, or BMI z
score after 2 or 6
months supple-
mentation with
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Table 1. Effect of multi-micronutrient supplementation on nutritional recovery (Continued)
micronu-
trients with or
without zinc (1
trial, 302 partic-
ipants, Analysis
3.7)
Praygod 2011a
TZA1
HIV-posi-
tive and negative
adults
Mean weight
gain (SD)
Mean BMI (SD)
: 18.9 kg/m² (2.
8)
mean BMI (SD)
: 18.9 kg/m² (3.
1)
Supplement for
2 months
Follow-up at 2
and 5 months
Therewas no sta-
tistically signifi-
cant difference in
weight gain at
2 or 5 months.
Subgroup analy-
sis by HIV sta-
tus found a sta-
tistically signifi-
cant difference in
weight gain in
favour of supple-
ments in HIV-
nega-
tive participants,
and in favour of
placebo in HIV-
positive partici-
pants (trial au-
thors’ own fig-
ures)
Villamor 2008
TZA
HIV-posi-
tive and negative
adults
Mean BMI (SD) HIV-negative
mean BMI (SD)
: 18.9 kg/m² (2.
5)
HIV-positive
mean BMI (SD)
: 19.3 kg/m² (2.
8)
HIV-negative
mean BMI (SD)
: 18.9 kg/m² (2.
5)
HIV-positive
mean BMI (SD)
: 19.6 kg/m² (2.
9)
Supplement for
24 months and
follow-up at 8
and 24 months
The trial authors
reported no sta-
tistically signif-
icant effect of
supplement
on BMI, mid-
upper arm cir-
cumference, fat
mass, or fat free
mass at 8 or 24
months, regard-
less of HIV sta-
tus (nofigures re-
ported)
Range 2005
TZA2
HIV-posi-
tive and negative
adults
Mean weight
gain (SD)
Mean BMI (SD)
: 18.3 kg/m² (2.
5) zinc + MMN
group
Mean BMI (SD)
: 18.7 kg/m² (2.
7)
Supplement for
8
months and fol-
low-up 8 weeks
and 7 months
There was
a statistically sig-
nificantly greater
weight
gain in supple-
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Table 1. Effect of multi-micronutrient supplementation on nutritional recovery (Continued)
mented group at
7 months. While
the difference in
weight was ap-
preciable in both
treatment (zinc +
MMN and
MMN groups)
arms compared
to placebo, the
weight gain in
the zinc + MMN
arm appeared to
be clinically im-
portant
Abbreviations: SD = standard deviation; BMI = body mass index; MMN = multi-micronutrient; HIV = human immunodeficiency
virus; IQR = interquartile range; MUAC = mid-upper arm circumference; NR = not reported;
1The supplement administered by Praygod 2011a TZA included a similar dose of zinc to that used by Range 2005 TZA.
22 X 2 factorial design; Group 1: zinc plus placebo; Group 2: multivitamin and mineral tablet plus placebo; Group 3: zinc plus
multivitamin and mineral tablet; Group 4: placebo plus placebo.
Table 2. Effects of vitamin A supplementation on serum vitamin A levels
Trial ID Supple-
ment dose
Measure Baseline Follow-up Follow-up Comment
Supple-
ment
Control Supple-
ment
Control
Hanekom
1997 ZAF
200 000 IU
vitamin
A 2 doses at
baseline
Mean µg/L
(SD)
17.6
(10.1)
18.6
(10.5)
34.8
(10.1)
33.5
(14.2)
6 weeks No sta-
tistically sig-
nificant dif-
ference
in serum vita-
min A levels
at 6 weeks or
2 months
Ginawi
2013 IND
5000 IU vi-
tamin A
daily
Mean µmol/
L
(SD)
0.77
(0.21)
0.82
(0.29)
1.2
(0.27)
1.13
(0.34)
2 months No sta-
tistically sig-
nificant dif-
ference
in serum vi-
tamin A lev-
els at 2 or 6
months
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Table 2. Effects of vitamin A supplementation on serum vitamin A levels (Continued)
Pakasi 2010
IDN
5000 IU vi-
tamin
A daily for 6
months
Median
µmol/L
(IQR)
0.7
(0.5 to 1.5)
0.7
(0.5 to 1.0)
1.5
(1.0 to 2.0)
1.2
(0.9 to 1.6)
2 months No sta-
tistically sig-
nificant dif-
ference at 2 or
6 months
Armijos
2010 MEX
5000 IU vi-
tamin A plus
50 mg zinc
daily for 4
months
Mean µmol/
L
(SD)
1.03
(0.46)
1.04
(0.48)
1.4
(0.47)
1.29
(0.35)
2 months No sta-
tistically sig-
nificant dif-
ference
in serum vi-
tamin A lev-
els at 2 or 6
months
Karyadi
2002 IDN
5000 IU vi-
tamin A plus
15 mg zinc
daily for 6
months
Mean µmol/
L
(SD)
0.82
(0.25)
0.9
(0.25)
1.14
(0.32)
1.08
(0.25)
2 months No sta-
tistically sig-
nificant dif-
ference
in serum vi-
tamin A lev-
els at 2 or 6
months
Ginawi
2013 IND
5000 IU vi-
tamin A plus
15
mg zinc sul-
phate daily
Mean µmol/
L
(SD)
0.78
(0.23)
0.82
(0.29)
1.14
(0.25)
1.13
(0.34)
2 months No sta-
tistically sig-
nificant dif-
ference
in serum vi-
tamin A lev-
els at 2 or 6
months
Pakasi 2010
IDN
5000 IU vi-
tamin A plus
15 mg zinc
sulphate
daily for 6
months
Median
µmol/L
(IQR)
0.7
(0.4 to 1.1)
0.7
(0.5 to 1.0)
1.3
(1.0 to 1.9)
1.2
(0.9 to 1.6)
2 months No sta-
tistically sig-
nificant dif-
ference
in serum vi-
tamin A lev-
els at 2 or 6
months
Visser 2011
ZAF
200,000 IU
vitamin A
once plus 15
mg zinc sul-
phate 5 days
per week for
8 weeks
Median µd/
dL
(IQR)
21.1 (15.1
to 27.8)
21.2 (15.7
to 28.9)
40.3 (28.7
to 48.5)
35.8 (27.7
to 43.2)
2 months No sta-
tistically sig-
nificant dif-
ference
in serum vi-
tamin A lev-
els at 2 or 8
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Table 2. Effects of vitamin A supplementation on serum vitamin A levels (Continued)
weeks
Semba 2007
MWI
8000 IU vi-
tamin A
daily as part
of a multi-
micronutri-
ent supple-
ment
Geometric
mean µmol/
L (95% CI)
0.60 (0.54
to 0.66)1
0.69 (0.63
to 0.75)1
NR NR 8 months Pre-
sented graph-
ically with an
increase
in serum vi-
tamin A lev-
els in both
groups
Abbreviations: IU = international units; IQR = interquartile range; CI = confidence interval; SD = standard deviation.
1Serum vitamin A levels for HIV-negative participants.
Table 3. Effects of zinc supplementation on serum zinc levels
Trial ID Supple-
ment dose
Measure Baseline Follow-up Follow-up Comment
Supple-
ment
Control Supple-
ment
Control
Ginawi
2013 IND
15
mg zinc sul-
phate daily
Mean µmol/
L
(SD)
9.86
(0.87)
9.88
(1.44)
12.23
(1.12)
11.23
(1.34)
2 months Statis-
tically signif-
icant increase
in serum zinc
levels in the
zinc group at
2 and 6
months
Pakasi 2010
IDN
15 mg zinc
sulphate
daily for 6
months
Mean µmol/
L
(SD)
11.6
(2.2)
11.8
(2.4)
11.7
(2.43)
11.7
(2.33)
2 months No statis-
tically signifi-
cant differ-
ence in serum
zinc levels at 2
months
Armijos
2010 MEX
50 mg zinc
plus 5000
IU vitamin
A daily for 4
months
Mean µmol/
L
(SD)
11.29
(2.57)
11.69
(2.1)
12.85
(3.4)
10.13
(1.61)
2 months Statis-
tically signif-
icant increase
in serum zinc
levels in zinc
plus vitamin
A group at
2 months. In-
crease
not sustained
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Table 3. Effects of zinc supplementation on serum zinc levels (Continued)
post supple-
mentation
Karyadi
2002 IDN
15 mg zinc
plus 5000
IU vitamin
A daily for 6
months
Mean µmol/
L
(SD)
11.52
(1.64)
11.15
(1.77)
11.22
(2.4)
10.22
(2.28)
2 months No statis-
tically signifi-
cant differ-
ence in serum
zinc levels at 2
months
Ginawi
2013 IND
15 mg zinc
sulphate
plus 5000
IU vitamin
A daily
Mean µmol/
L
(SD)
9.56
(0.77)
9.88
(1.4)
11.17
(0.86)
11.23
(1.34)
2 months No statis-
tically signifi-
cant differ-
ence in serum
zinc levels at 2
months
Pakasi 2010
IDN
15 mg zinc
sulphate
plus 5000
IU vitamin
A daily for 6
months
Mean µmol/
L
(SD)
12.1
(3.0)
11.8
(2.4)
12.5
(2.33)
11.7
(2.33)
2 months No statis-
tically signifi-
cant differ-
ence in serum
zinc levels at 2
months
Abbreviations: IU = international unit; SD = standard deviation.
Table 4. Effect of vitamin A plus zinc supplementation on nutritional recovery
Trial ID Population Baseline nutritional status
Mean BMI (SD) kg/m²
Endpoint nutritional status Comments
Vitamin A plus
zinc
Placebo Vitamin A plus
zinc
Placebo
Karyadi 2002
IDN
Adults HIV sta-
tus unknown
17.6 (1.9) 18.1 (3.2) Mean BMI (SD)
6 months: 19.4
(2.5)
Mean BMI (SD)
6 months: 20.0
(3.2)
Statistically sig-
nificantly greater
body weight (kg)
in supplemented
group at
6 months (3.10
kg, 95% CI 0.74
to 5.46). No sta-
tistically signifi-
cant differences
in BMI, mid-
upper arm cir-
cumference, bi-
112Nutritional supplements for people being treated for active tuberculosis (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Table 4. Effect of vitamin A plus zinc supplementation on nutritional recovery (Continued)
ceps skinfold
thickness, triceps
skinfold
thickness, sub-
scapular skinfold
thickness, supra-
iliac skinfold
thickness, body
fat (%), or fat
mass (kg) be-
tween groups at
2 or 6 months
Lawson 2010
NGA
Adults HIV-pos-
itive and HIV-
negative
19.6 (3.5) 19.8 (3.3) BMI data reported graphically BMI appears to
increase along a
similar trajectory
for both supple-
mented and
placebo
groups at 2 and 6
months
Pakasi 2010
IDN
Adults HIV sta-
tus unknown
16.6 (2.1) 16.4 (2.5) Mean BMI (SD)
6 months: 18.3
(2.0)
Mean BMI (SD)
6 months: 18.4
(2.6)
No sta-
tistically signifi-
cant differences
in BMI between
the
supplement and
placebo group at
2 or 6 months
Visser 2011 ZAF Adults HIV-pos-
itive and HIV-
negative
Male: 18.9 (2.7)
Female: 23.0 (4.
3)
Male: 19.0 (2)
Female: 21.6 (4.
8)
Mean weight
gain 2.3 kg
Mean weight
gain 2.2 kg
No sta-
tistically signifi-
cant difference in
weight gain dur-
ing the first 2
months of treat-
ment (P = 0.
68, trial authors’
own figures)
Abbreviations: HIV = human immunodeficiency virus; BMI = body mass index; SD = standard deviation.
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Table 5. Effects of vitamin D supplementation on serum vitamin D levels
Trial ID Supple-
ment dose
Measure Baseline Follow-up Follow-up Comment
Supple-
ment
Control Supple-
ment
Control
Mily 2015
BGD
5000
IU daily for
8 weeks
Mean nmol/
L
(SD)
28.0
(17.5)
28.1
(16.2)
102
(NR)
30
(NR)
8 weeks The follow-
up mean val-
ues inserted
here have
been approxi-
mated from a
graph in the
published pa-
per. The trial
authors
reported that
the group re-
ceiving vita-
min D3 sup-
ple-
mentation ex-
hibited signif-
icantly higher
concentration
of plasma 25-
hydroxyvita-
min D[25
(OH) D3] at
week 8 com-
pared
to placebo af-
ter initiation
of therapy (P
< 0.000)
Tukvadze
2015 GEO
50000 IU 3
times a week
for 8 weeks,
then every 2
weeks for 8
weeks
Mean nmol/
L
(SD)
30
(NR)
30
(NR)
250
(NR)
40
(NR)
8 weeks The
mean values
inserted here
have
been approxi-
mated from a
graph in the
published pa-
per. The trial
authors
reported that
high-dose vi-
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Table 5. Effects of vitamin D supplementation on serum vitamin D levels (Continued)
tamin D3 re-
sulted in a sig-
nif-
icant increase
in plasma 25
(OH)D con-
centrations to
250 nmol/L
at study week
8
Daley 2015
IND1
2.5 mg vita-
min D3 on
days 0, 14,
28, and 42
Mean nmol/
L
(SD)
63.1
(46.6)
62.2 (51.0) 72.2
(NR)
60.4
(NR)
26 weeks Authors re-
ported signif-
icant increase
serum vi-
tamin D lev-
els in supple-
ment group
(P = 0.001)
but not in the
placebo group
(P = 0.15).
No difference
in serum vita-
min D levels
be-
tween groups
at week 26 (P
= 0.24)
Kota 2011
IND2
60,000
IU vitamin
D3 per week
plus 1000
mg calcium
carbonate
per day
Mean ng/ml
(SD)
12.8
(4.5)
11.1 (4.7) 22.3
(5.9)
11.1
(1.6)
8 weeks Statis-
tically signif-
icant increase
in serum vi-
tamin D level
in the supple-
ment
group (P = 0.
0001) at 4, 8,
and 12 weeks
Martineau
2011 GBR3
2.5 mg on
days 0, 14,
28, and 42
Mean nmol/
L
(SD)
21.1
(20.0)
21.3 (19.0) 101.4
(NR)
22.8
(NR)
8 weeks Statis-
tically signif-
icant increase
in serum vi-
tamin D level
in the supple-
ment group
(P < 0.001)
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Table 5. Effects of vitamin D supplementation on serum vitamin D levels (Continued)
Wejse 2008
GNB4
100,000 IU
vitamin D3
at 0, 5, and 8
months
Mean nmol/
L
(SD)
77.5
(23.8)
79.1 (21.8) 105
(95% CI 99
to 110)
103
(95% CI 96
to 110)
8 weeks There was no
statistically
significant
difference
in serum vita-
min D levels
at 8 weeks or
8 months be-
tween the
groups
Morcos
1998 EGY5
1000
IU daily for
8 weeks
NR NR NR NR NR 16 weeks The trial au-
thors
reported that
the serum vi-
tamin D level
rose in both
groups and
was not statis-
tically differ-
ent between
groups (P > 0.
05)
Abbreviations: NR = not reported; IU = international units; SD = standard deviation; 25(OH) D3 = 25-hydroxyvitamin D.
1Daley 2015 IND only included HIV-negative participants.
2Kota 2011 IND only enrolled newly diagnosed tuberculosis cases with uncontrolled diabetes and serum vitamin D < 20 ng/mL.
3Martineau 2011 GBR reported that at baseline almost all participants had serum vitamin D levels below the definition of insufficiency
used by Wejse 2008 GNB (95% supplement group versus 98% control group).
4Wejse 2008 GNB reports that at baseline approximately 10% of participants were defined as being vitamin D deficient (serum 25
(OH)D3< 50 nmol/L), and 45% as vitamin D insufficient (serum 25(OH)D3 < 75 nmol/L).
5Morcos 1998 EGY reported a mean vitamin D level of 17.91 pg/mL at baseline which is below the normal reference range (20 to 42
pg/mL).
Table 6. Adverse effects of vitamin D
Trial ID Dose Severe adverse events Effects on calcium Other
Mily 2015 BGD 5000 IUdaily for 8weeks None in the vitamin D
group
Hypercalcemia: none
Hypocalcemia: common
but no differences be-
tween groups
No differences between
study arms
Tukvadze 2015 GEO 50,000 IU 3 times a week
for 8 weeks, then every 2
weeks for 8 weeks
5/100 vitamin D versus
15/99 placebo
Hypercalcemia: 3/
100 vitamin D versus 7/
99 placebo
No differences between
study arms
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Table 6. Adverse effects of vitamin D (Continued)
Daley 2015 IND 2.5 mg vitamin D3 on
days 0, 14, 28, and 42
None in the vitamin D
group
Hypercalcaemia: none 4/121 vitamin D versus
3/126 placebo
(none required a change
in medical therapy)
Martineau 2011 GBR 2.5 mg on days 0, 14, 28,
and 42
7/71 vitamin D versus 2/
70 placebo
Hypercalcemia: 2/71 vi-
tamin D versus 0/70
placebo
Hypocalcaemia: 5/71 vi-
tamin D versus 2/70
placebo
No differences between
study arms
Wejse 2008 GNB 100,000 IU vitamin D3
at 0, 5, and 8 months
No comment Hypercalcemia: at
2 months: 1/157 vitamin
D versus 2/147 placebo
At 8 months: none
At 2 months: only 24
reported any symptom,
most commonly exces-
sive thirst: 10/157 vi-
tamin D versus 14/147
placebo (P = 0.31)
Abbreviations: IU = international units.
WH A T ’ S N E W
Last assessed as up-to-date: 4 February 2016.
Date Event Description
28 June 2016 New citation required but conclusions have not changed We performed a new literature search and included 12
new trials (from 15 articles). The author team has been
updated
28 June 2016 New search has been performed We amended the objective of this Cochrane Review to
simplify the wording and to reflect the need to assess
any differences in response depending onHIV status. We
amended some of the outcomes. Also, we added total
calorie intake and micronutrient levels before and after
supplementation as outcomes in the review as there are
important explanatory factors for any effects seen. Also,
we adapted themethods to reflect changes in themethods
of assessing and reporting risk of bias
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H I S T O R Y
Protocol first published: Issue 3, 2006
Review first published: Issue 4, 2008
Date Event Description
30 September 2011 New citation required but conclusions have not
changed
We added eight new trials and have considered more
carefully the nutritional status at baseline (both weight
and biochemical status of individual micronutrients).
The author team has also been updated
20 September 2011 New search has been performed We performed a new search, and included eight new
trials. We constructed ’Summary of findings’ tables,
which summarize the quality of the evidence. Also we
performed a calculation of the optimal information
size to reliably detect clinically important effects if they
exist
We updated the ’Risk of bias’ assessments to the new
format.
10 November 2009 Amended An observant reader noted that there was an error in
referencing in the ’Risk of bias’ tables. This error has
now been corrected
10 November 2008 Amended We corrected minor errors. There were no changes to
the conclusions
C O N T R I B U T I O N S O F A U T H O R S
Thambu David Sudarsanam conceived this Cochrane protocol, and designed it in collaboration with all review authors (Abba 2006).
We performed the selection of trials for inclusion, ’Risk of bias’ assessments, and data extraction as indicated in the Methods. Katharine
Abba and David Sinclair mainly undertook the analyses of previous versions of the review, in consultation with the other review authors.
In the most recent update of this Cochrane review, Liesl Grobler, Sukrti Nagpal, and Thambu David Sudarsanam screened the search
results and extracted the data from the eligible studies. Liesl Grobler and David Sinclair, in consultation with the other review authors,
analysed the data and wrote the review.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We amended the objective of this Cochrane Review from “To assess the provision of oral nutritional supplements to promote the
recovery of people being treated with anti-TB drug therapy for active TB” to the current objective to simplify the wording and reflect
the need to assess any differences in response depending on HIV status.
Also we changed some of the outcomes, as follows: we expanded “change in weight or skinfold thickness” to “change in weight, skinfold
thickness, or other measure of lean or total mass” because we became aware that other measures, besides skinfold thickness, are equally
valid indicators of overall nutritional status; we added “any measure of growth in children” because it is a useful indicator of health and
nutritional status in children, which we had overlooked at the protocol stage; and included “sputum positive at follow-up” because it
was a primary outcome of many included trials, and it became apparent that it is a meaningful outcome as, depending on the period
of follow-up, it may be used as a proxy for cure or as an indicator of the time taken to become sputum-smear negative. Early sputum
conversion is a desirable outcome because on becoming smear-negative, patients become less ill and less infectious to those around
them.
Between the publication of the original review (Abba 2008; Sinclair 2011), and this review update, themethod of assessing and reporting
risk of bias has changed slightly. We have adapted the methods to reflect this.
For this review update, we included additional details on the nutritional and micronutrient status at baseline. Where reported, we have
also included plasma micronutrient levels during follow-up as an outcome. This outcome is not a patient important outcome, and is
of little interest on its own, but does contribute to the understanding of the results.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Dietary Supplements; Antitubercular Agents [therapeutic use]; Energy Intake; HIV Infections [complications; mortality]; Malnutri-
tion [complications; ∗diet therapy]; Micronutrients [administration & dosage]; Randomized Controlled Trials as Topic; Tuberculosis
[complications; ∗diet therapy; drug therapy; mortality]
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Adult; Child; Humans
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